AUTHOR INDEX

Aalders JG, *see* van der Zee AGJ
— *see* Veldhuis GJ
Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin, 2094
Abbruzzese MC, *see* Abbruzzese JL
Abeloff MD, *see* Budd GT
Abels RI, *see* Henry DH
Abigerges D, Chabot GG, Armand J-P, Hérait P, Gouyette A, Gandia D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients, 210
— *see* Gonçalves E
Abrams J, *see* Aisner J
Abrams JS, Vena DA, Baltz J, Adams J, Montello M, Christian M, Onetto N, Desmond-Hellmann S, Canetta R, Friedman MA, Arbuck SG. Paclitaxel activity in heavily pretreated breast cancer: A National Cancer Institute Treatment Referral Center trial, 2056
Abramson SJ, *see* Kushner BH
Abu-Jawdeh G, *see* Cannistra SA
Acimovic L, *see* Jeremic B
Adami H-O, *see* Sparén P
Adams J, *see* Abrams JS
Adamson PC, Bailey J, Pluda J, Poplack DG, Bauza S, Murphy RF, Yarchoan R, Balis FM. Pharmacokinetics of all-*trans*-retinoic acid administered on an intermittent schedule, 1238
— *see* Bailey J
Adelson MD, *see* Gandara DR
Agadir A, Cornic M, Lefebvre P, Gourmel B, Jérôme M, Degos L, Fenaux P, Chomienne C. All-*Trans* retinoic acid pharmacokinetics and bioavailability in acute promyelocytic leukemia: Intracellular concentrations and biologic response relationship, 2517
Agulló JA, *see* Palomera L
A'Hern RP, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer, 726
Ahlström H, *see* Jansson T
Ahmad B, *see* Somlo G
Ahmann DL, *see* Creagan ET
Ahmed F, *see* Hill M
Ahn C, *see* Morgan RJ Jr
Ahn DC, *see* Somlo G
Ahsan H, Neugut AI, Bruce JN. Association of malignant brain tumors and cancers of other sites, 2931
Aisenberg AC. Coherent view of non-Hodgkin's lymphoma, 2656
Aisner J, Cirrincione C, Perloff M, Perry M, Budman D, Abrams J, Panasci L, Muss H, Citron M, Holland J, Wood W, Henderson IC. Combination chemotherapy for metastatic or recurrent carcinoma of the breast—A randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B study 8281, 1443
Akira M, *see* Furuse K
Akman S, *see* Morgan RJ Jr
Akman SA, *see* Somlo G
Alastuey I. Intensified concomitant chemoradiotherapy for poor-prognosis head and neck cancer (letter), 1281
Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT III, Weick JK, Lonchyna VA, Presant CA, McKenna RJ, Gandara DR, Fosmire H, Taylor SA, Stelzer KJ, Beasley KR, Livingston RB. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA(N2) and IIIB non–small-cell lung cancer: Mature results of Southwest Oncology Group phase II study 8805, 1880
Albeck M, *see* Sredni B
Albertioni F, *see* Juliusson G
Albino AP, *see* Motzer RJ
Albo VC, *see* Rowland P
Albright AL, *see* Cohen BH
— *see* Jakacki RI
Aledo A, *see* Kushner BH
Alexander HR, *see* Thom AK
Alexanian R, *see* Moulopoulos LA
Allen JC, *see* Cohen BH
— *see* Finlay JL
— *see* Jakacki RI
Allen SL, *see* Ratain MJ
Allgayer H, *see* Heiss MM
Allhoff E, *see* Atzpodien J
Alvisi P, *see* De Bernardi B
Alyea EP, *see* Pichert G
Amato RJ, *see* Logothetis CJ
Ambinder RF, *see* Bedi A
Amess JAL, *see* Johnson PWM
Amoroso D, *see* Sertoli MR
Amsterdam A, *see* Ghossein RA
Amylon M, *see* O'Donnell MR
Anasetti C, *see* Demirer T
Anderlini P, Benjamin RS, Wong FC, Kantarjian HM, Andreeff M, Kornblau SM, O'Brien S, Mackay B, Ewer MS, Pierce SA, Estey EH. Idarubicin cardiotoxicity: A retrospective study in acute myeloid leukemia and myelodysplasia, 2827
Andersen J, *see* Cannistra SA
Anderson EM, *see* Navari RM
Anderson GB, *see* Johnson BE
Anderson JR, *see* Bennett CL
— *see* Yan Y
Anderson KC. Who benefits from high-dose therapy for multiple myeloma? (editorial), 1291
Anderson N, *see* Navari RM
Andersson BS, *see* van Besien KW
Ando Y, *see* Minami H
Andreeff M, *see* Anderlini P
Andreola S, *see* Silvestrini R
Andreyev HJN, Scott-Mackie P, Cunningham D, Nicolson V, Norman AR, Badve SS, Iveson A, Nicolson MC. Phase II study of continuous infusional fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors, 1486
Andrich MP, *see* Thom AK
Ansari R, *see* Blanke C
— *see* Faylona EA
— *see* Loehrer PJP Sr
Antin JH, *see* Mitus AJ
Antman K, *see* Ayash LJ
Antman KH, *see* Lew MA
Antoine E, *see* Le Cesne A

Anton P, *see* Atzpodien J
Appelbaum F, *see* Bensinger W
— *see* Grever M
Appelbaum FR, *see* Demirer T
Appelbaum JW, *see* Weiden PL
Arbuck S, *see* Seidman AD
Arbuck SG, *see* Abrams JS
Archimbaud E, Thomas X, Leblond V, Michallet M, Fenaux P, Cordonnier C, Dreyfus F, Troussard X, Jaubert J, Travade P, Troncy J, Assouline D, Fiere D. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: Long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial, 11
Ardalan B, *see* Leichman CG
Ardizzoni A, *see* Postmus PE
Aricò M, *see* Conter V
Arimoto Y, *see* Maeda K
Armand J-P, *see* Abigerges D
Armand JP, *see* Gonçalves E
— *see* Schornagel JH
Armitage GO, *see* Bennett CL
Armitage JL, *see* Bennett CL
Armitage JO, *see* Bennett CL
— *see* Vaughan WP
— *see* Vose JM
— *see* Vose MJ
— *see* Yan Y
Armstrong C, Ruffer J, Corn B, DeVries K, Mollman J. Biphasic patterns of memory deficits following moderate-dose partial-brain irradiation: Neuropsychologic outcome and proposed mechanisms, 2263
Armstrong DK, *see* Kennedy MJ
Armstrong JG, *see* Pfister DG
Arnott S, *see* Radford JA
Arosio M, *see* Uderzo C
Arriagada R, Rutqvist LE, Mattsson A, Kramar A, Rotstein S. Adequate locoregional treatment for early breast cancer may prevent secondary dissemination, 2869
Arroyo CD, *see* Rosen PP
Arthur RR, *see* Bedi A
Arvizu C, *see* Valone FH
Ashley SE, *see* Powles TJ
Asselain B, *see* Broët P
Assouline D, *see* Archimbaud E
Atkins CD. Effect of flutamide withdrawal on response assessment of estramustine and etoposide for prostate cancer (letter), 797
Atkins MB. In reply (letter), 796
Atmore K, *see* Waber DP
Atzpodien J, Hänninen EL, Kirchner H, Bodenstein H, Pfreundschuh M, Rebmann U, Metzner B, Illiger H-J, Jakse G, Niesel T, Scholz H-J, Wilhelm S, Pielmeier T, Zakrzewski G, Blum G, Beier J, Müller G-W, Duensing S, Anton P, Allhoff E, Jonas U, Poliwoda H. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma, 497
— *see* Buer J
Avramis VI, *see* Villablanca JG
Ayash LJ, Wheeler C, Fairclough D, Schwartz G, Reich E, Warren D, Schnipper L, Antman K, Frei E III, Elias A. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer, 2043
Ayers G, *see* Finlay JL
Azhar T, *see* Tattersall MHN
Aziz, F for the Cervical Cancer Study Group of the Asian Oceanian Clinical Oncology Association, *see* Tattersall MHN
Azli N, *see* Chevallier B

Baars JW, *see* Dercksen MW
Babic R, *see* Heiss MM
Babul N, *see* Bruera E
Bacigalupo A, *see* Corvò R
— *see* Uderzo C
Badve SS, *see* Andreyev HJN
Bailey J, Pluda JM, Foli A, Saville MW, Bauza S, Adamson PC, Murphy RF, Cohen RB, Broder S, Yarchoan R. Phase I/II study of intermittent all-*trans*-retinoic acid, alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi's sarcoma, 1966
— *see* Adamson PC
Bain C, *see* Merrouche Y
Bajetta E, Colleoni M, Di Bartolomeo M, Buzzoni R, Bozzetti F, Doci R, Somma L, Cappuzzo F, Stampino CG, Guenzi A, Balant LP, Zilembo N, Di Leo A. Doxifluridine and leucovorin: An oral treatment combination in advanced colorectal cancer, 2613
Bajorin D, *see* Steyerberg EW
Bajorin DF, Nichols CR, Schmoll H-J, Kantoff PW, Bokemeyer C, Demetri GD, Einhorn LH, Bosl GJ. Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: A randomized trial, 79
— *see* Motzer RJ
— *see* Sarkis AS
Balant LP, *see* Bajetta E
Balat O, *see* Kudelka AP
Balch CM, *see* Buzaid AC
Balduzzi A, *see* Uderzo C
Balis FM, *see* Adamson PC
— *see* Berg SL
— *see* Blaney SM
— *see* Wilson WH
Ball H, *see* McGuire WP
Ballard D, *see* Millikan R
Ballester OF, *see* Fields KK
Ballestrero A, *see* Patrone F
Baltz J, *see* Abrams JS
Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LH. Late relapse of testicular cancer, 1170
Banks W, *see* Kelsen DP
Barakat R, *see* Fennelly D
Barbhaiya RH, *see* Kaul S
Barbieri M, *see* Corvò R
Barbot D, *see* Mohiuddin M
Barbui T, *see* Cortelazzo S
Barcos M, *see* Canellos GP
Barker WC, *see* Thom AK

Barnes J, *see* Pritchard J
Barnhill DR, Kurman RJ, Brady MF, Omura GA, Yordan E, Given FT, Kucera PR, Roman LD. Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: A Gynecologic Oncology Group study, 2752
Barr R, *see* Browman GP
Barraclough B, *see* Ung O
Barret S, *see* Seidman AD
Bar-Shalom R, *see* Even-Sapir E
Bartels P, *see* Elledge RM
Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report, 1080
Baselga J, *see* Seidman AD
Basler GA, Desmond-Hellmann S, Florczyk AP. Paclitaxel-induced "recall" soft tissue injury (letter), 531
Bassan R, *see* Cortelazzo S
Basso G, *see* Conter V
Bast MA, *see* Yan Y
Basta P, *see* Patrone F
Bates S, *see* Wilson WH
Bates SE, *see* Wilson WH
Batist G, *see* Wainer IW
Baum M, *see* Smith IE
Bauza S, *see* Adamson PC
— *see* Bailey J
Bavinck JNB, Tieben LM, Van Der Woude FJ, Tegzess AM, Hermans J, Schegget JT, Vermeer BJ. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: A double-blind, placebo-controlled study, 1933
Bayssas M, *see* Chevallier B
Beasley K, *see* Bunn PA Jr
— *see* Kelly K
Beàsley KR, *see* Albain KS
Beaty O III, Hudson MM, Greenwald C, Luo X, Fang L, Wilimas JA, Thompson EI, Kun LE, Pratt CB. Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease, 603
Beck T, *see* Hesketh PJ
Beck TM, *see* Navari RM
Bedi A, Miller CB, Hanson JL, Goodman S, Ambinder RF, Charache P, Arthur RR, Jones RJ. Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation, 1103
Bedikian AY, Weiss GR, Legha SS, Burris HA III, Eckardt JR, Jenkins J, Eton O, Buzaid AC, Smetzer L, Von Hoff DD, Benjamin RS. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy, 2895
Beier J, *see* Atzpodien J
Beijnen JH, *see* van Warmerdam LJC
Bélanger R, *see* Pichert G
Belani CP, *see* Hainsworth JD
— *see* Vokes EE
Belch A, *see* Browman GP
Bellare N, *see* van Besien KW
Bellavita P, *see* Cortelazzo S
Bellet RE, *see* Ravdin PM
— *see* Valero V
Belt R, *see* Elledge RM
Bengala C, *see* Fennelly D
Benger AM, *see* Meyer RM
Benjamin RS, *see* Anderlini P
— *see* Bedikian AY
— *see* Buzaid AC
Benner S, *see* Fossella FV
Bennett CL, Armitage JL, Armitage GO, Vose JM, Bierman PJ, Armitage JO, Anderson JR. Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: Results from the University of Nebraska 1987 through 1991, 969
—, Smith TJ, George SL, Hillner BE, Fleishman S, Niell HB. Free-riding and the prisoner's dilemma: Problems in funding economic analyses of phase III cancer clinical trials, 2457
Bennett JM, *see* Grever M
— *see* Tallman MS
Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, Gooley T, Demirer T, Schiffman K, Weaver C, Clift R, Chauncey T, Klarnet J, Montgomery P, Petersdorf S, Weiden P, Witherspoon R, Buchner CD. Factors that influence collection and engraftment of autologous peripheral-blood stem cells, 2547
Bensinger WI, *see* Demirer T
Benson, AB III, *see* Giovanazzi-Bannon S
— *see* Whittington R
Bentel JM, *see* Birrell SN
Benzies T, *see* Triozzi PL
Berard CW, *see* Hutchison RE
Berd D, Mastrangelo MJ. Combination chemotherapy of metastatic melanoma (letter), 796
Berek JS, *see* McGuire WP
Berg SL, Tolcher A, O'Shaughnessy JA, Denicoff AM, Noone M, Ognibene FP, Cowan KH, Balis FM. Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer, 2039
Berger MS, *see* Finlay JL
Bergeron A, Raffy O, Vannetzel JM. Myocardial ischemia and infarction associated with vinorelbine (letter), 531
Bergh J, *see* Jansson T
Bergman B, *see* Lassen U
Bergsagel D, *see* Browman GP
Bergsagel DE. Do glucocorticoids influence the survival of myeloma patients? (letter), 1045
Bergström R, *see* Sparén P
Berman E. Chemotherapy in acute myelogenous leukemia: High dose, higher expectations? (editorial), 1
Berman ML, *see* McGuire WP
Bernardi D, Salvioni R, Vaccher E, Repetto L, Piersantelli N, Marini B, Talamini R, Tirelli U for the Italian Cooperative Group on AIDS and Tumors. Testicular germ cell tumors and human immunodeficiency virus infection: A report of 26 cases, 2705
— *see* Tirelli U
Berris RF, *see* Hayes DF
Bertelli G, Gozza A, Forno GB, Vidili MG, Silvestro S, Venturini M, Del Mastro L, Garrone O, Rosso R, Dini D. Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: A prospective clinical study, 2851

— *see* Sertoli MR
Berthold F, *see* Boos J
Berti E, *see* Paulli M
Bertolone SJ, *see* Finlay JL
Beutler E, *see* Saven A
Beyer J, Schwella N, Zingsem J, Strohscheer I, Schwaner I, Oettle H, Serke S, Huhn D, Siegert W. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: A randomized comparison, 1328
Beykirch M, *see* Carmichael J
Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial, 2483
— *see* Hayes DF
Bierman PJ, *see* Bennett CL
— *see* Vaughan WP
— *see* Yan Y
Bierman WA, *see* Ravdin PM
Biermann W, *see* Mohiuddin M
Biesma B, *see* Veldhuis GJ
Bigley J, *see* Jones S
— *see* Weber BL
Bigley JW, *see* Vokes EE
Bijnens L, *see* Teodorovic I
Bildet F, *see* Woll PJ
Binet J-L, *see* Leblond V
Birrell SN, Roder DM, Horsfall DJ, Bentel JM, Tilley WD. Medroxyprogesterone acetate therapy in advanced breast cancer: The predictive value of androgen receptor expression, 1572
Bishop JF, *see* Phillips K-A
Bissett D. In reply (letter), 304
Bitker M-O, *see* Leblond V
Bitran JD, *see* Gulati SC
— *see* Samuels BL
Bitton RJ, Figg WD, Venzon DJ, Dalakas MC, Bowden C, Headlee D, Reed E, Myers CE, Cooper MR. Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin, 2223
Bjordal K, *see* Hjermstad MJ
Bladé J, *see* Gahrton G
Blaney SM, Poplack DG, Godwin K, McCully CL, Murphy R, Balis FM. Effect of body position on ventricular CSF methotrexate concentration following intralumbar administration, 177
Blanke C, Ansari R, Mantravadi R, Gonin R, Tokars R, Fisher W, Pennington K, O'Connor T, Rynard S, Miller M, Einhorn L. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non–small-cell lung cancer: A Hoosier Oncology Group protocol, 1425
Blatt J, *see* Rowland P
Bleehen NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH, Rustin GJS, Brampton M, Stevens MFG. Cancer research campaign phase II trial of temozolomide in metastatic melanoma, 910
Bleyer A. CNS chemoradiotherapy of childhood leukemia: The plot thickens but the ending bodes well (editorial), 2480
Blum G, *see* Atzpodien J
Blume KG, *see* O'Donnell MR
Boccardo F, *see* Sertoli MR
Bode U, *see* Boos J
Bodenstein H, *see* Atzpodien J
— *see* Köhne C-H
Bodurtha JN, *see* Smith TJ
Boiocchi M, *see* Tirelli U
Bokemeyer C, Schmoll H-J. Treatment of testicular cancer and the development of secondary malignancies, 283
— *see* Bajorin DF
Boland P, *see* Kushner BH
Bolton AE, *see* Hardingham JE
Bonadonna G, *see* Gianni L
Bonichon F, *see* Bui BN
Bonilla MA, *see* Kushner BH
Bonjo CA, *see* Langer CJ
Bonny Y, *see* Pichert G
Bonomi PD, *see* Wolff AC
Boos J, Krümpelmann S, Schulze-Westhoff P, Euting T, Berthold F, Jürgens H. Steady-state levels and bone marrow toxicity of etoposide in children and infants: Does etoposide require age-dependent dose calculation? 2954
—, Nowak-Göttl U, Jürgens H, Fleischhack G, Bode U. Loss of activity of *Erwinia* asparaginase on repeat applications (letter), 2474
Boracchi P, *see* Silvestrini R
Borgen P, *see* Rosen PP
Borleri GM, *see* Cortelazzo S
Borroni G, *see* Paulli M
Bortolussi R, *see* Valentini M
Bortoluzzi F, *see* Valentini M
Bosl GJ, *see* Bajorin DF
— *see* Motzer RJ
— *see* Pfister DG
— *see* Steyerberg EW
Bouffet E, *see* Doz F
Boveri E, *see* Paulli M
Bowden C, *see* Bitton RJ
Bowling MK, *see* Rowinsky EK
Boyages J, *see* Ung O
Boyer MW, Moertel CL, Priest JR, Woods WG. Use of intracavitary cisplatin for the treatment of childhood solid tumors in the chest or abdominal cavity, 631
Boyett JM, *see* Cohen BH
— *see* Finlay JL
— *see* Jakacki RI
Bozzetti F, *see* Bajetta E
Bracken SP, *see* Brandes LJ
Brady MF, *see* Barnhill DR
— *see* McGuire WP
Brain E, *see* Le Cesne A
Braine HG, *see* Passos-Coelho JL
Braly P, *see* Gandara DR
Brampton M, *see* Bleehen NM
Brandes LJ, Bracken SP, Ramsey EW. *N,N*-diethyl-2-[4-(phenylmethyl)phenoxy]ethananmine in combination with cyclophosphamide: An active, low-toxicity regimen for metastatic hormonally unresponsive prostate cancer, 1398
Brandi M, *see* De Lena M

Brandt L, *see* Gahrton G
Brandwein JM, *see* Colwill R
Brawley O, *see* Harlan L
Brema F, *see* Patrone F
Brennan MF, *see* Kelsen DP
Breslow NE, Takashima JR, Whitton JA, Moksness J, D'Angio GJ, Green DM. Second malignant neoplasms following treatment for Wilms' tumor: A report from the National Wilms' Tumor Study Group, 1851
Brewster L, *see* Lilenbaum RC
Broder S, *see* Bailey J
Broët P, de la Rochefordière A, Scholl SM, Fourquet A, Mosseri V, Durand J-C, Pouillart P, Asselain B. Contralateral breast cancer: Annual incidence and risk parameters, 1578
Brook J. Fluorouracil and low-dose leucovorin versus fluorouracil and high-dose leucovorin: What is the real cost? What is the answer? (letter), 1830
Brosteanu O, *see* Munker R
Broun ER, Sridhara R, Sledge GW, Loesch D, Kneebone PH, Hanna M, Hromas R, Cornetta K, Einhorn LH. Tandem autotransplantation for the treatment of metastatic breast cancer, 2050
Browman GP, Bergsagel D, Sicheri D, O'Reilly S, Wilson KS, Rubin S, Belch A, Shustik C, Barr R, Walker I, James K, Zee B, Johnston D. Randomized trial of interferon maintenance in multiple myeloma: A study of the National Cancer Institute of Canada Clinical Trials Group, 2354
—, Levine MN, Mohide EA, Hayward RSA, Pritchard KI, Gafni A, Laupacis A. The practice guidelines development cycle: A conceptual tool for practice guidelines development and implementation, 502
— *see* Meyer RM
Brown J, *see* Elledge RM
Bruce JN, *see* Ahsan H
Bruderman I, *see* Sredni B
Bruera E, Fainsinger R, Spachynski K, Babul N, Harsanyi Z, Darke AC. Clinical efficacy and safety of a novel controlled-release morphine suppository and subcutaneous morphine in cancer pain: A randomized evaluation, 1520
— *see* De Conno F
Bruijn JA, *see* Bunt AMG
Brunet J, *see* De Andrés L
Bruzzi P, *see* De Bernardi B
— *see* Sertoli MR
Bryant G, *see* Wilson WH
Bryant J, *see* Lyter DW
Bryant-Lukosius D, *see* Meyer RM
Buchner CD, *see* Bensinger W
Buckels J, *see* Kerr DJ
Buckner CD, *see* Demirer T
Budd GT, Green S, O'Bryan RM, Martino S, Abeloff MD, Rinehart JJ, Hahn R, Harris J, Tormey D, O'Sullivan J, Osborne CK. Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: An intergroup study, 831
Budden J, *see* Kerr DJ
Budman D, *see* Aisner J
— *see* Jones S
Buelli M, *see* Cortelazzo S
Buer J, Probst M, Ganser A, Atzpodien J. Response to 13-*cis*-retinoic acid plus interferon alfa-2a in two patients with therapy-refractory advanced renal cell carcinoma (letter), 2679
Buesa J, *see* Santoro A
Bui BN, Chevallier B, Chevreau C, Krakowski I, Peny A-M, Thyss A, Maugard-Louboutin C, Cupissol D, Fargeot P, Bonichon F, Coindre JM, Gil B, Cour-Chabernaud V. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity, 2629
Bukowski R, *see* Kaul S
Bull C, *see* Sorensen K
Bunn PA Jr, Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C, Livingston R, Weiss GR, Hicks WJ, Gandara DR, Rivkin S. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: A prospective phase III randomized study of the Southwest Oncology Group, 1632
— *see* Kelly K
Bunt AMG, Hermans J, Smit VTHBM, van de Velde CJH, Fleuren GJ, Bruijn JA. Surgical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and western countries, 19
—, Hogendoorn PCW, van de Velde CJH, Bruijn JA, Hermans J. Lymph node staging standards in gastric cancer, 2309
Bureau G, *see* Paesmans M
Burg G, *see* Paulli M
Burgués J, *see* De Andrés L
Burris, H III, *see* Grunberg SM
Burris HA, *see* Rinaldi DA
Burris, HA III, *see* Bedikian AY
— *see* Ravdin PM
Busch ORC, Hop WCJ, Marquet RL, Jeekel J. Autologous blood transfusions and prognosis in colorectal cancer surgery (letter), 1280
Buurman WA, *see* Staal-van den Brekel AJ
Buyse M, *see* Lise M
Buzaid AC, Tinoco LA, Jendiroba D, Tu ZN, Lee JJ, Legha SS, Ross MI, Balch CM, Benjamin RS. Prognostic value of size of lymph node metastases in patients with cutaneous melanoma, 2361
—, Tinoco L, Ross MI, Legha SS, Benjamin RS. Role of computed tomography in the staging of patients with local-regional metastases of melanoma, 2104
— *see* Bedikian AY
Buzdar AU, *see* Jaiyesimi IA
— *see* Valero V
Buzzoni R, *see* Bajetta E
Byrd JC, Edenfield WJ, Shields DJ, Dawson NA. Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: A clinical review, 1800

Cabanillas F. Remarks on "Molecular markers and stem-cell transplants: Are they made for each other?" (letter), 2472
Cabanillas F, Lee MS. Polymerase chain reaction monitoring for *bcl*-2 can be a dependable test under the right conditions (letter), 795

— *see* Seymour JF
— *see* Touroutoglou N
— *see* Younes A
Cabanillas FC, *see* Rodriguez MA
Cabanillas FF, *see* van Besien KW
Cabriales S, *see* Gill PS
Cafiero F, *see* Sertoli MR
Cain JM, *see* Seewaldt VL
Cairncross JG, Eisenhauer EA. Response and control: Lessons from oligodendroglioma (letter), 2475
Calayag M, *see* Fossella FV
— *see* Lee JS
Caldwell KC, *see* Navari RM
Calvert AH, *see* Bleehen NM
Calvert L, *see* Kantarjian HM
Campora E, *see* Sertoli MR
Canavese G, *see* Sertoli MR
Canellos GP, Petroni GR, Barcos M, Duggan DB, Peterson BA for the Cancer and Leukemia Group B. Etoposide, vinblastine, and doxorubicin: An active regimen for the treatment of Hodgkin's disease in relapse following MOPP, 2005
— *see* Mauch PM
— *see* Shipp MA
Canetta R, *see* Abrams JS
Cannistra SA, Abu-Jawdeh G, Niloff J, Strobel T, Swanson L, Andersen J, Ottensmeier C. CD44 variant expression is a common feature of epithelial ovarian cancer: Lack of association with standard prognostic factors, 1912
Cannizzaro R, *see* Valentini M
Cantor R, *see* Mohiuddin M
Cappelaere P, *see* Schornagel JH
Cappuzzo F, *see* Bajetta E
Capri G, *see* Gianni L
Caraceni A, *see* Gianni L
Carbone A, *see* Tirelli U
Carli M, *see* De Bernardi B
Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, Harris AL. Advanced breast cancer: A phase II trial with gemcitabine, 2731
Carpenter PJ, *see* Waber DP
Carroll M, *see* Morgan RJ Jr
Carron G, *see* Navari RM
Casale F, *see* De Bernardi B
Casali P, *see* Santoro A
Cascinu S, Cordella L, Del Ferro E, Fronzoni M, Catalano G. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: A randomized double-blind placebo-controlled trial, 26
Casey S, *see* Powles TJ
Casper ES, *see* Kushner BH
Cassileth PA, *see* Grever M
Castleberry RP. In reply (letter), 302
Castro R, *see* Waber DP
Catalano G, *see* Cascinu S
Catane R, *see* Sredni B
Catovsky D, *see* Hill M
Catton CN, *see* Warde P
Catturich A, *see* Sertoli MR
Cavalli F, *see* Sessa C
Cavo M, *see* Gahrton G
Cella DF, *see* Yellen SB
Cerny T, *see* Sessa C
Cha S, *see* Donohue JH
Chabernaud VC, *see* Chevallier B
Chabner BA, *see* Clark JW
— *see* Wilson WH
Chabot GG, *see* Abigerges D
Chaganti RSK, *see* Motzer RJ
Chamberlain MC, Grafe MR. Recurrent chiasmatic-hypothalamic glioma treated with oral etoposide, 2072
—, Kormanik P. Salvage chemotherapy with paclitaxel for recurrent primary brain tumors, 2066
Champlin RE, *see* van Besien KW
Chan HSL, *see* Theis JGW
Chan TK, *see* Liang R
Chan WC, *see* Yan Y
Chan W-K, *see* Chi K-H
Chang AY. Ifosfamide: Let's not end the honeymoon too soon (letter), 1824
— *see* Navari RM
Chang C-Y, *see* Chi K-H
Chang F, Syrjänen S, Syrjänen K. Implications of the p53 tumor-suppressor gene in clinical oncology, 1009
Chao JY, *see* Chi K-H
Chao N, *see* O'Donnell MR
Charache P, *see* Bedi A
Charlotte F, *see* Leblond V
Chasen M, *see* Fossella FV
Chaumette M-T, *see* Hammel P
Chauncey T, *see* Bensinger W
— *see* Demirer T
Cheirsilpa A, *see* Tattersall MHN
Chen C-H, *see* Chi K-H
Chen KY, *see* Chi K-H
Chen S-Y, *see* Chi K-H
Chen T-L, *see* Kennedy MJ
— *see* Rowinsky EK
Chéradame S, *see* Etienne MC
Cherlow JM, *see* Finlay JL
Cheson BD. Infectious and immunosuppressive complications of purine analog therapy, 2431
— *see* Grever M
— *see* Wilson WH
Cheung, N-KV, *see* Kushner BH
Chevallier B, Chollet P, Merrouche Y, Roche H, Fumoleau P, Kerbrat P, Genot JY, Fargeot P, Olivier JP, Fizames C, Clavel M, Yver A, Chabernaud VC. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer, 1564
—, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, Azli N, Bayssas M, Lentz MA, Van Glabbeke M. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer, 314
— *see* Bui BN
Chevreau C, *see* Bui BN
Chi K-H, Chen C-H, Chan W-K, Chow K-C, Chen S-Y, Yen S-H, Chao JY, Chang C-Y, Chen KY. Effect of

granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy, 2620
Chilosi M, *see* Nadali G
Chinchilli VM, *see* Leitzel K
Chiu E, *see* Liang R
Chmielowska E, Potemski P, Plużańska A. Three-drug combination of cisplatin, dacarbazine, and tamoxifen in metastatic malignant melanoma (letter), 2146
Cho KH, *see* Hall WA
Chollet P, *see* Chevallier B
Chomienne C, *see* Agadir A
Chong SF, *see* Goldberg RM
Chooback L, *see* Wolfe JT
Chopra R, *see* Mills W
Chow K-C, *see* Chi K-H
Chow WA, *see* Somlo G
Choy D, *see* Liang R
Christian M, *see* Abrams JS
Chung Y-S, *see* Maeda K
Cirrincione C, *see* Aisner J
Citron M, *see* Aisner J
Clahsen PC, van de Velde CJH, Welvaart K, van Driel OJR, Sylvester RJ, Cooperating Investigators. Ten-year results of a randomized trial evaluating prolonged low-dose adjuvant chemotherapy in node-positive breast cancer: A joint European Organization for Research and Treatment of Cancer-Dutch Breast Cancer Working Party study, 33
Clark G, *see* Rinaldi DA
Clark GM, *see* Elledge RM
Clark HB, *see* Hall WA
Clark JW, Chabner BA. Suramin and prostate cancer: Where do we go from here? (editorial), 2155
Clark ST, Radford JA, Crowther D, Swindell R, Shalet SM. Gonadal function following chemotherapy for Hodgkin's disease: A comparative study of MVPP and a seven-drug hybrid regimen, 134
Clarke B, *see* Passos-Coelho JL
Clarke BV, *see* Kennedy MJ
Clavel M, *see* Chevallier B
— *see* Schornagel JH
Cleeland CS, *see* Love RR
Clift R, *see* Bensinger W
Clift RA, *see* Demirer T
Coen J, *see* Willett CG
Cognetti F, *see* Schornagel JH
Cohen BH, Zeltzer PM, Boyett JM, Geyer JR, Allen JC, Finlay JL, McGuire-Cullen P, Milstein JM, Rorke LB, Stanley P, Stehbens JA, Shurin SB, Wisoff J, Stevens KR, Albright AL. Prognostic factors and treatment results for supratentorial primitive neuroectodermal tumors in children using radiation and chemotherapy: A Childrens Cancer Group randomized trial, 1687
Cohen JR, *see* Hesketh PJ
Cohen L, *see* Kelly WK
Cohen PR, *see* Sacchi S
Cohen RB, *see* Bailey J
Coia LR, *see* Fein DA
Coindre JM, *see* Bui BN
Colella R, *see* Conter V
— *see* Uderzo C
Coleman CN, *see* Mauch PM
Colleoni M, *see* Bajetta E
Collins RD, *see* Greer JP
Colon-Otero G, *see* Witzig TE
Coluzzi P, *see* Ferrell BR
Coluzzi PH, Grant M, Doroshow JH, Rhiner M, Ferrell B, Rivera L. Survey of the provision of supportive care services at National Cancer Institute-designated cancer centers, 756
Colvin OM, *see* Kamen BA
— *see* Kennedy MJ
Colwill R, Crump M, Couture F, Danish R, Stewart AK, Sutton DMC, Scott JG, Sutcliffe SB, Brandwein JM, Keating A. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation, 396
Combaret V, *see* Merrouche Y
Come S, *see* Mauch PM
Comis RL, *see* Langer CJ
— *see* Wolff AC
Comotti B, *see* Cortelazzo S
Compton CC, *see* Willett CG
Conrad AJ, *see* Hoon DSB
Conte M, *see* De Bernardi B
Conter V, Aricò M, Valsecchi MG, Rizzari C, Testi AM, Messina C, Mori PG, Miniero R, Colella R, Basso G, Rondelli R, Pession A, Masera G for the Associazione Italiana di Ematologia ed Oncologia Pediatrica. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster–based intensive chemotherapy, 2497
Contesso G, *see* Le Cesne A
Conti JA, *see* Minsky BD
Conway K, *see* Millikan R
Cook G, *see* Ravdin PM
Cooper BW, *see* Fields KK
Cooper DL, Salloum E. Application of the Cotswolds criteria for the assessment of disease response in patients treated for Hodgkin's disease (letter), 1283
— *see* Doria R
Cooper MA, Einhorn LH. Maintenance chemotherapy with daily oral etoposide following salvage therapy in patients with germ cell tumors, 1167
Cooper MR, *see* Bitton RJ
Cooperating Investigators, *see* Clahsen PC
Coppin MC, *see* Preudhomme C
Corbett WEN, *see* Grever M
Cordella L, *see* Cascinu S
Cordon-Cardo C, *see* Motzer RJ
— *see* Sarkis AS
Cordonnier C, *see* Archimbaud E
Corfu-A Study Group. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer, 921
Corkill M, *see* Leonard C
Corn B, *see* Armstrong C
Corn BW, *see* Lee WR
Cornelli PE, *see* De Bernardi B

Cornetta K, *see* Broun ER
Cornic M, *see* Agadir A
Corominas JM, *see* Malats N
Coronel B, *see* Merrouche Y
Corso SW, *see* Rinaldi DA
Cortelazzo S, Rambaldi A, Barbui T. In reply (letter), 2144
—, Viero P, Bellavita P, Rossi A, Buelli M, Borleri GM, Marziali S, Bassan R, Comotti B, Rambaldi A, Barbui T. Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma, 935
Cortes JE, Pazdur R. Docetaxel, 2643
Corvò R, Giaretti W, Sanguineti G, Geido E, Orecchia R, Guenzi M, Margarino G, Bacigalupo A, Garaventa G, Barbieri M, Vitale V. In vivo cell kinetics in head and neck squamous cell carcinomas predicts local control and helps guide radiotherapy regimen, 1843
Cosgrove D, *see* Powles TJ
Costanza M, *see* Ratain MJ
Cotterill S, *see* Pritchard J
Courbon B, *see* Doz F
Cour-Chabernaud V, *see* Bui BN
— *see* Woll PJ
Cousar JB, *see* Greer JP
Couture F, *see* Colwill R
Couzi RJ, Helzlsouer KJ, Fetting JH. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy, 2737
Cowan KH, *see* Berg SL
Cox J, *see* Touroutoglou N
Craig JB, *see* Vokes EE
Cranor M, *see* Rosen PP
Craven B, *see* McQuellon RP
Creagan ET, Dalton RJ, Ahmann DL, Jung S-H, Morton RF, Langdon RM Jr, Kugler J, Rodrigue LJ. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma, 2776
Creasman WT, *see* Mackey SE
— *see* McGuire WP
Creger RJ, *see* Fields KK
Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, Hammond D, Hays DM, Herrmann J, Heyn R, Jones PM, Lawrence W, Newton W, Ortega J, Raney RB, Ruymann FB, Tefft M, Webber B, Wiener E, Wharam M, Vietti TJ, Maurer HM. The third intergroup rhabdomyosarcoma study, 610
Crist WM, *see* Pappo AS
Crist WM, *see* Ribeiro RC
Crowley J, *see* Bunn PA Jr
Crowley JJ, *see* Albain KS
— *see* Kelly K
— *see* Salmon SE
Crown J, *see* Fennelly D
— *see* Seidman AD
Crown JPA, *see* Seidman AD
Crowther D, *see* Clark ST
— *see* Radford JA
Crump M, *see* Colwill R
— *see* Winquist EW
Cubeddu LX, O'Connor DT, Parmer RJ. Plasma chromogranin a: A marker of serotonin release and of emesis associated with cisplatin chemotherapy, 681
Cummings FJ, *see* Falkson G
Cunningham D, *see* Andreyev HJN
— *see* Hill M
Cupissol D, *see* Bui BN
Curley T, *see* Ghossein RA
— *see* Kelly WK
Curran WJ Jr, *see* Fein DA
Currie V, *see* Seidman AD
Curtin J, *see* Fennelly D
Curtis RE, *see* Travis LB

da Costa L, *see* Gonçalves E
Dabouis G, *see* Paesmans M
Daidone MG, *see* Silvestrini R
Dalakas MC, *see* Bitton RJ
Dale BM, *see* Hardingham JE
Dale PS, *see* Hoon DSB
Dalton RJ, *see* Creagan ET
Daly WJ, *see* Willett CG
D'Angio GJ, *see* Breslow NE
Danish R, *see* Colwill R
Dansey RD, *see* Bezwoda WR
Dargent J-L, *see* Ravoet C
Darke AC, *see* Bruera E
Dassonville O, *see* Etienne MC
— *see* Schneider M
Daugherty C, Ratain MJ, Grochowski E, Stocking C, Kodish E, Mick R, Siegler M. Perceptions of cancer patients and their physicians involved in phase I trials, 1062
Davi F, *see* Leblond V
Davidson NE, *see* Kennedy MJ
— *see* Passos-Coelho JL
Davies BE, *see* van Warmerdam LJC
Davies HA, *see* Didcock E
Davis JM, *see* Passos-Coelho JL
Dawson NA, *see* Byrd JC
De Andrés L, Brunet J, López-Pousa A, Burgués J, Vega M, Tabernero JM, Mesía R, López JJ. Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer, 1493
De Bernardi B, Conte M, Mancini A, Donfrancesco A, Alvisi P, Tomà P, Casale F, di Montezemolo LC, Cornelli PE, Carli M, Tonini GP, Pession A, Giaretti W, Garaventa A, Marchese N, Magillo P, Nigro M, Kotitsa Z, Tamaro P, Tamburrini A, Rogers D, Bruzzi P. Localized resectable neuroblastoma: Results of the second study of the Italian Cooperative Group for Neuroblastoma, 884
de Bruijn HWA, *see* Gels ME
de Campos E, Radford J, Steward W, Milroy R, Dougal M, Swindell R, Testa N, Thatcher N. Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer, 1623
De Conno F, Ripamonti C, Saita L, MacEachern T, Hanson J, Bruera E. Role of rectal route in treating cancer pain: A randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain, 1004

De Fusco M, *see* Sessa C
de Graeff A, *see* Schornagel JH
De Jong J, *see* Sessa C
de la Rochefordière A, *see* Broët P
de Laurenzi A, *see* Gahrton G
De Lena M, Ditonno P, Lorusso V, Brandi M, Timurian A, Marzullo F, Ventrella V, Pellecchia A. CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: A pilot study, 953
de Leon CG, *see* Kudelka AP
de Mulder PHM, *see* Schornagel JH
de Ridder M, *see* Sonneveld P
de Valeriola D, *see* Roy J-A
de Vries EGE, *see* van der Zee AGJ
— *see* Veldhuis GJ
de Witte T, *see* Gahrton G
De Wolf Peeters C for the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group, *see* Teodorovic I
Deakin DP, *see* Radford JA
Dean GE, *see* Ferrell BR
Dearnaley DP, *see* Stevens MJ
Decker DA, *see* Jaiyesimi IA
Degos L, *see* Agadir A
Deisseroth AB, *see* Kantarjian HM
— *see* van Besien KW
Del Ferro E, *see* Cascinu S
Del Mastro L, *see* Bertelli G
— *see* Sertoli MR
Delasalle KB, *see* Moulopoulos LA
Delchier J-C, *see* Hammel P
Demard F, *see* Etienne MC
— *see* Schneider M
Demers L, *see* Leitzel K
Demetri GD, *see* Bajorin DF
Demirer T, Rowley S, Buckner CD, Appelbaum FR, Lilleby K, Storb R, Schiffman K, Bensinger WI. Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer, 1714
—, Weaver CH, Buckner CD, Petersen FB, Bensinger WI, Sanders J, Clift RA, Lilleby K, Anasetti C, Martin P, Storb R, Chauncey T, Doney K, Sullivan K, Appelbaum FR. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy, 596
— *see* Bensinger W
Denicoff AM, *see* Berg SL
Dentener MA, *see* Staal-van den Brekel AJ
Deo Y, *see* Valone FH
Dercksen MW, Rodenhuis S, Dirkson MKA, Schaasberg WP, Baars JW, van der Wall E, Slaper-Cortenbach ICM, Pinedo HM, Von dem Borne AEGKr, van der Schoot CE, Gerritsen WR. Subsets of $CD34^+$ cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation, 1922
Dervite I, *see* Preudhomme C
Desjardins L, *see* Doz F
Desmond-Hellmann S, *see* Abrams JS
— *see* Basler GA
DeVries K, *see* Armstrong C
Dexter TM, *see* Pettengell R
Di Bartolomeo M, *see* Bajetta E
Di Cataldo A, *see* Dibenedetto SP
Di Fronzo G, *see* Silvestrini R
Di Girolamo G, *see* Uderzo C
Di Leo A, *see* Bajetta E
di Montezemolo LC, *see* De Bernardi B
Di Tullio MT, *see* Uderzo C
Diasio RB, *see* Gandara DR
Dibenedetto SP. In reply (letter), 2475
—, Di Cataldo A, Ragusa R, Meli C, Nigro LL. Levels of L-asparagine in CSF after intramuscular administration of asparaginase from *Erwinia* in children with acute lymphoblastic leukemia, 339
Dickman PS, *see* Crist W
Didcock E, Davies HA, Didi M, Stuart ALO, Wales JKH, Shalet SM. Pubertal growth in young adult survivors of childhood leukemia, 2503
Didi M, *see* Didcock E
Diehl V for the German Hodgkin's Lymphoma Study Group, *see* Munker R
Dieras V, *see* Chevallier B
Díez-Itza I, *see* Vizoso F
Dimopoulos MA, *see* Moulopoulos LA
— *see* Touroutoglou N
D'Incalci M, *see* Sessa C
Dini D, *see* Bertelli G
Dini G, *see* Uderzo C
Dirkson MKA, *see* Dercksen MW
Ditonno P, *see* De Lena M
Divine M, *see* Hammel P
Djalilian HR, *see* Hall WA
Djuric L, *see* Jeremic B
Dnistrian A, *see* Kelly WK
Dobrovic A, *see* Hardingham JE
Doci R, *see* Bajetta E
Dolcetti R, *see* Tirelli U
Dombernowsky P, *see* Lassen U
Domingo JM, *see* Palomera L
Donahue BR, *see* Jakacki RI
Donaldson SS, *see* Crist W
Donehower RC, *see* Rowinsky EK
Doney K, *see* Demirer T
Donfrancesco A, *see* De Bernardi B
Donohue JH, Williams S, Cha S, Windschitl HE, Witzig TE, Nelson H, Fitzgibbons RJ Jr, Wieand HS, Moertel CG. Perioperative blood transfusions do not affect disease recurrence of patients undergoing curative resection of colorectal carcinoma: A Mayo North Central Cancer Treatment Group study, 1671
— *see* Wiesenfeld M
Donohue JP, *see* Baniel J
— *see* Steyerberg EW
Dorent R, *see* Leblond V
Doria R, Holford T, Farber LR, Prosnitz LR, Cooper DL. Second solid malignancies after combined modality therapy for Hodgkin's disease, 2016
Doroshow JH, *see* Coluzzi PH
— *see* Leichman CG
— *see* Morgan RJ Jr

— *see* Somlo G
Dorr FA, *see* Rinaldi DA
Dorssers L, *see* Lambrechts C
Dos Santos JG, *see* Lise M
Dougal M, *see* de Campos E
Doughty J, *see* Kerr DJ
Douglass EC, *see* Heideman RL
Doukas DJ, Waterhouse D, Gorenflo DW, Seid J. Attitudes and behaviors on physician-assisted death: A study of Michigan oncologists, 1055
Douville LM, *see* Goedegebuure PS
Doyle J, *see* Theis JGW
Doz F, Neuenschwander S, Plantaz D, Courbon B, Gentet JC, Bouffet E, Mosseri V, Vannier JP, Mechinaud F, Desjardins L, Vielh P, Zucker JM. Etoposide and carboplatin in extraocular retinoblastoma: A study by the Société Française d'Oncologie Pédiatrique, 902
Dreyfus F, *see* Archimbaud E
Droste JHJ, *see* Gels ME
Ducharme J, *see* Wainer IW
Duensing S, *see* Atzpodien J
Duez N, *see* Lise M
Duggan DB, *see* Canellos GP
Durand J-C, *see* Broët P
Dutcher JP, *see* Einzig AI

Eastridge BJ, Lefor AT. Complications of indwelling venous access devices in cancer patients, 233
Ebbs S, *see* Smith IE
Eberlein TJ, *see* Goedegebuure PS
Eckardt JR, *see* Bedikian AY
— *see* Rinaldi DA
Edenfield WJ, *see* Byrd JC
Edgerton S, *see* Millikan R
Edmonson JH. Needed: Qualitative improvement in antisarcoma therapy (editorial), 1531
Edwards C, *see* Kavanagh J
Edwards M, *see* Finlay JL
Egorin M, *see* Seidman AD
Egorin MJ, *see* Eisenberger MA
— *see* Gianni L
— *see* Reyno LM
— *see* Sridhara R
Einhorn L, *see* Blanke C
Einhorn LH, *see* Bajorin DF
— *see* Baniel J
— *see* Broun ER
— *see* Cooper MA
— *see* Faylona EA
— *see* Johnson DH
— *see* Loehrer PJ Sr
— *see* Loehrer PJP Sr
— *see* Stephenson WT
— *see* Warren GP
Einzig AI, Dutcher JP, Wiernik PH. Life-threatening hyperleukocytosis and pulmonary compromise after priming with recombinant human granulocyte-macrophage colony-stimulating factor in a patient with acute myelomonocytic leukemia (letter), 304
Eisenberg P, *see* Ravdin PM
Eisenberger MA, Sinibaldi VJ, Reyno LM, Sridhara R, Jodrell DI, Zuhowski EG, Tkaczuk KH, Lowitt MH, Hemady RK, Jacobs SC, VanEcho D, Egorin MJ. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer, 2174
— *see* Reyno LM
— *see* Sridhara R
Eisenhauer E, *see* Grever M
Eisenhauer EA. Docetaxel: Current status and future prospects (editorial), 2865
— *see* Cairncross JG
Eissner H-J, *see* Heiss MM
El Saghir NS. Combination chemotherapy with tetracycline and aggressive supportive care for immunoproliferative small-intestinal disease (letter), 794
Elfenbein GJ, *see* Fields KK
Elias A, *see* Ayash LJ
Elledge RM, Clark GM, Hon J, Thant M, Belt R, Maguire YP, Brown J, Bartels P, Von Hoff DD. Rapid in vitro assay for predicting response to fluorouracil in patients with metastatic breast cancer, 419
Ellerhorst JA, *see* Logothetis CJ
Ellerton J, *see* Miller AA
Elson P, *see* Loehrer PJ Sr
Elting LS, *see* Rubenstein EB
Emanuel EJ, A phase I trial on the ethics of phase I trials (editorial), 1049
Emanuel EJ, *see* Patterson WB
Emerson WA, *see* Moertel CG
Engstrom PF, *see* Langer CJ
Epelbaum R, *see* Even-Sapir E
Epstein F, *see* Finlay JL
Errante D, *see* Tirelli U
Esparza L, *see* Valero V
Espina BM, *see* Gill PS
Esplin JA, *see* Gill PS
Estey EH, *see* Anderlini P
Etienne MC, Chéradame S, Fischel JL, Formento P, Dassonville O, Renée N, Schneider M, Thyss A, Demard F, Milano G. Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity, 1663
— *see* Schneider M
Eton O, *see* Bedikian AY
Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: An Eastern Cooperative Oncology Group study, 1430
— *see* Wolff AC
European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group, *see* Postmus PE
Euting T, *see* Boos J
Evans C, *see* Hill M
Even-Sapir E, Bar-Shalom R, Israel O, Frenkel A, Iosilevsky G, Haim N, Epelbaum R, Gaitini D, Kolodny GM, Front D. Single-photon emission computed tomography quantitation of gallium citrate uptake for the differentiation of lymphoma from benign hilar uptake, 942
Evensen SA, *see* Juliusson G
Ewer MS, *see* Anderlini P
Exelby PR, *see* Faulkner LB

Faccini P, *see* Uderzo C
Façon T, *see* Gahrton G

Fain K, *see* Seidman AD
Fainsinger R, *see* Bruera E
Fair WR, *see* Herr HW
Fairclough D, *see* Ayash LJ
— *see* Waber DP
Falkson G, Holcroft C, Gelman RS, Tormey DC, Wolter JM, Cummings FJ. Ten-year follow-up study of premenopausal women with metastatic breast cancer: An Eastern Cooperative Oncology Group study, 1453
Fang L, *see* Beaty O III
Fanger MW, *see* Valone FH
Farber LR, *see* Doria R
Fargeot P, *see* Bui BN
— *see* Chevallier B
Faries D, *see* Rinaldi DA
Fass DE, *see* Pfister DG
Faulkner LB, Hajdu SI, Kher U, La Quaglia M, Exelby PR, Heller G, Wollner N. Pediatric desmoid tumor: Retrospective analysis of 63 cases, 2813
Favrot MC, *see* Merrouche Y
Faylona EA, Loehrer PJ, Ansari R, Sandler AB, Gonin R, Einhorn LH. Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: A Hoosier Oncology Group trial, 1209
Fein DA, Lee WR, Hanlon AL, Ridge JA, Langer CJ, Curran WJ Jr, Coia LR. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx, 2077
Feldman E, *see* Kantarjian HM
Feller AC, *see* Paulli M
Fenaux P, *see* Agadir A
— *see* Archimbaud E
— *see* Preudhomme C
Fender A, *see* Rubenstein EB
Fennelly D, Schneider J, Spriggs D, Bengala C, Hakes T, Reich L, Barakat R, Curtin J, Moore MAS, Hoskins W, Norton L, Crown J. Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses, 1160
Feremans W, *see* Ravoet C
Ferguson DJ, *see* Quiet CA
Fernando I, *see* Powles TJ
Ferrando F, *see* Patrone F
Ferrell B, *see* Coluzzi PH
Ferrell BR, Dean GE, Grant M, Coluzzi P. An institutional commitment to pain management, 2158
Fetting JH, *see* Couzi RJ
Fields KK, Elfenbein GJ, Lazarus HM, Cooper BW, Perkins JB, Creger RJ, Ballester OF, Hiemenz JH, Janssen WE, Zorsky PE. Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: Toxicity profile, 323
—, Perkins J, Elfenbein GJ. In reply (letter), 1826
Fields SM, *see* Rinaldi DA
Fields SZ, *see* Kaul S
Fiere D, *see* Archimbaud E
Figg WD, *see* Bitton RJ
Figge DC, *see* Seewaldt VL
Finberg R, *see* Lew MA
Findlay M, *see* Hill M
Finkelstein DM, *see* Ettinger DS
Finlay JL, Boyett JM, Yates AJ, Wisoff JH, Milstein JM, Geyer JR, Bertolone SJ, McGuire P, Cherlow JM, Tefft M, Turski PA, Wara WM, Edwards M, Sutton LN, Berger MS, Epstein F, Ayers G, Allen JC, Packer RJ for the Childrens Cancer Group. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen, 112
— *see* Cohen BH
— *see* Jakacki RI
Finn DT, *see* Wolfe JT
Finn LD, *see* Logothetis CJ
Fiorentino M, *see* Lise M
Fischel JL, *see* Etienne MC
Fischer A, *see* Leblond V
Fischer P, *see* Motzer RJ
Fisher B, Mamounas EP. Preoperative chemotherapy: A model for studying the biology and therapy of primary breast cancer (editorial), 537
Fisher DE, *see* Fung CY
Fisher JL, *see* Valone FH
Fisher RI, *see* Fyfe G
Fisher W, *see* Blanke C
— *see* Loehrer PJP Sr
Fishman A, *see* Kavanagh J
Fitts, D on behalf of the Granisetron Study Group, *see* Navari R
Fitzgibbons RJ Jr, *see* Donohue JH
— *see* Wiesenfeld M
Fizames C, *see* Chevallier B
Flactif M, *see* Preudhomme C
Flandrin G, *see* Troussard X
Fleischhack G, *see* Boos J
Fleishman S, *see* Bennett CL
Fleming TR, *see* Leichman CG
— *see* Moertel CG
Fleuren GJ, *see* Bunt AMG
Flexner JM, *see* Greer JP
Florczyk AP, *see* Basler GA
Fojo A, *see* Wilson WH
Foley KM. Pain relief into practice: Rhetoric without reform (editorial), 2149
— *see* Kelsen DP
Foli A, *see* Bailey J
Fonseca GA, *see* Valero V
Fontaine F, *see* Le Cesne A
Ford HT, *see* Powles TJ
Forman SJ, *see* O'Donnell MR
— *see* Somlo G
Formento P, *see* Etienne MC
Fornasarig M, *see* Valentini M
Forno GB, *see* Bertelli G
Forssen E, *see* Gill PS
Forsythe P, *see* Seidman AD
Foshag LJ, *see* Hoon DSB
Fosmire H, *see* Albain KS
Fossa SD, *see* Hjermstad MJ
Fosså SD, *see* Steyerberg EW

Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, Murphy WK, Lippman S, Benner S, Glisson B, Chasen M, Hong WK, Raber M. Phase II study of docetaxel for advanced or metastatic platinum-refractory non–small-cell lung cancer, 645
— *see* Lee JS
Foster GA, *see* Meyer RM
Foster R, *see* Nichols CR
Foster RS, *see* Baniel J
Foucar MK, *see* Grever M
Fourcade C, *see* Leblond V
Fourquet A, *see* Broët P
Fracasso A, *see* Valentini M
Fraker DL, *see* Thom AK
Franceschi S, *see* Tirelli U
Francis P, Rowinsky E, Schneider J, Hakes T, Hoskins W, Markman M. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: A Gynecologic Oncology Group pilot study, 2961
Frank GL, *see* Meyer RM
Fraschini G, *see* Valero V
Freedman R, *see* Kavanagh J
Frei E III, *see* Ayash LJ
Freifeld AG, Walsh T, Marshall D, Gress J, Steinberg SM, Hathorn J, Rubin M, Jarosinski P, Gill V, Young RC, Pizzo PA. Monotherapy for fever and neutropenia in cancer patients: A randomized comparison of ceftazidime versus imipenem, 165
Freling NJM, *see* Gels ME
Frenkel A, *see* Even-Sapir E
Frenkel E, *see* Kamen BA
Friberg L-G, *see* Sparén P
Friedman C, *see* Navari R
Friedman MA, *see* Abrams JS
Frisbee-Hume S, *see* Rubenstein EB
Front D, *see* Even-Sapir E
Fronzoni M, *see* Cascinu S
Fryer C, *see* Crist W
Fuks Z, *see* Zelefsky MJ
Fukuoka, M for the Southern Osaka Lung Cancer Study Group, *see* Furuse K
Fulfaro F, *see* Gianni L
Fumoleau P, *see* Chevallier B
Fung CY, Fisher DE. p53: From molecular mechanisms to prognosis in cancer (editorial), 808
Furuse K, Kubota K, Kawahara M, Kodama N, Ogawara M, Akira M, Nakajima S, Takada M, Kusunoki Y, Negoro S, Matsui K, Masuda N, Takifuji N, Kudoh S, Nishioka M, Fukuoka M for the Southern Osaka Lung Cancer Study Group. Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non–small-cell lung cancer, 869
Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy, 688

Gabarre J, *see* Leblond V
Gabizon A, *see* Uziely B
Gadner H, *see* Reiter A
Gafni A, *see* Browman GP
— *see* Rajan R
— *see* Whelan TJ
Gahrton G, Tura S, Ljungman P, Bladé J, Brandt L, Cavo M, Façon T, Gratwohl A, Hagenbeek A, Jacobs P, de Laurenzi A, Van Lint M, Michallet M, Nikoskelainen J, Reiffers J, Samson D, Verdonck L, de Witte T, Volin L. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma, 1312
Gaitini D, *see* Even-Sapir E
Gajewski JL, *see* van Besien KW
Gajjar AJ, *see* Heideman RL
Gambini C, *see* Paulli M
Gams RA, *see* Vogel CL
Gandara D, *see* Kaul S
— *see* Navari R
Gandara DR, Nahhas WA, Adelson MD, Lichtman SM, Podczaski ES, Yanovich S, Homesley HD, Braly P, Ritch PS, Weisberg SR, Williams L, Diasio RB, Perez EA, Karp D, Reich SD, McCarroll K, Hoff JV. Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities, 490
— *see* Albain KS
— *see* Bunn PA Jr
— *see* Kelly K
— *see* Roach M III
Gandia D, *see* Abigerges D
Gandjbakhch I, *see* Leblond V
Ganser A, *see* Buer J
Garaventa A, *see* De Bernardi B
Garaventa G, *see* Corvò R
Gareis D, *see* Krismann M
Garewal H, *see* Navari RM
Garrison D, *see* Hoon DSB
Garrone O, *see* Bertelli G
Gasparini G. p53 and angiogenesis (letter), 1830
—, Harris AL. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool, 765
Gaulard P, *see* Hammel P
Gebhardt MC, *see* Scully SP
Geerts ML, *see* Paulli M
Gehan EA, *see* Crist W
Geido E, *see* Corvò R
Gelman RS, *see* Falkson G
Gels ME, Hoekstra HJ, Sleijfer DTh, Marrink J, de Bruijn HWA, Molenaar WM, Freling NJM, Droste JHJ, Koops HS. Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: A single-center 10-year experience, 1188
Genevois E, *see* Ravdin PM
Genin J, *see* Le Cesne A
Genot JY, *see* Chevallier B
Gent M, *see* Rajan R
Gentet JC, *see* Doz F
Gentili D, *see* Sessa C
George SL, *see* Bennett CL
Gerald WL, *see* Ghossein RA
— *see* Kushner BH
Gerbi BJ, *see* Hall WA
Gerritsen WR, *see* Dercksen MW
Gerson SL, *see* Willson JKV

Gerstner J, *see* Witzig TE
Gerstner JB, *see* Wiesenfeld M
Geyer JR, *see* Cohen BH
— *see* Finlay JL
— *see* Jakacki RI
Ghio R, *see* Patrone F
Ghosh C, *see* Goldberg RM
Ghossein RA, Scher HI, Gerald WL, Kelly WK, Curley T, Amsterdam A, Zhang Z-F, Rosai J. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: Clinical implications, 1195
Ghoussoub J-J, *see* Leblond V
Giaccone G, *see* Postmus PE
Giani A, *see* Gianni L
Gianni L, Kearns CM, Giani A, Capri G, Viganó L, Locatelli A, Bonadonna G, Egorin MJ. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans, 180
—, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C, Stefanelli M, Valagussa P, Bonadonna G. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study, 2688
Giaretti W, *see* Corvò R
— *see* De Bernardi B
Gibbons JP, *see* Hall WA
Gignoux M, *see* Lise M
Gil B, *see* Bui BN
Gilewski T, *see* Seidman AD
Gilewski TA, *see* Seidman AD
Gill PS, Espina BM, Muggia F, Cabriales S, Tulpule A, Esplin JA, Liebman HA, Forssen E, Ross ME, Levine AM. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin, 996
Gill V, *see* Freifeld AG
Giovanazzi-Bannon S, Rademaker A, Benson AB III. In reply (letter), 1283
Giralt SA, *see* van Besien KW
Girgis A, Sanson-Fisher RW. Breaking bad news: Consensus guidelines for medical practitioners, 2449
Given FT, *see* Barnhill DR
Glick JH, *see* Moertel CG
Glisson B, *see* Fossella FV
Gloghini A, *see* Tirelli U
Glomstein A, *see* Schmiegelow K
Gobbi M, *see* Patrone F
Godwin K, *see* Blaney SM
Goedegebuure PS, Douville LM, Li H, Richmond GC, Schoof DD, Scavone M, Eberlein TJ. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: A pilot study, 1939
Goedhals L, *see* Hayes DF
Goh GR, *see* Schipper H
Goldberg HL, Vannice SB. Pneumonitis related to treatment with paclitaxel (letter), 534
Goldberg RM, Loprinzi CL, Mailliard JA, O'Fallon JR, Krook JE, Ghosh C, Hestorff RD, Chong SF, Reuter NF, Shanahan TG. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial, 2856
Goldberg SL, *see* Klumpp TR
Goldman JM, *see* O'Brien SG
Goldspiel BR, *see* Wilson WH
Goldstone AH, *see* Mills W
Gollub M, *see* Seidman AD
Golomb H, *see* Grever M
Gonçalves E, da Costa L, Abigerges D, Armand JP. A new enkephalinase inhibitor as an alternative to loperamide in the prevention of diarrhea induced by CPT-11 (letter), 2144
Gonchoroff NJ, *see* Wiesenfeld M
Gonin R, *see* Baniel J
— *see* Blanke C
— *see* Faylona EA
— *see* Loehrer PJP Sr
— *see* Nichols CR
— *see* Pichert G
Gonzalez de Leon C, *see* Kavanagh J
Goodman P, *see* Warde P
Goodman S, *see* Bedi A
Gooley LT, *see* Hardingham JE
Gooley T, *see* Bensinger W
Gordon NH, *see* Willson JKV
Gore M, *see* Hill M
Gore ME, *see* A'Hern RP
Gorenflo DW, *see* Doukas DJ
Gospodarowicz MK, *see* Warde P
Goss G, *see* Kaul S
Gosselin B, *see* Preudhomme C
Gough D, *see* Pritchard J
Gould JR, *see* Navari RM
Gourmel B, *see* Agadir A
Gouyette A, *see* Abigerges D
Gozza A, *see* Bertelli G
Grafe MR, *see* Chamberlain MC
Gralla RJ, *see* Vokes EE
Grant M, *see* Coluzzi PH
— *see* Ferrell BR
Gratwohl A, *see* Gahrton G
Gray R, *see* Tallman MS
Graziano R, *see* Valone FH
Grazioli I, *see* Valentini M
Greco FA, *see* Hainsworth JD
Green DM. Treatment of stage I Wilms' tumor (letter), 1530
— *see* Breslow NE
Green MR, *see* Kosty MP
— *see* Lilenbaum RC
— *see* Miller AA
Green S, *see* Budd GT
— *see* Rivkin SE
Greenberg B, *see* Navari RM
Greenberg ML, *see* Theis JGW
Greenwald C, *see* Beaty O III
— *see* Heideman RL
Greer BE, *see* Seewaldt VL
Greer JP, Macon WR, Lamar RE, Wolff SN, Stein RS, Flexner JM, Collins RD, Cousar JB. T-cell–rich B-cell lymphomas: Diagnosis and response to therapy of 44 patients, 1742
— *see* Nadali G

Grem J, *see* Köhne C-H
Gress J, *see* Freifeld AG
Grever M, Kopecky K, Appelbaum F, Foucar MK, Bennett JM, Habermann T, Rai K, Eisenhauer E, Cheson BD. In reply (letter), 2678
—, Kopecky K, Foucar MK, Head D, Bennett JM, Hutchison RE, Corbett WEN, Cassileth PA, Habermann T, Golomb H, Rai K, Eisenhauer E, Appelbaum F, Cheson BD. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: An intergroup study, 974
Griffen D, *see* Hesketh PJ
Grochow LB, *see* Kennedy MJ
— *see* Rowinsky EK
Grochowski E, *see* Daugherty C
Groen HJM, *see* Veldhuis GJ
Grossberg H, *see* Leitzel K
Gruetzner KU, *see* Heiss MM
Grunberg SM, Burris H III, Livingston R. The price of success (letter), 797
Guenzi A, *see* Bajetta E
Guenzi M, *see* Corvò R
Guillot T, *see* Schneider M
Gulati SC, Bitran JD. Cost-effectiveness analysis: Sleeping with an enemy or a friend? (editorial), 2152
Gupta RK, *see* Radford JA
Gustafsson G, *see* Schmiegelow K
Gustafsson L, *see* Sparén P
Gusterson B, *see* Smith IE
Guyre PM, *see* Valone FH
Guyre V, *see* Valone FH
Gwilt P, *see* Vaughan WP
Gyger M, *see* Pichert G
Gylling H, Pyrhönen S, Mäntylä E, Mäenpää H, Kangas L, Miettinen TA. Tamoxifen and toremifene lower serum cholesterol by inhibition of Δ^8-cholestenol conversion to lathosterol in women with breast cancer, 2900

Haaga JR, *see* Willson JKV
Haas F, *see* Jakacki RI
Haaxma-Reiche H, *see* Postmus PE
Habbema JDF, *see* Steyerberg EW
— *see* van der Donk J
Habermann T, *see* Grever M
Hacking A, *see* Hayes DF
Hagan MP, *see* Willett CG
Hagemeister F, *see* Younes A
Hagemeister FB, *see* Rodriguez MA
Hagenbeek A, *see* Gahrton G
— *see* Teodorovic I
Hahn R, *see* Budd GT
Haim N, *see* Even-Sapir E
Hainsworth JD, Levitan N, Wampler GL, Belani CP, Seyedsadr MS, Randolph J, Schacter LP, Greco FA. Phase II randomized study of cisplatin plus etoposide phosphate or etoposide in the treatment of small-cell lung cancer, 1436
—, Thompson DS, Greco FA. Paclitaxel by 1-hour infusion: An active drug in metastatic non–small-cell lung cancer, 1609
— *see* Hesketh PJ
Haioun C, *see* Hammel P
Hajdu SI, *see* Faulkner LB
Hakes T, *see* Fennelly D
— *see* Francis P
— *see* Seidman AD
Hakes TB, *see* Seidman AD
Hakimian D, *see* Tallman MS
Hall S, *see* Navari R
Hall WA, Djalilian HR, Sperduto PW, Cho KH, Gerbi BJ, Gibbons JP, Rohr M, Clark HB. Stereotactic radiosurgery for recurrent malignant gliomas, 1642
Haller DG, *see* Moertel CG
— *see* Whittington R
Halpern J, *see* Yuen AR
Hamasaki VK, *see* Somlo G
Hammel P, Haioun C, Chaumette M-T, Gaulard P, Divine M, Reyes F, Delchier J-C. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression, 2524
Hammond D, *see* Crist W
Hanada R, *see* Yamamoto K
Hancock ML, *see* Ribeiro RC
Hancock SL, *see* Bartlett NL
Hankey BF, *see* Travis LB
Hanks GE, *see* Lee WR
Hanlon AL, *see* Fein DA
Hanna M, *see* Broun ER
Hänninen EL, *see* Atzpodien J
Hansen HH, *see* Lassen U
Hansen M, *see* Lassen U
Hanson J, *see* De Conno F
Hanson JL, *see* Bedi A
Haraf DJ, *see* Vokes EE
Hardingham JE, Kotasek D, Sage RE, Gooley LT, Mi J-X, Dobrovic A, Norman JE, Bolton AE, Dale BM. Significance of molecular marker-positive cells after autologous peripheral-blood stem-cell transplantation for non-Hodgkin's lymphoma, 1073
Hargis JB, *see* Lilenbaum RC
Harker WG, *see* Hesketh PJ
Harlan L, Brawley O, Pommerenke F, Wali P, Kramer B. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate, 93
—, Brawley O, Pommerenke F, Wali P, Kramer B. In reply (letter), 1823
Harpole DH, *see* Strauss GM
Harris AL, *see* Carmichael J
— *see* Gasparini G
Harris J, *see* Budd GT
— *see* Hughes-Davies L
Harrison LB, *see* Pfister DG
Harrison M, Tomlinson D, Stewart S. Liposomal-entrapped doxorubicin: An active agent in AIDS-related Kaposi's sarcoma, 914
Harrison-Woermke D, *see* Sawka CA
Harsanyi Z, *see* Bruera E
Harvey H, *see* Leitzel K
— *see* Weber BL
Hasenclever D, *see* Munker R
Hathorn J, *see* Freifeld AG
Hayashi Y, *see* Yamamoto K
Hayes DF, Van Zyl JA, Hacking A, Goedhals L, Bezwoda

WR, Mailliard JA, Jones SE, Vogel CL, Berris RF, Shemano I, Schoenfelder J. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer, 2556
— *see* Vogel CL
Haynes H, *see* Wadler S
Hays DM, *see* Crist W
Hayward RSA, *see* Browman GP
Hazuka MB, *see* Bunn PA Jr
— *see* Kelly K
He M, *see* Millikan R
Head D, *see* Grever M
Headlee D, *see* Bitton RJ
Healey JH, *see* Kushner BH
Hecquet B, *see* Preudhomme C
Hedenus M, *see* Juliusson G
Heideman RL, Kovnar EH, Kellie SJ, Douglass EC, Gajjar AJ, Walter AW, Langston JA, Jenkins JJ, Li Y, Greenwald C, Sanford RA, Kun LE. Preirradiation chemotherapy with carboplatin and etoposide in newly diagnosed embryonal pediatric CNS tumors, 2247
Heiss MM, Babic R, Allgayer H, Gruetzner KU, Jauch K-W, Loehrs U, Schildberg FW. Tumor-associated proteolysis and prognosis: New functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system, 2084
—, Jauch K-W, Mempel W, Eissner H-J, Shildberg FW. In reply (letter), 1280
Heldal D, *see* Juliusson G
Heller G, *see* Faulkner LB
— *see* Kushner BH
Hellman S, Weichselbaum RR. Oligometastases (editorial), 8
— *see* Quiet CA
Helzlsouer KJ, *see* Couzi RJ
Hemady RK, *see* Eisenberger MA
Henderson IC, *see* Aisner J
— *see* Ratain MJ
Henry DH, Abels RI. Benefits of epoetin alfa therapy in anemic cancer patients receiving chemotherapy (letter), 2473
Henze G, *see* Reiter A
Hérait P, *see* Abigerges D
Herdt J, *see* Wilson WH
Hermans J, *see* Bavinck JNB
— *see* Bunt AMG
Herndon, JE II, *see* Kosty MP
— *see* Miller AA
Herpst JM, Klein JL, Leichner PK, Quadri SM, Vriesendorp HM. Survival of patients with resistant Hodgkin's disease after polyclonal yttrium 90-labeled antiferritin treatment, 2394
Herr H, *see* Motzer RJ
Herr HW, Schwalb DM, Zhang Z-F, Sogani PC, Fair WR, Whitmore WF Jr, Oettgen HF. Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: Ten-year follow-up of a prospective randomized trial, 1404
— *see* Sarkis AS
Herrmann J, *see* Crist W
Herrmann JJ, *see* Kuzel TM
Hesketh P, *see* Navari R
Hesketh PJ, Beck T, Uhlenhopp M, Kris MG, Hainsworth JD, Harker WG, Cohen JR, Lester E, Kessler JF, Griffen D, Rouse P. Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen, 2117
Hess KR, *see* Abbruzzese JL
Hess M, *see* Touroutoglou N
Hester J, *see* Kantarjian HM
Hestorff RD, *see* Goldberg RM
Heyn R, *see* Crist W
Hickish T, *see* Hill M
Hickish TF, *see* Powles TJ
Hicks WJ, *see* Bunn PA Jr
— *see* Kelly K
Hiddemann W, *see* Köhne C-H
Hiemenz JH, *see* Fields KK
Hill A, *see* Hill M
Hill M, Milan S, Cunningham D, Mansi J, Smith I, Catovsky D, Gore M, Zulian G, Selby P, Horwich A, O'Brien M, Nicolson M, Hickish T. Evaluation of the efficacy of the VEEP regimen in adult Hodgkin's disease with assessment of gonadal and cardiac toxicity, 387
—, Norman A, Cunningham D, Findlay M, Watson M, Nicolson V, Webb A, Middleton G, Ahmed F, Hickish T, Nicolson M, O'Brien M, Iveson T, Iveson A, Evans C. Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer, 2317
—, Norman A, Cunningham D, Findlay M, Nicolson V, Hill A, Iveson A, Evans C, Joffe J, Nicolson M, Hickish T. Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer, 1297
Hiller E, *see* Munker R
Hillner BE, *see* Bennett CL
— *see* Smith TJ
Hippe E, *see* Juliusson G
Hirsh J, *see* Rajan R
Hittelman WN, *see* Lee JS
Hjermstad MJ, Fossa SD, Bjordal K, Kaasa S. Test/retest study of the European Organization for Research and Treatment of Cancer Core quality-of-life questionnaire, 1249
Ho FCS, *see* Liang R
Hodgetts J, *see* Woll PJ
Hoekstra HJ, *see* Gels ME
Hoff JV, *see* Gandara DR
Hoffman AD, *see* Motzer RJ
Hoffman SL, *see* McQuellon RP
Hogan DK, *see* Tallman MS
Hogendoorn PCW, *see* Bunt AMG
Hohn DC, *see* Rubenstein EB
Hohneker J, *see* Jones S
— *see* Weber BL
Hohneker JA, *see* Vokes EE
Holcombe RF, *see* Leichman CG
Holcroft C, *see* Falkson G
Holford T, *see* Doria R
Holland J, *see* Aisner J
Holland JF, *see* Sundaresan N

Hollema H, *see* van der Zee AGJ
Hollis DR, *see* Lilenbaum RC
— *see* Miller AA
Holmberg L, *see* Jansson T
Holmes FA, *see* Valero V
Homesley HD, *see* Gandara DR
— *see* McGuire WP
Hon J, *see* Elledge RM
Hong WK, *see* Fossella FV
— *see* Lee JS
Hoon DSB, Wang Y, Dale PS, Conrad AJ, Schmid P, Garrison D, Kuo C, Foshag LJ, Nizze AJ, Morton DL. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay, 2109
Hop W, *see* Sonneveld P
Hop WCJ, *see* Busch ORC
— *see* van der Gaast A
Hoppe RT, *see* Bartlett NL
Hord M, *see* Kavanagh J
Horning SJ, *see* Bartlett NL
— *see* Yuen AR
Horsfall DJ, *see* Birrell SN
Hortobagyi GN, *see* Jaiyesimi IA
— *see* Valero V
Horwich A, *see* Hill M
— *see* Stevens MJ
Hoskins W, *see* Fennelly D
— *see* Francis P
Hoskins WJ, *see* McGuire WP
Hough L, *see* Sundaresan N
Houghton F, *see* O'Rourke N
Hou-Jensen K, *see* Pedersen-Bjergaard J
Howard S, *see* Hughes-Davies L
Howell K, *see* Leonard CE
Hromas R, *see* Broun ER
Huang Y, *see* Minsky BD
Huber M, *see* Fossella FV
Hudis C, *see* Seidman AD
Hudis CA, *see* Seidman AD
Hudson M, *see* Ribeiro RC
Hudson MM, Pratt CB. In reply (letter), 2143
— *see* Beaty O III
Huelskamp AM, *see* Kennedy MJ
Huelskamp A-M, *see* Passos-Coelho JL
Huffman DH, *see* Navari RM
Hughes-Davies L, Sacks D, Rescigno J, Howard S, Harris J. Serum cardiac troponin T levels during treatment of early-stage breast cancer, 2582
Huhn D, *see* Beyer J
Hulka B, *see* Millikan R
Hunt MA, *see* Lee WR
Hupkes PE, *see* Lambrechts C
Hurria A, *see* Kuzel TM
Huss H, *see* O'Rourke N
Hutchins L, *see* Jones S
— *see* Weber BL
Hutchison RE, Berard CW, Shuster JJ, Link MP, Pick TE, Murphy SB. B-cell lineage confers a favorable outcome among children and adolescents with large-cell lymphoma: A Pediatric Oncology Group study, 2023
— *see* Grever M
Hwang L, *see* Somlo G

Ichikawa M, *see* Yamamoto K
Igwemezie LN, *see* Kaul S
Illiger H-J, *see* Atzpodien J
Imeson J, *see* Pritchard J
Imeson JD, Pritchard J. In reply (letter), 1530
Inganäs M, *see* Jansson T
Iosilevsky G, *see* Even-Sapir E
Isacson R, *see* Uziely B
Isquith P, *see* Waber DP
Israel O, *see* Even-Sapir E
Iveson A, *see* Andreyev HJN
— *see* Hill M
Iveson T, *see* Hill M

Jacobs P, *see* Gahrton G
Jacobs SC, *see* Eisenberger MA
Jaffe ES, *see* Wilson WH
Jahanzeb M, *see* Vokes EE
Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: Twenty-eight years later, 513
Jakacki RI, Schramm CM, Donahue BR, Haas F, Allen JC. Restrictive lung disease following treatment for malignant brain tumors: A potential late effect of craniospinal irradiation, 1478
—, Zeltzer PM, Boyett JM, Albright AL, Allen JC, Geyer JR, Rorke LB, Stanley P, Stevens KR, Wisoff J, McGuire-Cullen PL, Milstein JM, Packer RJ, Finlay JL. Survival and prognostic factors following radiation and/or chemotherapy for primitive neuroectodermal tumors of the pineal region in infants and children: A report of the Childrens Cancer Group, 1377
Jakse G, *see* Atzpodien J
James K, *see* Browman GP
James RD, *see* Radford JA
Jamis-Dow C, *see* Wilson WH
Janicek M, *see* Shipp MA
Janin N, *see* Le Cesne A
Janisch L, *see* Kobayashi K
Janssen WE, *see* Fields KK
Jansson T, Inganäs M, Sjögren S, Norberg T, Lindgren A, Holmberg L, Bergh J. p53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: A novel hypothesis based on clinical findings, 2745
—, Westlin JE, Ahlström H, Lilja A, Långström B, Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: A method for early therapy evaluation? 1470
Jarosinski P, *see* Freifeld AG
Jaubert J, *see* Archimbaud E
Jauch K-W, *see* Heiss MM
Jaworsky C, *see* Wolfe JT
Jeekel J, *see* Busch ORC
Jeffers S, *see* Uziely B
Jendiroba D, *see* Buzaid AC
Jenkin D. Second malignancy tumors following Hodgkin's disease in children (letter), 2143
Jenkins J, *see* Bedikian AY
Jenkins T, *see* Heideman RL

Jeremic B, Shibamoto Y, Acimovic L, Djuric L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non–small-cell lung cancer, 452
Jérôme M, *see* Agadir A
Jessup JM. Is bigger better? (editorial), 5
Jewett MAS, *see* Warde P
Jodrell DI, *see* Eisenberger MA
Joensuu H, Toikkanen S. Cured of breast cancer? 62
Joffe J, *see* Hill M
Johanson WG for the American Board of Internal Medicine Recertification Committee. The American Board of Internal Medicine Recertification Program: Nearing liftoff (letter), 1831
Johansson H, *see* von Schoultz E
Johnson BE, Linnoila RI, Williams JP, Venzon DJ, Okunieff P, Anderson GB, Richardson GE. Risk of second aerodigestive cancers increases in patients who survive free of small-cell lung cancer for more than 2 years, 101
Johnson D, *see* Loehrer PJ Sr
Johnson DH, Einhorn LH. Paclitaxel plus carboplatin: An effective combination chemotherapy for advanced non–small-cell lung cancer or just another Elvis sighting? (editorial), 1840
— *see* Ettinger DS
— *see* Wolff AC
Johnson PWM, Rohatiner AZS, Whelan JS, Price CGA, Love S, Lim J, Matthews J, Norton AJ, Amess JAL, Lister TA. Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center, 140
Johnson RJ, *see* Radford JA
Johnston D, *see* Browman GP
Johnston S, *see* Smith IE
Jonas U, *see* Atzpodien J
Jones A, *see* Smith IE
Jones PM, *see* Crist W
Jones RJ, *see* Bedi A
Jones S, Winer E, Vogel C, Laufman L, Hutchins L, O'Rourke M, Lembersky B, Budman D, Bigley J, Hohneker J. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer, 2567
— *see* Weber BL
Jones SE, *see* Hayes DF
— *see* Vokes EE
Jønsson V, *see* Pedersen-Bjergaard J
Juliusson G, Heldal D, Hippe E, Hedenus M, Malm C, Wallman K, Stolt C-M, Evensen SA, Albertioni F, Tjønnfjord G, Lenkei R, Liliemark J. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia, 989
Jung S-H, *see* Creagan ET
Junghans RP, Kingsbury GA. Medullary carcinoma of breast: Pleural effusions, tumor tissue needed (letter), 799
Jürgens H, *see* Boos J

Kaasa S, *see* Hjermstad MJ
Kadin M, *see* Tubergen DG
Kadin ME, *see* Paulli M
Kalapurakal SK, *see* Lee JS
Kalechman Y, *see* Sredni B
Kalish LA, *see* Lew MA
Kamel OW, *see* Yuen AR
Kamen BA, Frenkel E, Colvin OM. Ifosfamide: Should the honeymoon be over? 307
—, Frenkel E, Colvin OM. In reply (letter), 1825
Kampono N, *see* Tattersall MHN
Kane M, *see* Ravdin PM
Kang SB, *see* Tattersall MHN
Kangas L, *see* Gylling H
Kanis JA, *see* O'Rourke N
Kantarjian H, *see* Sacchi S
Kantarjian HM, Talpaz M, Hester J, Feldman E, Korbling M, Liang J, Rios MB, Smith TL, Calvert L, Deisseroth AB. Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy, 553
— *see* Anderlini P
Kantoff PW, *see* Bajorin DF
Kaplan LD. Human immunodeficiency virus-associated neoplasia: Changing spectrum? (editorial), 2684
Karp D, *see* Gandara DR
Kato Y, *see* Maeda K
Kaufman B, *see* Sredni B
Kaufman PA, *see* Valone FH
Kaufmann SH, *see* Rowinsky EK
Kaul S, Igwemezie LN, Stewart DJ, Fields SZ, Kosty M, Levithan N, Bukowski R, Gandara D, Goss G, O'Dwyer P, Schacter LP, Barbhaiya RH. Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors, 2835
Kavanagh J, Tresukosol D, Edwards C, Freedman R, Gonzalez de Leon C, Fishman A, Mante R, Hord M, Kudelka A. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer, 1584
Kavanagh JJ, *see* Kudelka AP
Kawahara M, *see* Furuse K
Kaye S, *see* Paz-Ares L
Kayitalire L, *see* Le Cesne A
Kearns C, *see* Seidman AD
Kearns CM, *see* Gianni L
Keating A, *see* Colwill R
Kehoe K, *see* Lew MA
Keizer HJ, *see* Steyerberg EW
Kellie SJ, *see* Heideman RL
Kelligher K, *see* Sundaresan N
Kelly K, Crowley JJ, Bunn PA Jr, Hazuka MB, Beasley K, Upchurch C, Weiss GR, Hicks WJ, Gandara DR, Rivkin S, Livingston R. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: A Southwest Oncology Group study, 2924
— *see* Bunn PA Jr
Kelly WK, Curley T, Leibertz C, Dnistrian A, Schwartz M, Scher HI. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer, 2208
—, Scher HI, Mazumdar M, Pfister D, Curley T, Leibertz

C, Cohen L, Vlamis V, Dnistrian A, Schwartz M. Suramin and hydrocortisone: Determining drug efficacy in androgen-independent prostate cancer, 2214
— *see* Ghossein RA
Kelsen DP, Portenoy RK, Thaler HT, Niedzwiecki D, Passik SD, Tao Y, Banks W, Brennan MF, Foley KM. Pain and depression in patients with newly diagnosed pancreas cancer, 748
Kemeny N. Chemotherapy for colorectal carcinoma: One small step forward, one step backward (editorial), 1287
Kemeny NE. In reply (letter), 2677
Kennedy MJ. High-dose chemotherapy of breast cancer: Is the question answered? (editorial), 2477
—, Armstrong DK, Huelskamp AM, Ohly K, Clarke BV, Colvin OM, Grochow LB, Chen T-L, Davidson NE. Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer, 1136
— *see* Passos-Coelho JL
Kerbrat P, *see* Chevallier B
Kerr DJ, Ledermann JA, McArdle CS, Buckels J, Neoptolemos J, Seymour M, Doughty J, Budden J, Taylor I. Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil, 2968
Kerr H, *see* Carmichael J
Kersey JH, *see* Tubergen DG
Kessler JF, *see* Hesketh PJ
Khamsi F, *see* Winquist EW
Khan AA, *see* Villablanca JG
Kher U, *see* Faulkner LB
Khouri IF, *see* van Besien KW
Kies M, *see* Vokes EE
Kikuchi A, *see* Yamamoto K
Kilbourn RG, *see* Logothetis CJ
Kim JA, *see* Triozzi PL
Kindl S, *see* Paulli M
King D, *see* Tubergen DG
Kingsbury GA, *see* Junghans RP
Kingsley LA, *see* Lyter DW
Kingston JE, Plowman PN, Wright J. Radiotherapy still has a major role in the management of localized orbital rhabdomyosarcoma (letter), 798
Kinney MC, *see* Nadali G
Kinzie J, *see* Leonard C
Kirchner H, *see* Atzpodien J
Kirkpatrick A, *see* Postmus PE
— *see* Santoro A
— *see* Schornagel JH
Klarnet J, *see* Bensinger W
Klastersky, J for the European Lung Cancer Working Party, *see* Paesmans M
Klecker RW, *see* Wilson WH
Klein JL, *see* Herpst JM
Klersy C, *see* Paulli M
Kluin-Nelemans JC, *see* Teodorovic I
Klumpp TR, Goldberg SL, Mangan KF. Effect of granulocyte colony-stimulating factor on the rate of neutrophil engraftment following peripheral-blood stem-cell transplantation (letter), 2144
—, Mangan KF, Goldberg SL, Pearlman ES, Macdonald JS. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: A prospective, randomized trial, 1323
Kneebone PH, *see* Broun ER
Knopf K, *see* Minsky BD
Kobayashi K, Vokes EE, Vogelzang NJ, Janisch L, Soliven B, Ratain MJ. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer, 2196
Kodama N, *see* Furuse K
Kodish E, Post SG. Oncology and hope, 1817
— *see* Daugherty C
Kohler DR, *see* Wilson WH
Köhne C-H, Hiddemann W, Schüller J, Weiss J, Lohrmann H-P, Schmitz-Hübner U, Bodenstein H, Schöber C, Wilke H, Grem J, Schmoll H-J. Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: A prospective randomized trial, 1201
Koier I, *see* van Warmerdam LJC
Kojian A, *see* Somlo G
Kolodny GM, *see* Even-Sapir E
Kondo Y, *see* Maeda K
Konrad K, *see* Leitzel K
Koops HS, *see* Gels ME
— *see* Steyerberg EW
Kopecky K, *see* Grever M
Korbling M, *see* Kantarjian HM
— *see* van Besien KW
Koren G, *see* Theis JGW
Kormanik P, *see* Chamberlain MC
Kornblau SM, *see* Anderlini P
Kosty M, *see* Kaul S
— *see* Saven A
Kosty MP, Herndon JE II, Green MR, McIntyre OR for the Cancer and Leukemia Group B. Placebo-controlled randomized study of hydrazine sulfate in lung cancer (letter), 1529
Kotasek D, *see* Hardingham JE
Kotitsa Z, *see* De Bernardi B
Kovnar EH, *see* Heideman RL
Kozloff M, *see* Vokes EE
Krailo MD, *see* Tubergen DG
Krakoff IH, *see* Lee JS
Krakowski I, *see* Bui BN
— *see* Chevallier B
Kramar A, *see* Arriagada R
Kramer B, *see* Harlan L
Krans M, *see* van der Zee AGJ
Kraus DH, *see* Pfister DG
Kris E, *see* Vaughan WP
Kris MG, *see* Hesketh PJ
Krismann M, Todt B, Schröder J, Gareis D, Müller K-M, Seeber S, Schütte J. Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination, 2769
Kristinsson J, *see* Schmiegelow K
Kroll S, *see* Roach M III
Krook JE, *see* Goldberg RM

— *see* Wiesenfeld M
Krümpelmann S, *see* Boos J
Kubota K, *see* Furuse K
Kucera PR, *see* Barnhill DR
Kudelka A, *see* Kavanagh J
Kudelka AP, Siddik ZH, Balat O, Kavanagh JJ, de Leon CG, Tresukosol D. Carboplatin dosimetry in renal failure (letter), 2147
Kudoh S, *see* Furuse K
Kugler J, *see* Creagan ET
Kuhn JG, *see* Rinaldi DA
Kuijpers AJ, *see* van der Donk J
Kun L, *see* Ribeiro RC
Kun LE, *see* Beaty O III
— *see* Heideman RL
Kuo C, *see* Hoon DSB
Kurman RJ, *see* Barnhill DR
Kurzrock R, *see* Seymour JF
Kushner BH, Meyers PA, Gerald WL, Healey JH, La Quaglia MP, Boland P, Wollner N, Casper ES, Aledo A, Heller G, Schwartz GK, Bonilla MA, Lindsley KL, Merchant TE, Rosenfield NS, Abramson SJ, Cheung N-KV. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults, 2796
Kusunoki Y, *see* Furuse K
Kutsch K, *see* Uziely B
Kuzel TM, Roenigk HH Jr, Samuelson E, Herrmann JJ, Hurria A, Rademaker AW, Rosen ST. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome, 257
Kwiatkowski DJ, *see* Strauss GM
Kwong YL, *see* Liang R

La Quaglia M, *see* Faulkner LB
La Quaglia MP, *see* Kushner BH
Labianca R, *see* Lise M
Laffranchi A, *see* Gianni L
Lai JL, *see* Preudhomme C
Lamar RE, *see* Greer JP
Lambrechts C, Hupkes PE, Dorssers L, van't Veer MB. In reply (letter), 795
Langdon RM Jr, *see* Creagan ET
Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S, Ozols RF. Paclitaxel and carboplatin in combination in the treatment of advanced non–small-cell lung cancer: A phase II toxicity, response, and survival analysis, 1860
— *see* Fein DA
Langlands AO, *see* Ung O
Langleben A, *see* Miller AA
Langley C, *see* Rinaldi DA
Langston JA, *see* Heideman RL
Långström B, *see* Jansson T
Laskey J, *see* Winquist EW
Lassen U, Østerlind K, Hansen M, Dombernowsky P, Bergman B, Hansen HH. Long-term survival in small-cell lung cancer: Posttreatment characteristics in patients surviving 5 to 18+ years—An analysis of 1,714 consecutive patients, 1215
Latza U, *see* Nadali G
Laufman L, *see* Jones S
Laupacis A, *see* Browman GP
Laurence D, *see* Rubenstein EB
Laurie JA, *see* Moertel CG
Law TM, *see* Motzer RJ
Lawrence W, *see* Crist W
Lazarus HM, *see* Fields KK
Lazzarino M. In reply (letter), 530
— *see* Paulli M
Le Cesne A, Antoine E, Spielmann M, Le Chevalier T, Brain E, Toussaint C, Janin N, Kayitalire L, Fontaine F, Genin J, Vanel D, Contesso G, Tursz T. High-dose ifosfamide: Circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas, 1600
Le Chevalier T, *see* Le Cesne A
— *see* Smith TJ
Le Moine F, *see* Ravoet C
Leber BF, *see* Meyer RM
Leblond V, Sutton L, Dorent R, Davi F, Bitker M-O, Gabarre J, Charlotte F, Ghoussoub J-J, Fourcade C, Fischer A, Gandjbakhch I, Binet J-L, Raphael M. Lymphoproliferative disorders after organ transplantation: A report of 24 cases observed in a single center, 961
— *see* Archimbaud E
Ledermann JA, *see* Kerr DJ
Lee HP, *see* Tattersall MHN
Lee JJ, *see* Buzaid AC
— *see* Lee JS
Lee JS, Newman RA, Lippman SM, Fossella FV, Calayag M, Raber MN, Krakoff IH, Hong WK. Phase I evaluation of all-*trans* retinoic acid with and without ketoconazole in adults with solid tumors, 1501
—, Yoon A, Kalapurakal SK, Ro JY, Lee JJ, Tu N, Hittelman WN, Hong WK. Expression of p53 oncoprotein in non–small-cell lung cancer: A favorable prognostic factor, 1893
— *see* Fossella FV
Lee KE, *see* Mamby CC
Lee MS, *see* Cabanillas F
Lee SM, *see* Bleehen NM
Lee WR, Hanks GE, Schultheiss TE, Corn BW, Hunt MA. Localized prostate cancer treated by external-beam radiotherapy alone: Serum prostate-specific antigen-driven outcome analysis, 464
— *see* Fein DA
Lefebvre JL, *see* Schornagel JH
Lefebvre P, *see* Agadir A
Lefor AT, *see* Eastridge BJ
Legha SS, *see* Bedikian AY
— *see* Buzaid AC
Leibel SA, *see* Zelefsky MJ
Leibertz C, *see* Kelly WK
Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Holcombe RF, Weiss GR, Mangalik A, Macdonald JS. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study, 1303
Leichner PK, *see* Herpst JM
Leighton JC, *see* Langer CJ
Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, Harvey H, Demers L, Lipton A. Ele-

vated serum c-*erb*B-2 antigen levels and decreased response to hormone therapy of breast cancer, 1129
Lembersky B, *see* Jones S
Lemon RH, *see* Saven A
Lenkei R, *see* Juliusson G
Lentz MA, *see* Chevallier B
Lenzi R, *see* Abbruzzese JL
Leonard C, Corkill M, Tompkin J, Zhen B, Waitz D, Norton L, Kinzie J. Are axillary recurrence and overall survival affected by axillary extranodal tumor extension in breast cancer? Implications for radiation therapy, 47
Leonard CE, Wood ME, Zhen B, Rankin J, Waitz DA, Norton L, Howell K, Sedlacek S. Does administration of chemotherapy before radiotherapy in breast cancer patients treated with conservative surgery negatively impact local control? 2906
Leong L, *see* Morgan RJ Jr
Leong LA, *see* Somlo G
Lepore J, *see* Seidman AD
Lerra I, *see* Pichert G
Lesser ML, *see* Rosen PP
Lessin SR, *see* Wolfe JT
Lester E, *see* Hesketh PJ
Letendre L, *see* Witzig TE
Levendag PC, *see* van der Donk J
Levine AM, *see* Gill PS
Levine M, *see* Rajan R
Levine MN, *see* Browman GP
— *see* Meyer RM
— *see* Whelan TJ
Levitan N, *see* Hainsworth JD
Levithan N, *see* Kaul S
Levitt G, *see* Sorensen K
Lev-Ran A, *see* Somlo G
Lew MA, Kehoe K, Ritz J, Antman KH, Nadler L, Kalish LA, Finberg R. Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: A randomized, controlled trial, 239
Lewis LD, *see* Valone FH
Li H, *see* Goedegebuure PS
Li Y, *see* Heideman RL
Lianes P, *see* Motzer RJ
Liang J, *see* Kantarjian HM
Liang R, Todd D, Chan TK, Chiu E, Lie A, Kwong YL, Choy D, Ho FCS. Treatment outcome and prognostic factors for primary nasal lymphoma, 666
Liau-Chu M, *see* Theis JGW
Libert P, *see* Paesmans M
Libshitz HI, *see* Moulopoulos LA
Libson E, *see* Uziely B
Lichter AS. Duplicate publication (letter), 2140
Lichtman SM, *see* Gandara DR
Lie A, *see* Liang R
Liebman HA, *see* Gill PS
Lilenbaum RC, Ratain MJ, Miller AA, Hargis JB, Hollis DR, Rosner GL, O'Brien SM, Brewster L, Green MR, Schilsky RL. Phase I study of paclitaxel and topotecan in patients with advanced tumors: A Cancer and Leukemia Group B study, 2230
Liliemark J, *see* Juliusson G
Lilja A, *see* Jansson T
Lilleby K, *see* Bensinger W
— *see* Demirer T
Lim J, *see* Johnson PWM
Limburg PC, *see* Veldhuis GJ
Linch DC, *see* Mills W
Lindgren A, *see* Jansson T
Lindsley KL, *see* Kushner BH
Link MP, *see* Hutchison RE
Linnoila RI, *see* Johnson BE
Lippman S, *see* Fossella FV
Lippman SM, *see* Lee JS
Lipton A, *see* Leitzel K
Lise M, Nitti D, Marchet A, Sahmoud T, Buyse M, Duez N, Fiorentino M, Dos Santos JG, Labianca R, Rougier P, Gignoux M. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer, 2757
Lister TA, *see* Johnson PWM
— *see* Radford JA
Litwin S, *see* Langer CJ
Liu ET, *see* Millikan R
Livingston R, *see* Bunn PA Jr
— *see* Grunberg SM
— *see* Kelly K
Livingston RB, *see* Albain KS
— *see* Seewaldt VL
Ljungman P, *see* Gahrton G
Llewellyn-Thomas HA, *see* Sawka CA
Lo Curto M, *see* Uderzo C
Locatelli A, *see* Gianni L
Locatelli F, *see* Uderzo C
Lockwood L, *see* McCowage GB
Loehrer PJ, *see* Faylona EA
Loehrer PJ Sr, Johnson D, Elson P, Einhorn LH, Trump D. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: An Eastern Cooperative Oncology Group trial, 470
Loehrer PJP Sr, Ansari R, Gonin R, Monaco F, Fisher W, Sandler A, Einhorn LH. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: A Hoosier Oncology Group study, 2594
Loehrs U, *see* Heiss MM
Loesch D, *see* Broun ER
Logothetis CJ, Finn LD, Smith T, Kilbourn RG, Ellerhorst JA, Zukiwski AA, Sella A, Tu S-M, Amato RJ. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: Results of a randomized trial, 2272
Lohrmann H-P, *see* Köhne C-H
Lomax L, *see* Woll PJ
Lonchyna VA, *see* Albain KS
Long GD, *see* O'Donnell MR
Long HJ. Neoadjuvant chemotherapy in cervix cancer: Is it effective? (letter), 2141
López JJ, *see* De Andrés L
López-Otín C, *see* Vizoso F
López-Pousa A, *see* De Andrés L
Loprinzi CL, *see* Goldberg RM
Lorusso V, *see* De Lena M

Lorvidhaya V, *see* Tattersall MHN
Louie AC, *see* Fyfe G
Love RR, Cleeland CS, Sherman CD Jr. The role of the American Society of Clinical Oncology in cancer control worldwide (letter), 300
— *see* Mamby CC
Love S, *see* Johnson PWM
Lowitt MH, *see* Eisenberger MA
Löwenberg B, *see* Sonneveld P
Lu P, *see* Rinaldi DA
Lubejko BG, *see* Rowinsky EK
Ludwig Ch, *see* Pabst Th
Ludwig W-D, *see* Reiter A
Luisi A, *see* Silvestrini R
Lukka H, *see* Whelan TJ
Luo X, *see* Beaty O III
Lussier F, *see* Waber DP
Lyn P, *see* Motzer RJ
Lynch TJ, *see* St.auss GM
Lyter DW, Bryant J, Thackeray R, Rinaldo CR, Kingsley LA. Incidence of human immunodeficiency virus-related and nonrelated malignancies in a large cohort of homosexual men, 2540

Macdonald JS, *see* Klumpp TR
— *see* Leichman CG
— *see* Moertel CG
MacEachern T, *see* De Conno F
Mackay B, *see* Anderlini P
Mackey SE, Creasman WT. Ovarian cancer screening, 783
Mackillop WJ, *see* Raby B
Macon WR, *see* Greer JP
MacVicar D, *see* Powles TJ
Madajewicz S, *see* Navari RM
Maeda K, Chung Y-S, Takatsuka S, Ogawa Y, Sawada T, Yamashita Y, Onoda N, Kato Y, Nitta A, Arimoto Y, Kondo Y, Sowa M. Tumor angiogenesis as a predictor of recurrence in gastric carcinoma, 477
Mäenpää H, *see* Gylling H
Maes RAA, *see* van Warmerdam LJC
Magillo P, *see* De Bernardi B
Magrini U, *see* Paulli M
Maguire YP, *see* Elledge RM
Mahmoud H, *see* Ribeiro RC
Maillaird JA for the North Central Cancer Treatment Group, Southwest Oncology Group, and Eastern Cooperative Oncology Group, *see* Moertel CG
Mailliard J, *see* Navari R
Mailliard JA, *see* Goldberg RM
— *see* Hayes DF
— *see* Wiesenfeld M
— *see* Witzig TE
Makris A, *see* Powles TJ
Malats N, Porta M, Piñol JL, Corominas JM, Rifà J, Real FX for the PANK-ras I Project Investigators. *Ki-ras* mutations as a prognostic factor in extrahepatic bile system cancer, 1679
Malm C, *see* Juliusson G
Mamby CC, Love RR, Lee KE. Thyroid function test changes with adjuvant tamoxifen therapy in postmenopausal women with breast cancer, 854
Mameghan H, *see* McCowage GB
Mamounas EP, *see* Fisher B
Manalo A, *see* Tattersall MHN
Mancini A, *see* De Bernardi B
Mangalik A, *see* Leichman CG
Mangan KF, *see* Klumpp TR
Mankin HJ, *see* Scully SP
Mansi J, *see* Hill M
Mante R, *see* Kavanagh J
Mantravadi R, *see* Blanke C
Mäntylä E, *see* Gylling H
Marchese N, *see* De Bernardi B
Marchet A, *see* Lise M
Marchi PF, *see* Uderzo C
Margarino G, *see* Corvò R
Margolin K, *see* Morgan RJ Jr
Margolin KA, *see* Somlo G
Margolis L, *see* Roach M III
Marincola FM, White DE, Wise AP, Rosenberg SA. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer, 1110
Marini B, *see* Bernardi D
Markman M, *see* Francis P
Marks L, *see* Seidman AD
Marquet RL, *see* Busch ORC
Marraro G, *see* Uderzo C
Marrink J, *see* Gels ME
Marschke RF, *see* Witzig TE
Marsden HB, *see* Pritchard J
Marshall D, *see* Freifeld AG
Martin EW, *see* Triozzi PL
Martin P, *see* Demirer T
Martini C, *see* Gianni L
Martino S, *see* Budd GT
Marziali S, *see* Cortelazzo S
Marzullo F, *see* De Lena M
Masera G, *see* Uderzo C
Masera G for the Associazione Italiana di Ematologia ed Oncologia Pediatrica, *see* Conter V
Mastrangelo MJ, *see* Berd D
Masuda N, *see* Furuse K
Mata J, *see* Sartor O
Matsui K, *see* Furuse K
Matthay KK, *see* Villablanca JG
Matthews J, *see* Johnson PWM
Mattsson A, *see* Arriagada R
Mauch PM, Canellos GP, Shulman LN, Silver B, Tarbell NJ, Come S, Rabin MS, Coleman CN. Mantle irradiation alone for selected patients with laparotomy-staged IA to IIA Hodgkin's disease: Preliminary results of a prospective trial, 947
Maugard-Louboutin C, *see* Bui BN
Maurer HM, *see* Crist W
— *see* Pappo AS
Mazumdar M, *see* Kelly WK
— *see* Motzer RJ
McAleer CA, *see* Langer CJ
McArdle CS, *see* Kerr DJ
McCarroll K, *see* Gandara DR
McCarthy P, *see* van Besien KW
McCloskey E, *see* O'Rourke N
McCowage GB, Vowels MR, Shaw PJ, Lockwood L, Mameghan H. Autologous bone marrow transplantation

for advanced neuroblastoma using teniposide, doxorubicin, melphalan, cisplatin, and total-body irradiation, 2789
McCully CL, *see* Blaney SM
McDaniel C, *see* Sessa C
McGuire P, *see* Finlay JL
McGuire WP, Hoskins WJ, Brady MF, Homesley HD, Creasman WT, Berman ML, Ball H, Berek JS, Woodward J. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group study, 1589
McGuire-Cullen P, *see* Cohen BH
McGuire-Cullen PL, *see* Jakacki RI
McIntyre OR for the Cancer and Leukemia Group B, *see* Kosty MP
McKenna RJ, *see* Albain KS
McKinna JA, *see* Smith IE
McLaughlin P, *see* Rodriguez MA
— *see* van Besien KW
— *see* Younes A
McMillan A, *see* Mills W
McQuellon RP, Muss HB, Hoffman SL, Russell G, Craven B, Yellen SB. Patient preferences for treatment of metastatic breast cancer: A study of women with early-stage breast cancer, 858
McSorley PA, *see* Smith TJ
Meadows AT. Curing cancer in children: Minimizing price, maximizing value (editorial), 1837
— *see* Tubergen DG
Mechinaud F, *see* Doz F
Medeiros C, *see* Patterson WB
Meerwaldt JH, *see* Teodorovic I
Meeuwis CA, *see* van der Donk J
Mehra R, *see* van Besien KW
Meijer CJLM, *see* Paulli M
Meisenberg BR. High-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support (letter), 1826
Meli C, *see* Dibenedetto SP
Melnyk A, *see* Younes A
Meloni G, *see* Uderzo C
Melton LJ, *see* Millikan R
Memoli V, *see* Valone FH
Mempel W, *see* Heiss MM
Menard P, *see* Somlo G
Menestrina F, *see* Nadali G
— *see* Paulli M
Mercatello A, *see* Merrouche Y
Merchant TE, *see* Kushner BH
Merino AM, *see* Vizoso F
Merola MC, *see* Tirelli U
Merrouche Y, Negrier S, Bain C, Combaret V, Mercatello A, Coronel B, Moskovtchenko J-F, Tolstoshev P, Moen R, Philip T, Favrot MC. Clinical application of retroviral gene transfer in oncology: Results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin, 410
— *see* Chevallier B
Mesía R, *see* De Andrés L
Messemer JE, *see* Baniel J
— *see* Steyerberg EW
Messina C, *see* Conter V
— *see* Uderzo C
Metzner B, *see* Atzpodien J
Meyer L, *see* Valone FH
Meyer RM, Browman GP, Samosh ML, Benger AM, Bryant-Lukosius D, Wilson WEC, Frank GL, Leber BF, Sternbach MS, Foster GA, Skingley P, Levine MN. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma, 2386
Meyers FJ, *see* Leichman CG
Meyers PA, *see* Kushner BH
Mezzetti M, *see* Silvestrini R
Mi J-X, *see* Hardingham JE
Miccoli P, *see* Sertoli MR
Michallet M, *see* Archimbaud E
— *see* Gahrton G
Michel J, *see* Paesmans M
Mick R, *see* Daugherty C
— *see* Vokes EE
Middleton G, *see* Hill M
Miettinen TA, *see* Gylling H
Milan S, *see* Hill M
Milano G, *see* Etienne MC
— *see* Schneider M
Miller AA, Herndon JE II, Hollis DR, Ellerton J, Langleben A, Richards F II, Green MR. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: A randomized phase III study of the Cancer and Leukemia Group B, 1871
— *see* Lilenbaum RC
Miller CB, *see* Bedi A
Miller KB, *see* Mitus AJ
Miller M, *see* Blanke C
Millikan R, Hulka B, Thor A, Zhang Y, Edgerton S, Zhang X, Pei H, He M, Wold L, Melton LJ, Ballard D, Conway K, Liu ET. p53 mutations in benign breast tissue, 2293
Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma, 588
Milroy R, *see* de Campos E
Milstein JM, *see* Cohen BH
— *see* Finlay JL
— *see* Jakacki RI
Minami H, Ando Y, Sakai S, Shimokata K. Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide, 191
Miniero R, *see* Conter V
— *see* Uderzo C
Minsky BD, Conti JA, Huang Y, Knopf K. Relationship of acute gastrointestinal toxicity and the volume of irradiated small bowel in patients receiving combined modality therapy for rectal cancer, 1409
Mirro JR Jr, *see* Rowland P
Mittal B, *see* Vokes EE
Mitus AJ, Antin JH, Miller KB. In reply (letter), 1829
—, Miller KB, Schenkein DP, Ryan HF, Parsons SK, Wheeler C, Antin JH. Improved survival for patients with acute myelogenous leukemia, 560
Mobayen H, *see* Schneider M

Moen R, *see* Merrouche Y
Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Maillaird JA for the North Central Cancer Treatment Group, Southwest Oncology Group, and Eastern Cooperative Oncology Group. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II Dukes' B2 colon cancer, 2936
— *see* Donohue JH
Moertel CL, *see* Boyer MW
Mohide EA, *see* Browman GP
— *see* Whelan TJ
Mohiuddin M, Regine WF, Stevens J, Rosato F, Barbot D, Biermann W, Cantor R. Combined intraoperative radiation and perioperative chemotherapy for unresectable cancers of the pancreas, 2764
Moksness J, *see* Breslow NE
Molenaar WM, *see* Gels ME
Molina A, *see* Somlo G
Mollman J, *see* Armstrong C
Mommen P, *see* Paesmans M
Monaco F, *see* Loehrer PJP Sr
Monfardini S, *see* Tirelli U
Montello M, *see* Abrams JS
Montgomery P, *see* Bensinger W
Monzeglio C, *see* Sertoli MR
Moore D, *see* Younes A
Moore F, *see* Sundaresan N
Moore M, *see* Warde P
Moore MAS, *see* Fennelly D
Moraglio L, *see* Patrone F
Moran WJ, *see* Vokes EE
Morgan RJ, *see* Somlo G
Morgan RJ Jr, Margolin K, Raschko J, Akman S, Leong L, Somlo G, Scanlon K, Ahn C, Carroll M, Doroshow JH. Phase I trial of carboplatin and infusional cyclosporine in advanced malignancy, 2238
Mori PG, *see* Conter V
Morley TL, *see* Valone FH
Morosato L, *see* Nadali G
Morris-Jones P, *see* Pritchard J
Morse M, *see* Tubergen DG
Mortimer J, *see* Ravdin PM
Morton DL, *see* Hoon DSB
Morton RF, *see* Creagan ET
Moskovtchenko J-F, *see* Merrouche Y
Mosseri V, *see* Broët P
— *see* Doz F
Motzer RJ, Lyn P, Fischer P, Lianes P, Ngo RL, Cordon-Cardo C, O'Brien JP. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma, 1958
—, Rodriguez E, Reuter VE, Bosl GJ, Mazumdar M, Chaganti RSK. Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site, 274
—, Schwartz L, Law TM, Murphy BA, Hoffman AD, Albino AP, Vlamis V, Nanus DM. Interferon alfa-2a and 13-*cis*-retinoic acid in renal cell carcinoma: Antitumor activity in a phase II trial and interactions in vitro, 1950
—, Sheinfeld J, Mazumdar M, Bajorin DF, Bosl GJ, Herr H, Lyn P, Vlamis V. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors, 2700
Moulopoulos LA, Dimopoulos MA, Smith TL, Weber DM, Delasalle KB, Libshitz HI, Alexanian R. Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma, 251
Mouridsen H, *see* Santoro A
Moynihan ME, *see* Seidman AD
Mross K. Multidrug-resistance modulation in metastatic breast cancer patients (letter), 303
Mrozek-Orlowski M, *see* Valone FH
Muggia F, *see* Gill PS
Muggia FM, *see* Leichman CG
— *see* Uziely B
Mulder A, *see* Sonneveld P
Mulder NH, *see* Veldhuis GJ
Mulders PFA, *see* Steyerberg EW
Mulhern RK, *see* Ribeiro RC
Mull B, *see* Veldhuis GJ
Müller G-W, *see* Atzpodien J
Müller K-M, *see* Krismann M
Müller-Hermelink HK, *see* Paulli M
Müller-Weihrich S, *see* Reiter A
Munker R, Hasenclever D, Brosteanu O, Hiller E, Diehl V for the German Hodgkin's Lymphoma Study Group. Bone marrow involvement in Hodgkin's disease: An analysis of 135 consecutive cases, 403
Munzone E, *see* Gianni L
Murphy BA, *see* Motzer RJ
Murphy R, *see* Blaney SM
Murphy RF, *see* Adamson PC
— *see* Bailey J
Murphy SB, *see* Hutchison RE
Murphy WK, *see* Fossella FV
Murray C, *see* Pichert G
Muss H, *see* Aisner J
Muss HB, *see* McQuellon RP
Myers CE, *see* Bitton RJ

Nadali G, Vinante F, Stein H, Todeschini G, Tecchio C, Morosato L, Chilosi M, Menestrina F, Kinney MC, Greer JP, Latza U, Perona G, Pizzolo G. Serum levels of the soluble form of CD30 molecule as a tumor marker in $CD30^+$ anaplastic large-cell lymphoma, 1355
Nademanee A, *see* O'Donnell MR
Nadler L, *see* Lew MA
Nahhas WA, *see* Gandara DR
Nakajima S, *see* Furuse K
Nanus DM, *see* Motzer RJ
Nash AG, *see* Powles TJ
Nath R, *see* van Besien KW
Navari R, Gandara D, Hesketh P, Hall S, Mailliard J, Ritter H, Friedman C, Fitts D on behalf of the Granisetron Study Group. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis, 1242
Navari RM, Madajewicz S, Anderson N, Tchekmedyian NS, Whaley W, Garewal H, Beck TM, Chang AY, Greenberg B, Caldwell KC, Huffman DH, Gould JR, Carron G, Ossi M, Anderson EM. Oral ondansetron

for the control of cisplatin-induced delayed emesis: A large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo, 2408
Needles BM. Erratum (letter), 1046
Negoro S, *see* Furuse K
Negrier S, *see* Merrouche Y
Negrin RS, *see* O'Donnell MR
Neighbors DM, *see* Smith TJ
Nelken B, *see* Preudhomme C
Nelson H, *see* Donohue JH
Neoptolemos J, *see* Kerr DJ
Netto G, *see* Sarkis AS
Neuberg D, *see* Shipp MA
— *see* Whittington R
— *see* Wolff AC
Neuenschwander S, *see* Doz F
Neugut AI, *see* Ahsan H
Newlands ES, *see* Bleehen NM
Newman RA, *see* Lee JS
Newton W, *see* Crist W
Ney K, *see* Steyerberg EW
Ngo RL, *see* Motzer RJ
Nichols CR, Gonin R, Foster R. Defining new standards for adjuvant therapy of testis cancer (editorial), 2681
— *see* Bajorin DF
Nicolson M, *see* Hill M
Nicolson MC, *see* Andreyev HJN
Nicolson V, *see* Andreyev HJN
— *see* Hill M
Niedzwiecki D, *see* Kelsen DP
Niell HB, *see* Bennett CL
Niesel T, *see* Atzpodien J
Nieuwenhuis K, *see* Sonneveld P
Nigro LL, *see* Dibenedetto SP
Nigro M, *see* De Bernardi B
Nikoskelainen J, *see* Gahrton G
Niland J, *see* O'Donnell MR
Niloff J, *see* Cannistra SA
Nishioka M, *see* Furuse K
Nitta A, *see* Maeda K
Nitti D, *see* Lise M
Nizze AJ, *see* Hoon DSB
Noe DA, *see* Rowinsky EK
Noga SJ, *see* Passos-Coelho JL
Noone M, *see* Berg SL
Noordijk EM, *see* Teodorovic I
Norberg T, *see* Jansson T
Norman A, *see* Hill M
Norman AR, *see* Andreyev HJN
— *see* Stevens MJ
Norman JE, *see* Hardingham JE
North L, *see* Younes A
Northfelt DW, *see* Timmerman JM
Norton AJ, *see* Johnson PWM
Norton L, *see* Fennelly D
— *see* Leonard C
— *see* Leonard CE
— *see* Rosen PP
— *see* Seidman AD
Nowak-Göttl U, *see* Boos J

O'Brien JP, *see* Motzer RJ
O'Brien M, *see* Hill M
O'Brien MER, *see* Powles TJ
O'Brien S, *see* Anderlini P
— *see* Sacchi S
O'Brien SG, Goldman JM. Current approaches to hematopoietic stem-cell purging in chronic myeloid leukemia (editorial), 541
O'Brien SM, *see* Lilenbaum RC
O'Bryan RM, *see* Budd GT
O'Connell MJ, *see* Wiesenfeld M
O'Connor AM, *see* Sawka CA
O'Connor DT, *see* Cubeddu LX
O'Connor T, *see* Blanke C
O'Donnell MR, Long GD, Parker PM, Niland J, Nademanee A, Amylon M, Chao N, Negrin RS, Schmidt GM, Slovak ML, Smith EP, Snyder DS, Stein AS, Traweek T, Blume KG, Forman SJ. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia, 2973
O'Dwyer P, *see* Kaul S
O'Dwyer PJ, *see* Langer CJ
Oettgen HF, *see* Herr HW
Oettle H, *see* Beyer J
O'Fallon JR, *see* Goldberg RM
Ogawa Y, *see* Maeda K
Ogawara M, *see* Furuse K
Ognibene FP, *see* Berg SL
Ohly K, *see* Kennedy MJ
— *see* Passos-Coelho JL
O'Keefe RJ, *see* Scully SP
Okunieff P, *see* Johnson BE
Olivier JP, *see* Chevallier B
Omura GA, *see* Barnhill DR
Onetto N, *see* Abrams JS
— *see* Seidman AD
Onoda N, *see* Maeda K
Orecchia R, *see* Corvò R
O'Reilly S, *see* Browman GP
O'Rourke M, *see* Jones S
O'Rourke N, McCloskey E, Houghton F, Huss H, Kanis JA. Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases, 929
Ortega J, *see* Crist W
Osborne CK, *see* Budd GT
O'Shaughnessy JA, *see* Berg SL
Ossi M, *see* Navari RM
Østerlind K, *see* Lassen U
O'Sullivan J, *see* Budd GT
Ottensmeier C, *see* Cannistra SA
Otto J, *see* Schneider M
Oza A, *see* Radford JA
Ozols RF, *see* Langer CJ

Pabst Th, Ludwig Ch. CA-125: A tumor marker in non-Hodgkin's lymphomas? (letter), 1827
Paciucci PA, *see* Sundaresan N
Packer RJ, *see* Jakacki RI
Packer RJ for the Childrens Cancer Group, *see* Finlay JL
Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van Cutsem OV, Sergysels R, Mommen P, Klastersky J for the European Lung Cancer Working Party. Prognostic factors for survival in

advanced non–small-cell lung cancer: Univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients, 1221
Pagani O, *see* Sessa C
Paganini E, *see* Sertoli MR
Palmer J, *see* Rubenstein EB
Palomera L, Domingo JM, Agulló JA, Romero MS. Complete remission in T-cell prolymphocytic leukemia with 2-chlorodeoxyadenosine (letter), 1284
Panasci L, *see* Aisner J
Panje W, *see* Vokes EE
Panzarella T, *see* Warde P
Pappo AS, Shapiro DN, Crist WM, Maurer HM. Biology and therapy of pediatric rhabdomyosarcoma, 2123
Parker PM, *see* O'Donnell MR
Parkinson DR, *see* Fyfe G
Parmer RJ, *see* Cubeddu LX
Parsons SK, *see* Mitus AJ
Parwaresch R, *see* Reiter A
Passik SD, *see* Kelsen DP
Passos-Coelho JL, Braine HG, Davis JM, Huelskamp A-M, Schepers KG, Ohly K, Clarke B, Wright SK, Noga SJ, Davidson NE, Kennedy MJ. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization, 705
Pastorino G, *see* Sertoli MR
Patel M, *see* Whelan TJ
Pater J, *see* Raby B
Patrone F, Ballestrero A, Ferrando F, Brema F, Moraglio L, Valbonesi M, Basta P, Ghio R, Gobbi M, Sessarego M. Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer, 840
Patterson WB, Emanuel EJ, Editors; Medeiros C, Presenter. The eligibility of women for clinical research trials, 293
Paul J, *see* Paz-Ares L
Paulli M, Berti E, Rosso R, Boveri E, Kindl S, Klersy C, Lazzarino M, Borroni G, Menestrina F, Santucci M, Gambini C, Vassallo G, Magrini U, Sterry W, Burg G, Geerts ML, Meijer, CJLM, Willemze R, Feller AC, Müller-Hermelink HK, Kadin ME CD30/Ki-1–positive lymphoproliferative disorders of the skin—Clinicopathologic correlation and statistical analysis of 86 cases: A multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group, 1343
Paz-Ares L, Paul J, Kaye S. Prognostic factors in bladder cancer after primary M-VAC (letter), 300
Pazdur R, *see* Cortes JE
— *see* Wiesenfeld M
Pearce R, *see* Mills W
Pearlman ES, *see* Klumpp TR
Pearson D, *see* Pritchard J
Pedersen M, *see* Pedersen-Bjergaard J
Pedersen-Bjergaard J, Jønsson V, Pedersen M, Hou-Jensen K. Leiomyosarcoma of the urinary bladder after cyclophosphamide (letter), 532
— Long-term complications of cancer chemotherapy (editorial), 1534
Pei H, *see* Millikan R
Pellecchia A, *see* De Lena M
Pelzer H, *see* Vokes EE
Pennington K, *see* Blanke C
Peny A-M, *see* Bui BN
Perez EA. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis, 1036
— *see* Gandara DR
Perez-Soler R, *see* Fossella FV
Perkins J, *see* Fields KK
Perkins JB, *see* Fields KK
Perloff M, *see* Aisner J
Perona G, *see* Nadali G
Perreault C, *see* Pichert G
Perry M, *see* Aisner J
Pession A, *see* Conter V
— *see* De Bernardi B
Peters LJ, *see* Terry NHA
Petersdorf S, *see* Bensinger W
Petersen FB, *see* Demirer T
Peterson BA for the Cancer and Leukemia Group B, *see* Canellos GP
Petrelli NJ. It is time to stratify with prognostic factors for hepatic metastases (letter), 2471
Petroni GR, *see* Canellos GP
Pettengell R, Woll PJ, Thatcher N, Dexter TM, Testa NG. Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood, 148
Pfister D, *see* Kelly WK
Pfister DG, Harrison LB, Strong EW, Shah JP, Spiro RW, Kraus DH, Armstrong JG, Zelefsky MJ, Fass DE, Weiss MH, Wang RC, Schantz SP, Bosl GJ. Organ-function preservation in advanced oropharynx cancer: Results with induction chemotherapy and radiation, 671
Pfreundschuh M, *see* Atzpodien J
Philip T, *see* Merrouche Y
Phillip P, *see* Carmichael J
Phillips K-A, Urch M, Bishop JF. Radiation-recall dermatitis in a patient treated with paclitaxel (letter), 305
Phillips TL, *see* Roach M III
Piccart M, *see* Roy J-A
Pichert G, Roy D-C, Gonin R, Alyea EP, Bélanger R, Gyger M, Perreault C, Bonny Y, Lerra I, Murray C, Soiffer RJ, Ritz J. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia, 1704
Pick TE, *see* Hutchison RE
Pielmeier T, *see* Atzpodien J
Pienta KJ. In reply (letter), 797
Pierce S, *see* Sacchi S
Pierce SA, *see* Anderlini P
Piersantelli N, *see* Bernardi D
Pinedo HM, van Groeningen CJ. Invited commentary (letter), 532
— *see* Dercksen MW
Pinfold SP, *see* Sawka CA
Piñol JL, *see* Malats N
Piro LD, *see* Saven A

Pittaluga S, *see* Teodorovic I
Pizzo PA, *see* Freifeld AG
Pizzolo G, *see* Nadali G
Plantaz D, *see* Doz F
Planting AST, *see* van der Gaast A
Plourde PV, Scott M. Duration of tamoxifen therapy and occurrence of endometrial cancer (letter), 2142
Plowman PN, *see* Kingston JE
Pluda J, *see* Adamson PC
Pluda JM, *see* Bailey J
Płużańska A, *see* Chmielowska E
Podczaski ES, *see* Gandara DR
Poirier SM, *see* Stephenson WT
Polchi P, *see* Uderzo C
Poletti M, *see* Valentini M
Poliwoda H, *see* Atzpodien J
Pollock RE, *see* Rubenstein EB
Pommerenke F, *see* Harlan L
Pontén J, *see* Sparén P
Poplack DG, *see* Adamson PC
— *see* Blaney SM
Porta M, *see* Malats N
Portenoy RK, *see* Kelsen DP
Possinger K, *see* Carmichael J
Post SG, *see* Kodish E
Postmus PE, Smit EF, Haaxma-Reiche H, van Zandwijk N, Ardizzoni A, Quoix E, Kirkpatrick A, Sahmoud T, Giaccone G for the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Teniposide for brain metastases of small-cell lung cancer: A phase II study, 660
Potemski P, *see* Chmielowska E
Pouillart P, *see* Broët P
Powles TJ, Hickish TF, Makris A, Ashley SE, O'Brien MER, Tidy VA, Casey S, Nash AG, Sacks N, Cosgrove D, MacVicar D, Fernando I, Ford HT. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer, 547
Prasco P, *see* Rubenstein EB
Pratt CB, *see* Beaty O III
— *see* Hudson MM
Prendiville J, *see* Smith IE
Presant CA, *see* Albain KS
Preudhomme C, Dervite I, Wattel E, Vanrumbeke M, Flactif M, Lai JL, Hecquet B, Coppin MC, Nelken B, Gosselin B, Fenaux P. Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: A report of 48 cases, 812
Price CGA, *see* Johnson PWM
Priest JR, *see* Boyer MW
Prins C, *see* Sessa C
Pritchard J, Imeson J, Barnes J, Cotterill S, Gough D, Marsden HB, Morris-Jones P, Pearson D. Results of the United Kingdom Children's Cancer Study Group First Wilms' tumor study, 124
— *see* Imeson JD
Pritchard KI, *see* Browman GP
Probst M, *see* Buer J
Pronzato P, *see* Sertoli MR
Prosnitz LR, *see* Doria R
Przepiorka D, *see* van Besien KW
Pugh W, *see* Touroutoglou N
Pui C-H, *see* Ribeiro RC
— *see* Rivera GK
Pyrhönen S, *see* Gylling H

Quadri SM, *see* Herpst JM
Queirolo P, *see* Sertoli MR
Quiet CA, Ferguson DJ, Weichselbaum RR, Hellman S. Natural history of node-negative breast cancer: A study of 826 patients with long-term follow-up, 1144
Quoix E, *see* Postmus PE

Raad I, *see* Rubenstein EB
Raber M, *see* Fossella FV
Raber MN, *see* Abbruzzese JL
— *see* Lee JS
Rabin MS, *see* Mauch PM
Raby B, Pater J, Mackillop WJ. Does knowledge guide practice? Another look at the management of non–small-cell lung cancer, 1904
Rademaker A, *see* Giovanazzi-Bannon S
— *see* Tallman MS
Rademaker AW, *see* Kuzel TM
Radford J, *see* de Campos E
Radford JA, Crowther D, Rohatiner AZS, Ryder WDJ, Gupta RK, Oza A, Deakin DP, Arnott S, Wilkinson PM, James RD, Johnson RJ, Lister TA. Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease, 2379
— *see* Clark ST
Raffy O, *see* Bergeron A
Ragab AH, *see* Crist W
Ragusa R, *see* Dibenedetto SP
Rai K, *see* Grever M
Rajan R, Gafni A, Levine M, Hirsh J, Gent M. Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: An economic evaluation, 42
Ralston SH, *see* Robertson AG
Ramage F, *see* Smith IE
Rambaldi A, *see* Cortelazzo S
Ramsay N.C, *see* Villablanca JG
Ramsey EW, *see* Brandes LJ
Randolph J, *see* Hainsworth JD
Raney RB, *see* Crist W
Rankin E, *see* Santoro A
Rankin J, *see* Leonard CE
Raphael M, *see* Leblond V
Raschko J, *see* Morgan RJ Jr
Raschko JW, *see* Somlo G
Ratain MJ, Rosner G, Allen SL, Costanza M, Van Echo DA, Henderson IC, Schilsky RL. Population pharmacodynamic study of amonafide: A Cancer and Leukemia Group B study, 741
— *see* Daugherty C
— *see* Kobayashi K
— *see* Lilenbaum RC
Ravdin PM, Burris HA III, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevois E, Bellet RE. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer, 2879

Ravoet C, Dargent J-L, Le Moine F, Feremans W. CA-125 in primary mediastinal B-cell lymphoma with sclerosis (letter), 530
Real FX for the PANK-ras I Project Investigators, *see* Malats N
Rebmann U, *see* Atzpodien J
Recht A. The return (?) of postmastectomy radiotherapy (editorial), 2861
Reed E, *see* Bitton RJ
Reed NS, *see* Robertson AG
Regine WF, *see* Mohiuddin M
Regis JA, *see* Wilson WH
Reich E, *see* Ayash LJ
Reich L, *see* Fennelly D
Reich SD, *see* Gandara DR
Reichman BS, *see* Seidman AD
Reiffers J, *see* Gahrton G
Reiter A, Schrappe M, Parwaresch R, Henze G, Müller-Weihrich S, Sauter S, Sykora K-W, Ludwig W-D, Gadner H, Riehm H. Non-Hodgkin's lymphomas of childhood and adolescence: Results of a treatment stratified for biologic subtypes and stage—A report of the Berlin-Frankfurt-Münster Group, 359
Renée N, *see* Etienne MC
Repetto L, *see* Bernardi D
Rescigno J, *see* Hughes-Davies L
Reuter NF, *see* Goldberg RM
Reuter VE, *see* Motzer RJ
— *see* Sarkis AS
Reyes F, *see* Hammel P
Reyno LM, Egorin MJ, Eisenberger MA, Sinibaldi VJ, Zuhowski EG, Sridhara R. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin, 2187
— *see* Eisenberger MA
— *see* Sridhara R
Reynolds CP, *see* Villablanca JG
Rhiner M, *see* Coluzzi PH
Ribeiro RC, Rivera GK, Hudson M, Mulhern RK, Hancock ML, Kun L, Mahmoud H, Sandlund JT, Crist WM, Pui C-H. An intensive re-treatment protocol for children with an isolated CNS relapse of acute lymphoblastic leukemia, 333
— *see* Rivera GK
Rice TW, *see* Albain KS
Richard J. Avoiding treatment errors: A suggestion (letter), 2860
Richards AI. Response of meningeal Waldenström's macroglobulinemia to 2-chlorodeoxyadenosine (letter), 2476
Richards F II, *see* Miller AA
Richardson GE, *see* Johnson BE
Richmond GC, *see* Goedegebuure PS
Ridge JA, *see* Fein DA
Riehm H, *see* Reiter A
Rifà J, *see* Malats N
Rinaldi DA, Burris HA, Dorr FA, Woodworth JR, Kuhn JG, Eckardt JR, Rodriguez G, Corso SW, Fields SM, Langley C, Clark G, Faries D, Lu P, Von Hoff DD. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation, 2842
Rinaldo CR, *see* Lyter DW
Rinehart JJ, *see* Budd GT
Rios MB, *see* Kantarjian HM
Ripamonti C, *see* De Conno F
Ritch PS, *see* Gandara DR
Ritter H, *see* Navari R
Ritz J, *see* Lew MA
— *see* Pichert G
Riva A, *see* Uderzo C
Rivera GK, Ribeiro RC, Pui C-H. Retrieval therapy for isolated CNS relapse in childhood acute lymphoblastic leukemia (letter), 1528
— *see* Ribeiro RC
Rivera L, *see* Coluzzi PH
Rivkin S, *see* Bunn PA Jr
— *see* Kelly K
Rivkin SE, Green S. In reply (letter), 1044
Rizzari C, *see* Conter V
Ro JY, *see* Lee JS
Roach M III, Gandara DR, Yuo H-S, Swift PS, Kroll S, Shrieve DC, Wara WM, Margolis L, Phillips TL. Radiation pneumonitis following combined modality therapy for lung cancer: Analysis of prognostic factors, 2606
Robert N, *see* Tallman MS
Robertshaw H, *see* Smith IE
Robertson AG, Reed NS, Ralston SH. Effect of oral clodronate on metastatic bone pain: A double-blind, placebo-controlled study, 2427
Roche H, *see* Chevallier B
Rodenhuis S, *see* Dercksen MW
— *see* van Warmerdam LJC
Roder DM, *see* Birrell SN
Rodrigue LJ, *see* Creagan ET
Rodriguez E, *see* Motzer RJ
Rodriguez G, *see* Rinaldi DA
Rodriguez MA, Cabanillas FC, Velasquez W, Hagemeister FB, McLaughlin P, Swan F, Romaguera JE. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP, 1734
— *see* Younes A
Roenigk HH Jr, *see* Kuzel TM
Roest FHJ, *see* van der Donk J
Rogers D, *see* De Bernardi B
Rohatiner AZS, *see* Johnson PWM
— *see* Radford JA
Rohr M, *see* Hall WA
Rolston KVI, *see* Rubenstein EB
Romaguera J, *see* Younes A
Romaguera JE, *see* Rodriguez MA
— *see* van Besien KW
Roman LD, *see* Barnhill DR
Romero I, *see* Waber DP
Romero MS, *see* Palomera L
Rondelli R, *see* Conter V
Rook AH, *see* Wolfe JT
Rorke LB, *see* Cohen BH
— *see* Jakacki RI
Rosai J, *see* Ghossein RA
Rosato F, *see* Mohiuddin M
Rose E, *see* Tallman MS
Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. p53 in node-negative breast carcinoma: An

immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis, 821
Rosen ST, *see* Kuzel TM
Rosenberg RK, *see* Vokes EE
Rosenberg SA, *see* Bartlett NL
— *see* Fyfe G
— *see* Marincola FM
— *see* Thom AK
Rosenfield NS, *see* Kushner BH
Rosenstock J, *see* Tubergen DG
Rosing H, *see* van Warmerdam LJC
Rosner G, *see* Ratain MJ
Rosner GL, *see* Lilenbaum RC
Ross ME, *see* Gill PS
Ross MI, *see* Buzaid AC
Rossi A, *see* Cortelazzo S
Rosso R, *see* Bertelli G
— *see* Paulli M
— *see* Sertoli MR
Rotstein S, *see* Arriagada R
Rougier P, *see* Lise M
Rouse P, *see* Hesketh PJ
Rousseau P. In reply (letter), 798
Rovelli A, *see* Uderzo C
Rowe JM, *see* Tallman MS
Rowinsky E, *see* Francis P
Rowinsky EK, Noe DA, Grochow LB, Sartorious SE, Bowling MK, Chen T-L, Lubejko BG, Kaufmann SH, Donehower RC. Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules, 1975
Rowland P, Wald ER, Mirro JR Jr, Yunis E, Albo VC, Wollman MR, Blatt J. Progressive varicella presenting with pain and minimal skin involvement in children with acute lymphoblastic leukemia, 1697
Rowley S, *see* Bensinger W
— *see* Demirer T
Roy D-C, *see* Pichert G
Roy J-A, de Valeriola D, Piccart M. Regarding the dilemma of adjuvant therapy in postmenopausal patients with node-positive estrogen receptor-positive breast cancer: Are we better informed? (letter), 1044
Rubagotti A, *see* Sertoli MR
Rubenstein EB, Fender A, Rolston KVI, Elting LS, Prasco P, Palmer J, Raad I, Pollock RE, Frisbee-Hume S, Laurence D, Hohn DC. Vascular access by physician assistants: Evaluation of an implantable peripheral port system in cancer patients, 1513
Rubin L, *see* Stephenson WT
Rubin M, *see* Freifeld AG
Rubin S, *see* Browman GP
Ruckdeschel JC, *see* Wolff AC
Ruffer J, *see* Armstrong C
Rusch VW, *see* Albain KS
Russell G, *see* McQuellon RP
Rustin GJS, *see* Bleehen NM
Rutqvist LE, *see* Arriagada R
Rutqvist L-E, *see* von Schoultz E
Ruymann FB, *see* Crist W
Ryan HF, *see* Mitus AJ
Ryder WDJ, *see* Radford JA
Rynard S, *see* Blanke C
Sacchi S, Kantarjian H, O'Brien S, Cohen PR, Pierce S, Talpaz M. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia, 2401
Sachdev VP, *see* Sundaresan N
Sacks D, *see* Hughes-Davies L
Sacks N, *see* Powles TJ
— *see* Smith IE
Sage RE, *see* Hardingham JE
Sahmoud T, *see* Lise M
— *see* Postmus PE
— *see* Schornagel JH
Saita L, *see* De Conno F
Sakai S, *see* Minami H
Sallan SE, *see* Waber DP
Salloum E, *see* Cooper DL
Salmi T, *see* Schmiegelow K
Salmon SE, Crowley JJ. In reply (letter), 1046
Salvadori B, *see* Silvestrini R
Salvioni R, *see* Bernardi D
Samosh ML, *see* Meyer RM
Samson D, *see* Gahrton G
Samuels BL, Bitran JD. High-dose intravenous melphalan: A review, 1786
Samuelson E, *see* Kuzel TM
Sánchez LM, *see* Vizoso F
Sanders J, *see* Bensinger W
— *see* Demirer T
Sanders M, Zuurmond W. Safety of unilateral and bilateral percutaneous cervical cordotomy in 80 terminally ill cancer patients, 1509
Sandler A, *see* Loehrer PJP Sr
Sandler AB, *see* Faylona EA
Sandlund JT, *see* Ribeiro RC
Sanford RA, *see* Heideman RL
Sanguineti G, *see* Corvò R
Sanson-Fisher RW, *see* Girgis A
Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, Buesa J, Casali P, Spooner D, Rankin E, Kirkpatrick A, Van Glabbeke M, van Oosterom A. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, 1537
Santucci M, *see* Paulli M
Sarkis AS, Bajorin DF, Reuter VE, Herr HW, Netto G, Zhang Z-F, Schultz PK, Cordon-Cardo C, Scher HI. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC, 1384
Sarma RP, *see* Ettinger DS
Sarris A, *see* Younes A
Sarris AH, *see* Touroutoglou N
Sartor O, Venable D, Mata J. Racial differences in radical prostatectomy (letter), 1823
Sartorious SE, *see* Rowinsky EK
Saudes L, *see* Schneider M
Sauter S, *see* Reiter A
Saven A, Lemon RH, Kosty M, Beutler E, Piro LD. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia, 570

Saville MW, *see* Bailey J
Sawada T, *see* Maeda K
Sawka CA, O'Connor AM, Llewellyn-Thomas HA, To T, Pinfold SP, Harrison-Woermke D. Appropriateness of adjuvant systemic therapy for axillary node-negative breast cancer: A physician opinion survey, 1459
Scanlon K, *see* Morgan RJ Jr
Scarborough MT, *see* Scully SP
Scavone M, *see* Goedegebuure PS
Schaasberg WP, *see* Dercksen MW
Schacter L, *see* Sessa C
Schacter LP, *see* Hainsworth JD
— *see* Kaul S
Schantz SP, *see* Pfister DG
Schegget JT, *see* Bavinck JNB
Schenkein DP, *see* Mitus AJ
Schepers KG, *see* Passos-Coelho JL
Scher HI, *see* Ghossein RA
— *see* Kelly WK
— *see* Sarkis AS
— *see* Schultz P
Schiffman K, *see* Bensinger W
— *see* Demirer T
Schildberg FW, *see* Heiss MM
Schilder RJ. In reply (letter), 2473
— Molecular markers and stem-cell transplants: Are they made for each other? (editorial), 1052
Schiller G. Dose-intensive treatment of acute myelogenous leukemia: Improved survival? (letter), 1828
Schiller M, *see* Waber DP
Schilsky RL, *see* Lilenbaum RC
— *see* Ratain MJ
Schipper H, Goh GR, Wang TL. Shifting the cancer paradigm: Must we kill to cure? (editorial), 801
Schmid P, *see* Hoon DSB
Schmidt GM, *see* O'Donnell MR
Schmiegelow K, Schrøder H, Gustafsson G, Kristinsson J, Glomstein A, Salmi T, Wranne L for the Nordic Society for Pediatric Hematology and Oncology. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy, 345
Schmitz PIM, *see* van der Donk J
Schmitz-Hübner U, *see* Köhne C-H
Schmoll H-J, *see* Bajorin DF
— *see* Bokemeyer C
— *see* Köhne C-H
Schneider J, *see* Fennelly D
— *see* Francis P
Schneider M, Etienne MC, Milano G, Thyss A, Otto J, Dassonville O, Mobayen H, Saudes L, Guillot T, Demard F. Phase II trial of cisplatin, fluorouracil, and pure *l* folinic acid for locally advanced head and neck cancer: A pharmacokinetic and clinical survey, 1656
— *see* Etienne MC
Schnipper L, *see* Ayash LJ
Schöber C, *see* Köhne C-H
Schoenfelder J, *see* Hayes DF
— *see* Vogel CL
Scholl SM, *see* Broët P
Schols, AMWJ, *see* Staal-van den Brekel AJ
Scholz H-J, *see* Atzpodien J
Schoof DD, *see* Goedegebuure PS
Schornagel JH, Verweij J, de Mulder PHM, Cognetti F, Vermorken JB, Cappelaere P, Armand JP, Wildiers J, de Graeff A, Clavel M, Sahmoud T, Kirkpatrick A, Lefebvre JL. Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: A European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study, 1649
Schouten H, *see* Sonneveld P
Schramm CM, *see* Jakacki RI
Schrappe M, *see* Reiter A
Schrøder H, *see* Schmiegelow K
Schröder J, *see* Krismann M
Schroeder G, *see* Witzig TE
Schüller J, *see* Köhne C-H
Schultheiss TE, *see* Lee WR
Schultz P, Zhang Z-F, Scher HI. In reply (letter), 301
Schultz PK, *see* Sarkis AS
Schulze-Westhoff P, *see* Boos J
Schütte J, *see* Krismann M
Schwalb DM, *see* Herr HW
Schwaner I, *see* Beyer J
Schwartz EL, *see* Wadler S
Schwartz G, *see* Ayash LJ
Schwartz GK, *see* Kushner BH
Schwartz L, *see* Motzer RJ
Schwartz M, *see* Kelly WK
Schwella N, *see* Beyer J
Scott JG, *see* Colwill R
Scott M, *see* Plourde PV
Scott-Mackie P, *see* Andreyev HJN
Sculier JP, *see* Paesmans M
Scully SP, Temple HT, O'Keefe RJ, Scarborough MT, Mankin HJ, Gebhardt MC. Role of surgical resection in pelvic Ewing's sarcoma, 2336
Sebag-Montefiore D, *see* Sorensen K
Sedlacek S, *see* Leonard CE
Seeber S, *see* Krismann M
Seeger RC, *see* Villablanca JG
Seewaldt VL, Cain JM, Greer BE, Tamimi HK, Figge DC, Livingston RB. Reviving the pelvic examination for evaluating the status of ovarian carcinoma (letter), 799
Seid J, *see* Doukas DJ
Seidman AD, Reichman BS, Crown JPA, Yao T-J, Currie V, Hakes TB, Hudis CA, Gilewski TA, Baselga J, Forsythe P, Lepore J, Marks L, Fain K, Souhrada M, Onetto N, Arbuck S, Norton L. Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response, 1152
—, Tiersten A, Hudis C, Gollub M, Barret S, Yao T-J, Lepore J, Gilewski T, Currie V, Crown J, Hakes T, Baselga J, Sklarin N, Moynihan ME, Tong W, Egorin M, Kearns C, Spriggs D, Norton L. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer, 2575
Selby P, *see* Bleehen NM
— *see* Hill M
Sella A, *see* Logothetis CJ
Sergysels R, *see* Paesmans M

Serke S, *see* Beyer J
Serraino D, *see* Tirelli U
Sertoli MR, Bruzzi P, Pronzato P, Queirolo P, Amoroso D, Del Mastro L, Venturini M, Vigani A, Bertelli G, Campora E, Boccardo F, Monzeglio C, Paganini E, Pastorino G, Canavese G, Catturich A, Cafiero F, Vecchio C, Miccoli P, Rubagotti A, Rosso R. Randomized cooperative study of perioperative chemotherapy in breast cancer, 2712
Sessa C, Zucchetti M, Cerny T, Pagani O, Cavalli F, De Fusco M, De Jong J, Gentili D, McDaniel C, Prins C, Schacter L, Winograd B, D'Incalci M. Phase I clinical and pharmacokinetic study of oral etoposide phosphate, 200
Sessarego M, *see* Patrone F
Seyedsadr MS, *see* Hainsworth JD
Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma, 575
Seymour L, *see* Bezwoda WR
Seymour M, *see* Kerr DJ
Shah JP, *see* Pfister DG
Shalet SM, *see* Clark ST
— *see* Didcock E
Shanahan TG, *see* Goldberg RM
Shani A, *see* Sredni B
Shapira J, *see* Sredni B
Shapiro DN, *see* Pappo AS
Shaw PJ, *see* McCowage GB
Sheinfeld J, *see* Motzer RJ
Shellito PC, *see* Willett CG
Shemano I, *see* Hayes DF
— *see* Vogel CL
Shepherd FA, *see* Winquist EW
Sherman CD Jr, *see* Love RR
Shibamoto Y, *see* Jeremic B
Shields DJ, *see* Byrd JC
Shih L-Y. In reply (letter), 794
Shildberg FW, *see* Heiss MM
Shimokata K, *see* Minami H
Shin DM, *see* Fossella FV
Shipp MA, Neuberg D, Janicek M, Canellos GP, Shulman LN. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: A dose-finding pilot study, 2916
Shrieve DC, *see* Roach M III
Shulman LN, *see* Mauch PM
— *see* Shipp MA
Shurin SB, *see* Cohen BH
Shuster JJ, *see* Hutchison RE
Shustik C, *see* Browman GP
Sicheri D, *see* Browman GP
Siddik ZH, *see* Kudelka AP
Siegert W, *see* Beyer J
Siegler M, *see* Daugherty C
Silver B, *see* Mauch PM
Silvestrini R, Daidone MG, Luisi A, Boracchi P, Mezzetti M, Di Fronzo G, Andreola S, Salvadori B, Veronesi U. Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer, 697
Silvestro S, *see* Bertelli G
Sinibaldi VJ, *see* Eisenberger MA
— *see* Reyno LM
— *see* Sridhara R
Sjögren S, *see* Jansson T
Skarin AT, *see* Strauss GM
Skingley P, *see* Meyer RM
Sklarin N, *see* Seidman AD
Slaper-Cortenbach ICM, *see* Dercksen MW
Sledge GW, *see* Broun ER
Sleijfer DT, *see* Veldhuis GJ
Sleijfer DTh, *see* Gels ME
— *see* Steyerberg EW
Slovak ML, *see* O'Donnell MR
Sluiter WJ, *see* van der Zee AGJ
Small EJ, *see* Timmerman JM
Smalley SR, Townsend PW. In reply (letter), 2140
Smetzer L, *see* Bedikian AY
Smit EF, *see* Postmus PE
Smit VTHBM, *see* Bunt AMG
Smith EP, *see* O'Donnell MR
Smith I, *see* Hill M
Smith IE, Walsh G, Jones A, Prendiville J, Johnston S, Gusterson B, Ramage F, Robertshaw H, Sacks N, Ebbs S, McKinna JA, Baum M. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer, 424
Smith T, *see* Logothetis CJ
Smith TJ, Bodurtha JN. Ethical considerations in oncology: Balancing the interests of patients, oncologists, and society, 2464
—, Hillner BE, Neighbors DM, McSorley PA, Le Chevalier T. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non–small-cell lung cancer, 2166
— *see* Bennett CL
Smith TL, *see* Kantarjian HM
— *see* Moulopoulos LA
— *see* Younes A
Snyder DS, *see* O'Donnell MR
Sogani PC, *see* Herr HW
Soiffer RJ, *see* Pichert G
Soliven B, *see* Kobayashi K
Somers R, *see* Santoro A
— *see* Teodorovic I
Somlo G, Doroshow JH, Lev-Ran A, Ahn DC, Hwang L, Raschko JW, Forman SJ, Margolin KA, Morgan RJ, Leong LA, Hamasaki VK, Chow WA, Molina A, Ahmad B, Akman SA, Kojian A, Menard P. Effect of low-dose prophylactic dopamine on high-dose cisplatin-induced electrolyte wasting, ototoxicity, and epidermal growth factor excretion: A randomized, placebo-controlled, double-blind trial, 1231
— *see* Morgan RJ Jr
Somma L, *see* Bajetta E
Sonneveld P, de Ridder M, van der Lelie H, Nieuwenhuis K, Schouten H, Mulder A, van Reijswoud I, Hop W, Lõwenberg B. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy, 2530
Sorensen K, Levitt G, Sebag-Montefiore D, Bull C, Sullivan I. Cardiac function in Wilms' tumor survivors, 1546

Souhrada M, *see* Seidman AD
Sowa M, *see* Maeda K
Sozzi M, *see* Valentini M
Spachynski K, *see* Bruera E
Sparén P, Gustafsson L, Friberg L-G, Pontén J, Bergström R, Adami H-O. Improved control of invasive cervical cancer in Sweden over six decades by earlier clinical detection and better treatment, 715
Sperduto PW, *see* Hall WA
Spielmann M, *see* Le Cesne A
Spiro RW, *see* Pfister DG
Spooner D, *see* Santoro A
Spreafico C, *see* Gianni L
Spriggs D, *see* Fennelly D
— *see* Seidman AD
Sredni B, Albeck M, Tichler T, Shani A, Shapira J, Bruderman I, Catane R, Kaufman B, Kalechman Y. Bone marrow-sparing and prevention of alopecia by AS101 in non–small-cell lung cancer patients treated with carboplatin and etoposide, 2342
Sridhara R, Eisenberger MA, Sinibaldi VJ, Reyno LM, Egorin MJ. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy, 2944
— *see* Broun ER
— *see* Eisenberger MA
— *see* Reyno LM
Staal-van den Brekel AJ, Dentener MA, Schols AMWJ, Buurman WA, Wouters EFM. Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients, 2600
Stampino CG, *see* Bajetta E
Stanley P, *see* Cohen BH
— *see* Jakacki RI
Stefanelli M, *see* Gianni L
Stehbens JA, *see* Cohen BH
Stein AS, *see* O'Donnell MR
Stein H, *see* Nadali G
Stein RS, *see* Greer JP
Steinberg SM, *see* Freifeld AG
— *see* Wilson WH
Steinherz PG. CNS leukemia: Problem of diagnosis, treatment, and outcome, 310
— *see* Tubergen DG
Stellato TA, *see* Willson JKV
Stelzer KJ, *see* Albain KS
Stephenson WT, Poirier SM, Rubin L, Einhorn LH. Evaluation of reproductive capacity in germ cell tumor patients following treatment with cisplatin, etoposide, and bleomycin, 2278
Sternbach MS, *see* Meyer RM
Sterry W, *see* Paulli M
Stevens J, *see* Mohiuddin M
Stevens KR, *see* Cohen BH
— *see* Jakacki RI
Stevens MFG, *see* Bleehen NM
Stevens MJ, Norman AR, Dearnaley DP, Horwich A. Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma, 87
Steward W, *see* de Campos E
— *see* Santoro A
Stewart AK, *see* Colwill R
Stewart DJ, *see* Kaul S
Stewart S, *see* Harrison M
Steyerberg EW, Keizer HJ, Fosså SD, Sleijfer DTh, Toner GC, Koops HS, Mulders PFA, Messemer JE, Ney K, Donohue JP, Bajorin D, Stoter G, Bosl GJ, Habbema JDF. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: Multivariate analysis of individual patient data from six study groups, 1177
Stocking C, *see* Daugherty C
Stolt C-M, *see* Juliusson G
Storb R, *see* Bensinger W
— *see* Demirer T
Stoter G, *see* Steyerberg EW
— *see* van der Gaast A
Strauss GM, Kwiatkowski DJ, Harpole DH, Lynch TJ, Skarin AT, Sugarbaker DJ. Molecular and pathologic markers in stage I non–small-cell carcinoma of the lung, 1265
Streiner DL, *see* Whelan TJ
Strobel T, *see* Cannistra SA
Strohscheer I, *see* Beyer J
Strong EW, *see* Pfister DG
Stuart ALO, *see* Didcock E
Sturgeon JFG, *see* Warde P
Sugarbaker DJ, *see* Strauss GM
Sullivan I, *see* Sorensen K
Sullivan K, *see* Demirer T
Sundaresan N, Sachdev VP, Holland JF, Moore F, Sung M, Paciucci PA, Wu L-T, Kelligher K, Hough L. Surgical treatment of spinal cord compression from epidural metastasis, 2330
Sung M, *see* Sundaresan N
Sutcliffe SB, *see* Colwill R
Sutton DMC, *see* Colwill R
Sutton L, *see* Leblond V
Sutton LN, *see* Finlay JL
Suurmeijer AJH, *see* van der Zee AGJ
Swan F, *see* Rodriguez MA
— *see* Younes A
Swanson L, *see* Cannistra SA
Swift PS, *see* Roach M III
Swindell R, *see* Clark ST
— *see* de Campos E
Sykora K-W, *see* Reiter A
Sylvester RJ, *see* Clahsen PC
Syrjänen K, *see* Chang F
Syrjänen S, *see* Chang F
Sznol M, *see* Fyfe G

Tabernero JM, *see* De Andrés L
Takada M, *see* Furuse K
Takashima JR, *see* Breslow NE
Takatsuka S, *see* Maeda K
Takifuji N, *see* Furuse K
Talamini R, *see* Bernardi D
— *see* Tirelli U
Tallman MS, Gray R, Bennett JM, Variakojis D, Robert N, Wood WC, Rowe JM, Wiernik PH. Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: The Eastern Cooperative Oncology Group experience, 1557

—, Hakimian D, Zanzig C, Hogan DK, Rademaker A, Rose E, Variakojis D. Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia, 983
Talpaz M, *see* Kantarjian HM
— *see* Sacchi S
— *see* Seymour JF
Tamaro P, *see* De Bernardi B
— *see* Uderzo C
Tamburrini A, *see* De Bernardi B
Tamimi HK, *see* Seewaldt VL
Tangen CM, *see* Leichman CG
— *see* Moertel CG
Tanimura M, *see* Yamamoto K
Tao Y, *see* Kelsen DP
Tarbell NJ, *see* Mauch PM
— *see* Waber DP
Tarenzi E, *see* Gianni L
Tattersall M. In reply (letter), 2141
Tattersall MHN, Lorvidhaya V, Vootiprux V, Cheirsilpa A, Wong F, Azhar T, Lee HP, Kang SB, Manalo A, Yen M-S, Kampono N, Aziz F for the Cervical Cancer Study Group of the Asian Oceanian Clinical Oncology Association. Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer, 444
Tavio M, *see* Tirelli U
Taylor I, *see* Kerr DJ
Taylor SA, *see* Albain KS
Tchekmedyian NS, *see* Navari RM
Tecchio C, *see* Nadali G
Tefft M, *see* Crist W
— *see* Finlay JL
Tegzess AM, *see* Bavinck JNB
Temple HT, *see* Scully SP
ten Bokkel Huinink WW, *see* van Warmerdam LJC
Teodorovic I, Pittaluga S, Kluin-Nelemans JC, Meerwaldt JH, Hagenbeek A, van Glabbeke M, Somers R, Bijnens L, Noordijk EM, De Wolf Peeters C for the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: Clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes, 2819
Teramoto Y, *see* Leitzel K
Terry NHA, Peters LJ. The predictive value of tumor-cell kinetic parameters in radiotherapy: Considerations regarding data production and analysis (editorial), 1833
Testa N, *see* de Campos E
Testa NG, *see* Pettengell R
Testa V, *see* Valentini M
Tester WJ, *see* Whittington R
Testi AM, *see* Conter V
Thackeray R, *see* Lyter DW
Thaler HT, *see* Kelsen DP
Thant M, *see* Elledge RM
Thatcher N, *see* Bleehen NM
— *see* de Campos E
— *see* Pettengell R
— *see* Woll PJ
The Italian Group for Antiemetic Research. Persistence of efficacy of three antiemetic regimens and prognostic factors in patients undergoing moderately emetogenic chemotherapy, 2417
Theis JGW, Liau-Chu M, Chan HSL, Doyle J, Greenberg ML, Koren G. Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: The causative role of improper dissolution of Cremophor EL, 2508
Theriault RL, *see* Valero V
Thiriaux J, *see* Paesmans M
Thom AK, Alexander HR, Andrich MP, Barker WC, Rosenberg SA, Fraker DL. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan, 264
Thomas X, *see* Archimbaud E
Thompson DS, *see* Hainsworth JD
Thompson EI, *see* Beaty O III
Thor A, *see* Millikan R
Thyss A, *see* Bui BN
— *see* Etienne MC
— *see* Schneider M
Tichler T, *see* Sredni B
Tidy VA, *see* Powles TJ
Tieben LM, *see* Bavinck JNB
Tiersten A, *see* Seidman AD
Tilley WD, *see* Birrell SN
Timmerman JM, Northfelt DW, Small EJ. Malignant germ cell tumors in men infected with the human immunodeficiency virus: Natural history and results of therapy, 1391
Timurian A, *see* De Lena M
Tinoco L, *see* Buzaid AC
Tinoco LA, *see* Buzaid AC
Tirelli U, Errante D, Dolcetti R, Gloghini A, Serraino D, Vaccher E, Franceschi S, Boiocchi M, Carbone A. Hodgkin's disease and human immunodeficiency virus infection: Clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and tumors, 1758
—, Monfardini S. Treatment of elderly patients with antineoplastic chemotherapy (letter), 1282
—, Vaccher E, Zagonel V, Talamini R, Bernardi D, Tavio M, Gloghini A, Merola MC, Monfardini S, Carbone A. CD30 (Ki-1)-positive anaplastic large-cell lymphomas in 13 patients with and 27 patients without human immunodeficiency virus infection: The first comparative clinicopathologic study from a single institution that also includes 80 patients with other human immunodeficiency virus-related systemic lymphomas, 373
Tirelli U for the Italian Cooperative Group on AIDS and Tumors, *see* Bernardi D
Tjønnfjord G, *see* Juliusson G
Tkaczuk KH, *see* Eisenberger MA
To T, *see* Sawka CA
Todd D, *see* Liang R
Todeschini G, *see* Nadali G
Todt B, *see* Krismann M
Toikkanen S, *see* Joensuu H
Tokars R, *see* Blanke C
Tolcher A, *see* Berg SL
Tolstoshev P, *see* Merrouche Y
Tomà P, *see* De Bernardi B

Tomlinson D, *see* Harrison M
Tompkin J, *see* Leonard C
Toner GC, *see* Steyerberg EW
Tong W, *see* Seidman AD
Tonini GP, *see* De Bernardi B
Tormey D, *see* Budd GT
Tormey DC, *see* Falkson G
— *see* Moertel CG
Touroutoglou N, Dimopoulos MA, Younes A, Hess M, Pugh W, Cox J, Cabanillas F, Sarris AH. Testicular lymphoma: Late relapses and poor outcome despite doxorubicin-based therapy, 1361
Toussaint C, *see* Le Cesne A
Townsend PW, *see* Smalley SR
Travade P, *see* Archimbaud E
Travis LB, Curtis RE, Hankey BF. Second malignancies after testicular cancer (letter), 533
Traweek T, *see* O'Donnell MR
Tresukosol D, *see* Kavanagh J
— *see* Kudelka AP
Trey JE, *see* Willson JKV
Triozzi PL, Kim JA, Martin EW, Young DC, Benzies T, Villasmil PM. Phase I trial of escalating doses of interleukin-1β in combination with a fixed dose of interleukin-2, 482
Troncy J, *see* Archimbaud E
Troussard X, Flandrin G. Optimal treatment for untreated patients with hairy cell leukemia? (letter), 2677
— *see* Archimbaud E
Trump D, *see* Loehrer PJ Sr
Tu N, *see* Lee JS
Tu S-M, *see* Logothetis CJ
Tu ZN, *see* Buzaid AC
Tubergen DG, Krailo MD, Meadows AT, Rosenstock J, Kadin M, Morse M, King D, Steinherz PG, Kersey JH. Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: A Childrens Cancer Group study, 1368
Tulpule A, *see* Gill PS
Tura S, *see* Gahrton G
Turrisi AT III, *see* Albain KS
Turski PA, *see* Finlay JL
Tursz T, *see* Le Cesne A
— *see* Santoro A

Uderzo C, Faccini P, Rovelli A, Arosio M, Marchi PF, Riva A, Marraro G, Balduzzi A, Masera G. Pulmonary thromboembolism in childhood leukemia: Eight-years' experience in a pediatric hematology center, 2805
Uderzo C, Valsecchi MG, Bacigalupo A, Meloni G, Messina C, Polchi P, Di Girolamo G, Dini G, Miniero R, Locatelli F, Colella R, Tamaro P, Lo Curto M, Di Tullio MT, Masera G. Treatment of childhood acute lymphoblastic leukemia in second remission with allogeneic bone marrow transplantation and chemotherapy: Ten-year experience of the Italian Bone Marrow Transplantation Group and the Italian Pediatric Hematology Oncology Association, 352
Uhlenhopp M, *see* Hesketh PJ
Ung O, Langlands AO, Barraclough B, Boyages J. Combined chemotherapy and radiotherapy for patients with breast cancer and extensive nodal involvement, 435
Ungerleider JS, *see* Moertel CG
Upchurch C, *see* Bunn PA Jr
— *see* Kelly K
Urch M, *see* Phillips K-A
Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, Libson E, Muggia FM, Gabizon A. Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies, 1777

Vaccher E, *see* Bernardi D
— *see* Tirelli U
Valagussa P, *see* Gianni L
Valbonesi M, *see* Patrone F
Valentini M, Cannizzaro R, Poletti M, Bortolussi R, Fracasso A, Testa V, Sozzi M, Fornasarig M, Bortoluzzi F, Grazioli I. Nonsteroidal antiinflammatory drugs for cancer pain: Comparison between misoprostol and ranitidine in prevention of upper gastrointestinal damage, 2637
Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN. Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer, 2886
Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Deo Y, Graziano R, Fisher JL, Meyer L, Mrozek-Orlowski M, Wardwell K, Guyre V, Morley TL, Arvizu C, Fanger MW. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/*neu*, 2281
Valsecchi MG, *see* Conter V
— *see* Uderzo C
van Besien KW, Khouri IF, Giralt SA, McCarthy P, Mehra R, Andersson BS, Przepiorka D, Gajewski JL, Bellare N, Nath R, Romaguera JE, McLaughlin P, Korbling M, Deisseroth AB, Cabanillas FF, Champlin RE. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: The case for aggressive management, 1096
Van Cutsem OV, *see* Paesmans M
van de Velde CJH, *see* Bunt AMG
— *see* Clahsen PC
van der Donk J, Levendag PC, Kuijpers AJ, Roest FHJ, Habbema JDF, Meeuwis CA, Schmitz PIM. Patient participation in clinical decision-making for treatment of T3 laryngeal cancer: A comparison of state and process utilities, 2369
van der Gaast A, Verweij J, Planting AST, Hop WCJ, Stoter G. Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site, 1720
van der Graaf WTA, *see* Veldhuis GJ
van der Lelie H, *see* Sonneveld P
van der Schoot CE, *see* Dercksen MW
van der Wall E, *see* Dercksen MW
Van Der Woude FJ, *see* Bavinck JNB
van der Zee AGJ, Hollema H, Suurmeijer AJH, Krans M, Sluiter WJ, Willemse PHB, Aalders JG, de Vries EGE. Value of p-glycoprotein, glutathione s-transferase pi, c-*erb* B-2, and p53 as prognostic factors in ovarian carcinomas, 70

van Driel OJR, *see* Clahsen PC
Van Echo DA, *see* Ratain MJ
van Gameren MM, *see* Veldhuis GJ
Van Glabbeke M, *see* Chevallier B
— *see* Santoro A
— *see* Teodorovic I
van Groeningen CJ, *see* Pinedo HM
Van Lint M, *see* Gahrton G
van Oosterom A, *see* Santoro A
van Reijswoud I, *see* Sonneveld P
van Warmerdam LJC, ten Bokkel Huinink WW, Rodenhuis S, Koier I, Davies BE, Rosing H, Maes RAA, Beijnen JH. Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion, 1768
van Zandwijk N, *see* Postmus PE
Van Zyl JA, *see* Hayes DF
VanEcho D, *see* Eisenberger MA
Vanel D, *see* Le Cesne A
Vannetzel JM, *see* Bergeron A
Vannice SB, *see* Goldberg HL
Vannier JP, *see* Doz F
Vanrumbeke M, *see* Preudhomme C
van't Veer MB, *see* Lambrechts C
Variakojis D, *see* Tallman MS
Vassallo G, *see* Paulli M
Vaughan WP, Kris E, Vose J, Bierman PJ, Gwilt P, Armitage JO. Phase I/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractory intermediate-grade and high-grade malignant lymphoma, 1089
Vecchio C, *see* Sertoli MR
Veeder MH, *see* Moertel CG
Vega M, *see* De Andrés L
Velasquez W, *see* Rodriguez MA
Veldhuis GJ, Willemse PHB, van Gameren MM, Aalders JG, Mulder NH, Mull B, Biesma B, de Vries EGE. Recombinant human interleukin-3 to dose-intensify carboplatin and cyclophosphamide chemotherapy in epithelial ovarian cancer: A phase I trial, 733
—, Willemse PHB, Sleijfer DT, van der Graaf WTA, Groen HJM, Limburg PC, Mulder NH, de Vries EGE. Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non–small-cell lung cancer, 2585
Vena DA, *see* Abrams JS
Venable D, *see* Sartor O
Ventrella V, *see* De Lena M
Venturini M, *see* Bertelli G
— *see* Sertoli MR
Venzon DJ, *see* Bitton RJ
— *see* Johnson BE
Verdonck L, *see* Gahrton G
Vermeer BJ, *see* Bavinck JNB
Vermorken JB, *see* Schornagel JH
Veronesi U, *see* Silvestrini R
Verweij J, *see* Santoro A
— *see* Schornagel JH
— *see* van der Gaast A
Vidili MG, *see* Bertelli G
Vielh P, *see* Doz F
Viero P, *see* Cortelazzo S
Vietti TJ, *see* Crist W
Vigani A, *see* Sertoli MR
Viganó L, *see* Gianni L
Villablanca JG, Khan AA, Avramis VI, Seeger RC, Matthay KK, Ramsay NKC, Reynolds CP. Phase I trial of 13-*cis*-retinoic acid in children with neuroblastoma following bone marrow transplantation, 894
Villani F, *see* Gianni L
Villasmil PM, *see* Triozzi PL
Vinante F, *see* Nadali G
Vitale V, *see* Corvò R
Vizoso F, Sánchez LM, Díez-Itza I, Merino AM, López-Otín C. Pepsinogen C is a new prognostic marker in primary breast cancer, 54
Vlamis V, *see* Kelly WK
— *see* Motzer RJ
Vogel C, *see* Jones S
— *see* Weber BL
Vogel CL, Schoenfelder J, Shemano I, Hayes DF, Gams RA. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer, 1123
— *see* Hayes DF
Vogelzang NJ, *see* Kobayashi K
Vokes EE, Kies M, Haraf DJ, Mick R, Moran WJ, Kozloff M, Mittal B, Pelzer H, Wenig B, Panje W, Weichselbaum RR. Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: Impact on the natural history of the disease, 876
—, Mick R, Haraf DJ, Weichselbaum RR. In reply (letter), 1282
—, Rosenberg RK, Jahanzeb M, Craig JB, Gralla RJ, Belani CP, Jones SE, Bigley JW, Hohneker JA. Multicenter phase II study of weekly oral vinorelbine for stage IV non–small-cell lung cancer, 637
— *see* Kobayashi K
Volas G, *see* Leitzel K
Volin L, *see* Gahrton G
Von dem Borne AEGKr, *see* Dercksen MW
Von Hoff DD, *see* Bedikian AY
— *see* Elledge RM
— *see* Rinaldi DA
von Schoultz E, Johansson H, Wilking N, Rutqvist L-E. Influence of prior and subsequent pregnancy on breast cancer prognosis, 430
Vootiprux V, *see* Tattersall MHN
Vose J, *see* Vaughan WP
Vose JM, Armitage JO. In reply (letter), 2474
— *see* Bennett CL
— *see* Yan Y
Vose MJ, Armitage JO. Clinical applications of hematopoietic growth factors, 1023
Vowels MR, *see* McCowage GB
Vriesendorp HM, *see* Herpst JM

Waber DP, Tarbell NJ, Fairclough D, Atmore K, Castro R, Isquith P, Lussier F, Romero I, Carpenter PJ, Schiller M, Sallan SE. Cognitive sequelae of treatment in childhood acute lymphoblastic leukemia: Cranial radiation requires an accomplice, 2490

Wadler S, Haynes H, Wiernik PH. Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea, 222
—, Schwartz EL. Chemotherapy for colorectal carcinoma: Observations regarding recent clinical trials using biochemical modulation (letter), 2676
Wainer IW, Ducharme J, Batist G. "Ifosfamide: Should the honeymoon be over?": A two-dimensional question for a three-dimensional problem (letter), 1824
Waitz D, *see* Leonard C
Waitz DA, *see* Leonard CE
Wald ER, *see* Rowland P
Wales JKH, *see* Didcock E
Wali P, *see* Harlan L
Walker I, *see* Browman GP
Walling J, *see* Carmichael J
Wallman K, *see* Juliusson G
Wallner KE, *see* Zelefsky MJ
Walsh G, *see* Smith IE
Walsh T, *see* Freifeld AG
Walter AW, *see* Heideman RL
Walters RS, *see* Valero V
Wampler GL, *see* Hainsworth JD
Wang RC, *see* Pfister DG
Wang TL, *see* Schipper H
Wang Y, *see* Hoon DSB
Wara WM, *see* Finlay JL
— *see* Roach M III
Warde P, Gospodarowicz MK, Panzarella T, Catton CN, Sturgeon JFG, Moore M, Goodman P, Jewett MAS. Stage I testicular seminoma: Results of adjuvant irradiation and surveillance, 2255
Wardwell K, *see* Valone FH
Warland G, *see* Willett CG
Warren D, *see* Ayash LJ
Warren GP, Einhorn LH. Gallium scans in the evaluation of residual masses after chemotherapy for seminoma, 2784
Waterhouse D, *see* Doukas DJ
Watson M, *see* Hill M
Wattel E, *see* Preudhomme C
Weaver C, *see* Bensinger W
Weaver CH, *see* Demirer T
Webb A, *see* Hill M
Webber B, *see* Crist W
Weber BL, Vogel C, Jones S, Harvey H, Hutchins L, Bigley J, Hohneker J. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer, 2722
Weber DM, *see* Moulopoulos LA
Weichselbaum RR, *see* Hellman S
— *see* Quiet CA
— *see* Vokes EE
Weick JK, *see* Albain KS
Weiden P, *see* Bensinger W
Weiden PL, Appelbaum JW. Perceptions of cancer patients and their physicians involved in phase I clinical trials (letter), 2472
Weisberg SR, *see* Gandara DR
Weisenburger DD, *see* Yan Y
Weiss GB. New and improved titles (letter), 1829
Weiss GR, *see* Bedikian AY
— *see* Bunn PA Jr
— *see* Kelly K
— *see* Leichman CG
Weiss J, *see* Köhne C-H
Weiss MH, *see* Pfister DG
Wei-Tsao D, *see* Uziely B
Wells RJ. Phase II window therapy (letter), 302
Welvaart K, *see* Clahsen PC
Wenig B, *see* Vokes EE
Westlin JE, *see* Jansson T
Wetzler M, *see* Seymour JF
Whaley W, *see* Navari RM
Wharam M, *see* Crist W
Wheeler C, *see* Ayash LJ
— *see* Mitus AJ
Whelan JS, *see* Johnson PWM
Whelan TJ, Levine MN, Gafni A, Lukka H, Mohide EA, Patel M, Streiner DL. Breast irradiation postlumpectomy: Development and evaluation of a decision instrument, 847
White DE, *see* Marincola FM
Whitmore WF Jr, *see* Herr HW
— *see* Zelefsky MJ
Whittington R, Neuberg D, Tester WJ, Benson AB III, Haller DG. Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: A phase I Eastern Cooperative Oncology Group trial, 227
Whitton JA, *see* Breslow NE
Wieand HS, *see* Donohue JH
— *see* Wiesenfeld M
Wiener E, *see* Crist W
Wiernik PH, *see* Einzig AI
— *see* Tallman MS
— *see* Wadler S
Wiesenfeld M, O'Connell MJ, Wieand HS, Gonchoroff NJ, Donohue JH, Fitzgibbons RJ Jr, Krook JE, Mailliard JA, Gerstner JB, Pazdur R. Controlled clinical trial of interferon-γ as postoperative surgical adjuvant therapy for colon cancer, 2324
Wildiers J, *see* Schornagel JH
Wilhelm S, *see* Atzpodien J
Wilimas JA, *see* Beaty O III
Wilke H, *see* Köhne C-H
Wilking N, *see* von Schoultz E
Wilkinson PM, *see* Radford JA
Willemse PHB, *see* van der Zee AGJ
— *see* Veldhuis GJ
Willemze R, *see* Paulli M
Willett CG, Warland G, Hagan MP, Daly WJ, Coen J, Shellito PC, Compton CC. Tumor proliferation in rectal cancer following preoperative irradiation, 1417
Williams JP, *see* Johnson BE
Williams L, *see* Gandara DR
Williams S, *see* Donohue JH
Willson JKV, Haaga JR, Trey JE, Stellato TA, Gordon NH, Gerson SL. Modulation of O^6-alkylguanine alkyltransferase-directed DNA repair in metastatic colon cancers, 2301
Wilson KS, *see* Browman GP
Wilson WEC, *see* Meyer RM
Wilson WH, Bates SE, Fojo A, Bryant G, Zhan Z, Regis JA, Wittes RE, Jaffe ES, Steinberg SM, Herdt J, Chabner

BA. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy, 1995
—, Chabner BA, Bryant G, Bates S, Fojo A, Regis JA, Jaffe ES, Steinberg SM, Goldspiel BR, Cheson BD, Wittes RE. Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas, 381
—, Jamis-Dow C, Bryant G, Balis FM, Klecker RW, Bates SE, Chabner BA, Steinberg SM, Kohler DR, Wittes RE. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy, 1985
Windschitl HE, *see* Donohue JH
— *see* Witzig TE
Winer E, *see* Jones S
Winograd B, *see* Sessa C
Winquist EW, Laskey J, Crump M, Khamsi F, Shepherd FA. Ketoconazole in the management of paraneoplastic Cushing's syndrome secondary to ectopic adrenocorticotropin production, 157
Wise AP, *see* Marincola FM
Wisoff J, *see* Cohen BH
— *see* Jakacki RI
Wisoff JH, *see* Finlay JL
Witherspoon R, *see* Bensinger W
Wittes RE, *see* Wilson WH
Witzig TE, Letendre L, Gerstner J, Schroeder G, Mailliard JA, Colon-Otero G, Marschke RF, Windschitl HE. Evaluation of a somatostatin analog in the treatment of lymphoproliferative disorders: Results of a phase II North Central Cancer Treatment Group trial, 2012
— *see* Donohue JH
Wold L, *see* Millikan R
Wolfe JT, Chooback L, Finn DT, Jaworsky C, Rook AH, Lessin SR. Large-cell transformation following detection of minimal residual disease in cutaneous T-cell lymphoma: Molecular and in situ analysis of a single neoplastic T-cell clone expressing the identical T-cell receptor, 1751
Wolff AC, Ettinger DS, Neuberg D, Comis RL, Ruckdeschel JC, Bonomi PD, Johnson DH. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: An Eastern Cooperative Oncology Group pilot study, 1615
Wolff SN, *see* Greer JP
Woll PJ, Hodgetts J, Lomax L, Bildet F, Cour-Chabernaud V, Thatcher N. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer, 652
— *see* Pettengell R
Wollman MR, *see* Rowland P
Wollner N, *see* Faulkner LB
— *see* Kushner BH
Wolter JM, *see* Falkson G
Wong F, *see* Tattersall MHN
Wong FC, *see* Anderlini P
Wood ME, *see* Leonard CE
Wood W, *see* Aisner J
Wood WC, *see* Tallman MS
Woods WG, *see* Boyer MW
Woodward J, *see* McGuire WP
Woodworth JR, *see* Rinaldi DA
Wouters EFM, *see* Staal-van den Brekel AJ
Wranne L for the Nordic Society for Pediatric Hematology and Oncology, *see* Schmiegelow K
Wright J, *see* Kingston JE
Wright SK, *see* Passos-Coelho JL
Wu L-T, *see* Sundaresan N

Yamamoto K, Hayashi Y, Hanada R, Kikuchi A, Ichikawa M, Tanimura M, Yoshioka S. Mass screening and age-specific incidence of neuroblastoma in Saitama prefecture, Japan, 2033
Yamashita Y, *see* Maeda K
Yan Y, Chan WC, Weisenburger DD, Anderson JR, Bast MA, Vose JM, Bierman PJ, Armitage JO. Clinical and prognostic significance of bone marrow involvement in patients with diffuse aggressive B-cell lymphoma, 1336
Yanovich S, *see* Gandara DR
Yao T-J, *see* Seidman AD
Yarchoan R, *see* Adamson PC
— *see* Bailey J
Yates AJ, *see* Finlay JL
Yehoshua Z, *see* Uziely B
Yellen SB, Cella DF. Someone to live for: Social well-being, parenthood status, and decision-making in oncology, 1255
— *see* McQuellon RP
Yen M-S, *see* Tattersall MHN
Yen S-H, *see* Chi K-H
Yoon A, *see* Lee JS
Yordan E, *see* Barnhill DR
Yoshioka S, *see* Yamamoto K
Younes A, Sarris A, Melnyk A, Romaguera J, McLaughlin P, Swan F, Rodriguez MA, Hagemeister F, Moore D, North L, Smith TL, Cabanillas F. Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma, 583
— *see* Touroutoglou N
Young DC, *see* Triozzi PL
Young RC, *see* Freifeld AG
Yuen AR, Kamel OW, Halpern J, Horning SJ. Long-term survival after histologic transformation of low-grade follicular lymphoma, 1726
Yunis E, *see* Rowland P
Yuo H-S, *see* Roach M III
Yver A, *see* Chevallier B

Zagonel V, *see* Tirelli U
Zakrzewski G, *see* Atzpodien J
Zanzig C, *see* Tallman MS
Zee B, *see* Browman GP
Zelefsky MJ, Leibel SA, Wallner KE, Whitmore WF Jr, Fuks Z. Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostatic cancer, 459
— *see* Pfister DG
Zeltzer PM, *see* Cohen BH
— *see* Jakacki RI
Zhan Z, *see* Wilson WH
Zhang X, *see* Millikan R
Zhang Y, *see* Millikan R

Zhang Z-F, *see* Ghossein RA
— *see* Herr HW
— *see* Sarkis AS
— *see* Schultz P
Zhen B, *see* Leonard C
— *see* Leonard CE
Zilembo N, *see* Bajetta E
Zingsem J, *see* Beyer J
Zorsky PE, *see* Fields KK
Zucchetti M, *see* Sessa C
Zucker JM, *see* Doz F
Zuhowski EG, *see* Eisenberger MA
— *see* Reyno LM
Zukiwski AA, *see* Logothetis CJ
Zulian G, *see* Hill M
Zuurmond W, *see* Sanders M

SUBJECT INDEX

Abdominal irradiation, as second cancer risk factor, 1856
ABVD regimen, in adult Hodgkin's disease, 393
ABVD-MOPP regimen, Stanford V regimen *v*, in Hodgkin's disease, 1085-1087
Acitretin, in skin cancer, 1933-1938
Acute cholinergic syndrome, irinotecan-associated, 213
Adenocarcinoma, papillary serous, p-53 in, 73
Adjuvant chemotherapy
in contralateral breast cancer, 1578-1583
in early breast cancer, 515-517
leukemogenic potential of, 1557-1563
low-dose, in node-positive breast cancer, 33-41
physician perception of, in node-negative breast cancer, 1459-1469
Adrenal insufficiency, following suramin, 2183
Adrenocorticotropin production, ectopic, 157-164
Aerodigestive cancer, in small-cell lung cancer survivors, 101-111
Age
as contralateral breast cancer risk, 1578-1583
in primitive neuroectodermal tumors, 1694
Aggressive therapy, selection of, social well being and, 1255-1264
AGM-1470, pharmacologic characteristics of, 776
AIDS, associated with non-Hodgkin's lymphoma, 2669
Albumin, radiolabeled
continuous intraoperative monitoring of, 266
in perfusion circuit, 264-273
Alkaline phosphatase, as prognostic factor, in carcinoma of unknown primary, 1720-1725
Alopecia
AS101 prevention of, 2342-2353
evaluation of, following AS101, 2351
Alpha-fetoprotein, half-life of, as germ cell tumor prognostic factor, 87-92
American Society of Clinical Oncology
Awards Committee of, 2986
Clinical Practice Committee of, 2985-2986
Education Committee of, 2987
Executive Vice President of, 2986-2987
growing membership of, 2982
as international society, 2988
International Task Force of, 2988
members of, 2982
Membership Committee of, 2986
national *v* international submissions to, 2989
Patient Advocacy Committee of, 2986
Presidential Address to, 2981-2989
Prevention and Control Committee of, 2986
Program Committee of, 2987
Public Relations of, 2986
strategic planning of, 2987
Amonafide
pharmacodynamic study of, 741-747
pharmacology of, 743
toxicity of, pharmacodynamic analysis of, 745
Amsacrine, in combination chemotherapy, for desmoid tumor, 2815
Anaphylactoid reactions, in children, following high-dose cyclosporine, 2508-2516
Androgen receptor levels, predictive value of, in breast cancer, 1572-1577
Anemia
of cancer, erythropoietin for, 1623-1631
following interferon-alfa 2a plus interleukin-2, 1119
pretreatment therapy of, and laryngeal cancer survival, 2077-2083
Angiogenesis
agents for, 774-775
biochemical assessment methods of, 769
biochemical studies of, 771-772
biologic role of, 766
as biologic therapy target, 773-775
in breast cancer, 765-782
confirmatory studies of, 771
in early breast cancer, 769-772
immunocytochemical studies of, 769-772
immunohistochemical assessment methods of, 768-769
inhibitors of, 774-775
intratumoral vascularization in, prognosis and, 770
morphologic assessment methods of, 768-769
pilot studies of, 769-771
predictive value of, for chemotherapy response, 772-773
studies of, 767
Angiogenesis intensity, in stage I non–small-cell lung cancer, 1274
Angiostatin, 766
Anorexia, pentoxifylline for, 2856-2859
Anthracyclines, late cardiotoxicity following, 1546-1556
Anti-latent membrane protein-1, immunohistochemistry with, 1759
Antibiotic(s)
following chemoradiotherapy plus granulocyte-macrophage colony-stimulating factor, 1636
following peripheral-blood progenitor-cell transplant, 939
Antibody labeling, 2395
Antiemetic
cisplatin-based clinical trials for, 1040-1041
clinical trial design for, 1037-1038
costs of, 1042
dose adjustment of, by chemotherapy, 2117-2122
efficacy of, 2120
non–cisplatin-based clinical trials for, 1038-1040
Antiestrogens, 775
Antisense oligonucleotides, for in vitro purging, 543
Anti-B-cell moncolonal antibody therapy, for posttransplant lymphoproliferative disorders, 961-968

Anus, carcinoma of, in homosexual men, 2543
Appetite, variables in, 2858
Arato v Avedon case, in patient disclosure, 1817-1822
Area under the curve
  for etoposide phosphate, 207-208
  in PFL-induced mucositis, 2621-2623
  of topotecan, 1773-1775
Arrhythmia, associated with paclitaxel, doxorubicin regimen, 2693
AS101
  hair-sparing effect of, 2350
  hematologic toxicity following, 2347
  hematopoietic regulator levels following, 2347-2349
  neutrophil response to, 2345
  nonhematologic toxicity of, 2349-2350
  in non–small-cell lung cancer, 2342-2353
  preparation of, 2343
  thrombocytopenia following, 2345-2347
  treatment schedule of, 2345
  WBC toxicity of, 2345
Asparaginase, 339
  in non-Hodgkin's lymphoma therapy, stratified by histology, 359-372
  in R-11 protocol, for acute lymphoblastic leukemia CNS relapse, 335
Asparaginase, daunorubicin, methotrexate, cyclophosphamide, vincristine, prednisone regimen, 1368-1376
L-Asparagine, CSF levels of, in acute lymphoblastic leukemia, 339-344
Assay, predictive, for fluorouracil response, 419-423
Astrocytoma, high-grade
  in childhood, 112-123
  vincristine, lomustine, prednisone *v* eight-drugs-in-one-day regimen in, 112-123
area under the curve, *see* Area under the curve
Auer rod, in extramedullary leukemia, 1803-1804
Autograft, characteristics of, 1331
Autoimmunity, interferon alfa and, 2401-2407
Axillary extranodal tumor extension, in breast cancer, 47-53

Bacillus Calmette-Guérin
  in bladder cancer, 1404-1408
  therapy with, survival following, 1407
Bacterial infection, trimethoprim-sulfamethoxazole *v* ciprofloxacin for, 239-250
Basic fibroblast growth factor, 769
BB-94, pharmacologic characteristics of, 776
Bcl-2 protein, in stage I non–small-cell lung cancer, 1271
BCNU, *see* Carmustine
BCR-ABL encoded fusion peptides, antibodies to, for in vitro purging, 543
BCR-ABL-positive cell, following bone marrow transplantation, 1704-1713
Beck Depression Inventory, at pancreas cancer diagnosis, 748-755
Benzoporphyrin derivative photosensitization, for in vitro purging, 543
Berlin-Frankfurt-Munster–based chemotherapy, for childhood acute lymphoblastic leukemia, 2497-2502
Beta-human chorionic gonadotropin, half-life of, as germ cell tumor prognostic factor, 87-92
Bile system cancer, extrahepatic, *Ki-ras* mutations in, 1679-1686
Biliary cancer, radiotherapy plus protracted fluorouracil infusion in, 227-232
Bioavailability, of all-*trans* retinoic acid, in acute promyelocytic leukemia, 2517-2523
Biochemical effects, interleukin-6 and, in non–small-cell lung cancer therapy, 2589-2590
Biomarker(s)
  molecular, stem-cell transplantation and, 1052-1054
  in node-negative breast cancer, 697-704
  positive-, following stem-cell transplantation, 1073-1079
  serum tumor, in ovarian cancer, 785-787
  soluble CD30 as, 1355-1360
  in stage I non–small-cell lung cancer, 1265-1279
BK virus, hemorrhagic cystitis due to, 1103-1109
Bladder cancer
  brain tumor associated with, 2931-2935
  invasive, mutant p53 in, 1384-1390
  methotrexate, vinblastine, doxorubicin, cisplatin, granulocyte-macrophage colony-stimulating factor regimen in, 2272-2277
  neoadjuvant methotrexate, vinblastine, doxorubicin, cisplatin regimen in, 1384-1390
  p53 overexpression in, 1384-1390
  superficial, bacillus Calmette-Guérin therapy in, 1404-1408
  surgical management of, following chemotherapy, 1387
Bleomycin
  cisplatin plus, for carcinoma of unknown primary, 1720-1725
  in combination chemotherapy
    for mantle-cell lymphoma, 2819-2826
    for non-Hodgkin's lymphoma, 585, 2530
    residual lymphoma following, 594
    for stage II germ cell tumors, 2700
    for testicular cancer, 2681-2683
  in disseminated germ cell tumors, 470-476
  dosing of, in Stanford V regimen, 1086
  in Stanford V regimen, for Hodgkin's disease, 1081
Bleomycin, cisplatin, etoposide regimen
  for carcinoma of unknown primary, 1720-1725
  fertility following, 2278-2280
  in germ cell tumors, 470-476
  response to, 472-473
  survival following, 474
Bleomycin, cyclophosphamide, epirubicin, vincristine, prednisone, regimen
  dosing of, 954
  in non-Hodgkin's lymphoma, 953-960
  toxicity of, 957
Bleomycin, etoposide, ifosfamide, mitoxantrone regimen
  dosing of, 954
  in non-Hodgkin's lymphoma, 953-960
  toxicity of, 957
Blood group antigen, in stage I non–small-cell lung cancer, 1271-1272
Blood transfusion(s)
  cancer recurrence and, 1671-1678
  colorectal cancer prognosis and, 1671-1678
  following peripheral-blood progenitor-cell transplant, 939
BM deposition, in stage I non–small-cell lung cancer, 1274
Bone, metastases to, clodronate for, 929-934
Bone marrow
  acute lymphoblastic leukemia relapse to, 352-358
  B-cell lymphoma involvement of, patterns of, 1338-1339
  complications of, AS101 prevention of, 2342-2353
  harvesting of, 1329
  histologic assessment of, 1338-1339

involvement of, in Hodgkin's disease, 403-409
spinal
diffuse myeloma pattern in, 252
focal myeloma pattern in, 253
variegated myeloma pattern in, 252
storage of, 554
Bone marrow harvest, 707
Bone marrow transplantation
in acute myelogneous leukemia, 560-569
allogeneic
in acute lymphoblastic leukemia second remission, 352-358
busulfan, cyclophosphamide conditioning regimen for, 2973-2979
complete remission following, 1314
conditioning treatment for, 1100, 1313
with cyclophosphamide, carmustine, etoposide regimen, 596-602
graft-versus-host disease prevention in, 1313-1314
for lymphoma, 1096-1102
minimal residual disease patterns following, 1704-1713
in multiple myeloma, 1312-1322
response to, 1313-1314
survival following, 1314-1319
toxicity of, 1099
autologous
plus cyclophsophamide, thiopeta, novobiocin regimen, 1136-1143
following high-dose chemotherapy, 1328-1335
high-dose chemotherapy plus, in breast cancer, 2043-2049
in-hospital mortality rates for, 970
in non-Hodgkin's lymphoma, 588-595
survival following, 1332
teniposide, doxorubicin, melphalan, cisplatin, total-body irradiation regimen in, 2789-2795
autologous *v* allogeneic, survival following, 564-566
BK virus following, 1103-1109
in combination regimen, for non-Hodgkin's lymphoma, 585
deaths associated with, 598-599
hemorrhagic cystitis following, 1103-1109
in T-cell-rich B-cell lymphoma, 1746
infection following, trimethoprim-sulfamethoxazole *v* ciprofloxacin in, 239-250
neutropenia following, 245
novobiocin plus, in breast cancer, 1136-1143
and peripheral stem-cell therapy, for non-Hodgkin's lymphoma, 2669
13-*cis*-retinoic acid following, 894-901
Bone marrow transplantation, carmustine, cyclophosphamide, etoposide regimen, for lymphoid malignancies, 596-602
Bone marrow transplantation, carmustine, etoposide, cytarabine, melphalan regimen, in non-Hodgkin's lymphoma, 588-595
Bone pain, metastatic, oral clodronate for, 2427-2430
Bone scintigraphy, of tumor flare, following hormonal therapy, 1123-1128
Brain, irradiation of
biphasic memory deficits following, 2263-2271
early-delayed effects of, 2267
late-delayed effects of, 2267-2268
Brain tumor
cancers associated with, 2931-2935
craniospinal irradiation plus lomustine for, pulmonary function following, 1481
recurrent, paclitaxel for, 2066-2071
second primary, 2931-2935
Breaking bad news, *see* Disclosure
Breast, benign tissue of, p53 mutations in, 2293-2300
Breast cancer
adjuvant chemotherapy in, leukemogenic potential of, 1557-1563
adjuvant tamoxifen in, thyroid function test changes with, 854-857
advanced
docetaxel in, 314-322
intravenous vinorelbine for, 2722-2730
medroxyprogesterone in, 1572-1577
melphalan for, 2567-2574
phase II gemcitabine trial for, 2731-2736
vinorelbine for, 2567-2574
in axillary extranodal tumor extension, 47-53
chemoendocrine therapy in, pre- or postoperatively, 547-552
chemotherapy-resistant, paclitaxel in, 2056-2065
combined modality therapy for, 2585-2593
contralateral, 1578-1583
risk factors associated with, 1580-1581
cure in, possibility of, 62-69
cyclophosphamide, methotrexate, fluorouracil, vincristine, prednisone regimen in, 831-839
doxorubicin, fluorouracil, cyclophosphamide, methotrexate regimen in, 831-839
doxorubicin-resistant, docetaxel in, 2879-2885, 2886-2894
early-stage
adjuvant therapy in, 515-517
radiation therapy for, 2582-2584
extensive nodal involvement in
chemoradiotherapy for, 435-443
studies in, 441
fluorouracil, epirubicin, cisplatin regimen in, 424-429
high-dose chemotherapy for, 2477-2479
survival rates following, 2487-2488
high-dose melphalan in, 1794
hormonal therapy of
HER-2-*neu* overexpression following, 1129-1135
tumor flare following, 1123-1128
inflammatory
cyclophosphamide, epirubicin, fluorouracil, granulocyte colony-stimulating factor regimen in, 1564-1571
granulocyte colony-stimulating factor in, 1564-1571
ipsilateral breast tumor recurrences in, 537
late death in, 62-69
locoregional treatment of, in metastasis prevention, 2869-2878
lumpectomy in, radiotherapy following, decision instrument for, 847-853
menopausal symptoms in patients with, 2737-2744
metastatic
clinical treatment options in, 859-860
doxorubicin-based regimens in, 1443-1452
four-step high-dose sequential chemotherapy in, 840-846
high-dose chemotherapy in, 2483-2489
high-dose chemotherapy plus autotransplantation in, 2043-2049
paclitaxel in, 1152-1159
patient therapy preference in, 858-868
phase II paclitaxel trial in, 2575-2581
predicting fluorouracil response in, 419-423
quality-of-life assessment in, 860
tamoxifen in, 517-521, 2556-2566

tandem autotransplantation in, 2050-2055
ten year follow-up in, 1453-1458
toremifene in, 2556-2566
warfarin prophylaxis in, 42-46
mitoxantrone-resistant, docetaxel in, 2879-2885
node-negative
adjuvant therapy in, physician perception of, 1459-1469
natural history of, 1144-1151
p53 in, 821-830
prognostic factors in, 697-704
node-positive
cyclophosphamide, methotrexate, fluorouracil regimen in, 33-41
low-dose adjuvant chemotherapy in, 33-41
node-positive receptor-negative, short-course *v* 1-year regimen in, 831-839
non–small-cell, combined modality therapy for, 2585-2593
oophorectomy *v* tamoxifen in, 521
pepsinogen C in, 54-61
perioperative chemotherapy for, 2712-2721
peripheral-blood stem-cell treatment for, 2547-2555
PET studies in, for early therapy evaluation, 1470-1477
phase II trial of, doclataxel and, 2647-2649
postmenopausal
adjuvant tamoxifen results in, 855
tamoxifen in, 517-520
thyroid function test changes in, 854-857
pregnancy influence on, 430-434
premenopausal
tamoxifen in, 520-521
ten-year follow-up in, 1453-1458
prevention therapy in, 521
primary, preoperative chemotherapy in, 537-540
primary neoadjuvant chemotherapy in, 424-429
radiotherapy in, sequential chemotherapy prior to, 2906-2915
radiotherapy plus p53 in, 2745-2751
short-infusion paclitaxel plus bolus doxorubicin for, 2688-2699
tamoxifen in, 513-529
tamoxifen plus toremifene in, 2900-2905
tumor angiogenesis in, 765-782
Burkitt's lymphoma
p53 mutations in, 812-820
therapy for, 2666
Busulfan
in combination chemotherapy, following etoposide, carboplatin regimen, 906
in preparative bone marrow transplantation regimen, 1704-1713
Busulfan, cyclophosphamide regimen, as allogeneic bone marrow transplantation conditioning regimen, 2973-2979
Buthionine sulfoxamine, 1787

C-*erb*B-2
distribution of, in ovarian cancer, 73
elevated serum, following hormonal therapy, 1129-1135
as ovarian cancer prognostic factor, 70-78
as prognostic factor, for chemotherapy response, 70-78
C-*kit* ligand, 1027
CA 125, 785-787
Cachexia, pentoxifylline for, 2856-2859
Camptothecin, chemical structure of, 211
Cancer
as process, 801
autocrine model of, 802
classical *v* evolved model of, 801-807
killing strategy in, 802-803
as national health priority, 2981-2983
regulatory imbalance in, 802
reversibility of, 802
Cancer patient, social well being of, and decision making, 1255-1264
Cancer recurrence, blood transfusions and, 1671-1678
Candida albicans, 244
Candida difficile, 243
Carboplatin
in combination chemotherapy, following etoposide, carboplatin regimen, 906
complications of, AS101 prevention of, 2342-2353
cyclosporine plus
discontinuation of, 2243
dose-limiting toxicities of, 2241-2242
nonhematologic toxicities of, 2242-2243
phase I trial of, 2238-2246
etoposide plus
in embryonal CNS tumors, 2247-2254
in extraocular retinoblastoma, 902-909
phase II trial of, 902-909
response to, 2249, 2252
survival following, 2249-2250
toxicity of, 2250-2251
tumor response to, 903
following docetaxel, in ovarian cancer, 1584-1588
fluorouracil plus, in head and neck cancer, 1493-1500
high-dose, peripheral-blood progenitor-cell reinfusion and, 1329
in high-dose chemotherapy regimen, for breast cancer, 840-846
in ovarian cancer, following paclitaxel, 1584-1588
paclitaxel plus
cost of, 1841
dose-adjustment schema for, 1862
dose-intensity of, 1865
granulocytopenia following, 1864
in non–small-cell lung cancer, 1840-1842, 1860-1870
protocol schema for, 1862
response to, 1865-1867
thrombocytopenia following, 1865
toxicity of, 1863-1864
Carboplatin, etoposide, radiation regimen
metastasis-free survival following, 455
in non–small-cell lung cancer, 452-458
response to, 456
survival following, 454
Carboplatin, ifosfamide, etoposide regimen
dosing escalation of, 325-326
hematologic toxicity of, 326
hematopoietic recovery following, 327
maximum-tolerated doses of, 323-332
nonhematologic toxicity of, 326-329
outcomes of, 329
phase I dosing trial of, 323-332
published maximum-tolerated doses of, 331
in small-cell lung cancer, 1615-1622
toxic deaths of, 329
toxicity of, 1618-1619
Carboplatin, ifosfamide, etoposide, granulocyte colony-stimulating factor regimen

doubling dose intensity of, with blood reinfusion, 148-156
hematologic toxicity of, 154
toxicity of, 152-154
Carboplatin, interleukin-3, cyclophosphamide regimen
in ovarian cancer, 733-740
side effects of, 737-738
Carboplatin, vincristine, ifosfamide, etoposide regimen
response to, 656-657
in small-cell lung cancer, 652-659
toxicity of, 656
Carboplatin, vincristine, ifosfamide, etoposide, granulocyte colony-stimulating factor regimen
response to, 656-657
in small-cell lung cancer, 652-659
toxicity of, 656
Carcinoid tumor, interferon alfa-2b plus fluorouracil for, 1486-1492
Carcinoma of unknown primary site
poorly differentiated, diagnosis of, 274-282
prognostic factors in, 1720-1725
Cardiac function
following liposomal doxorubicin, 1782
following Wilms' tumor, 1546-1556
Cardiotoxicity
definition of, 2828
following idarubicin, 2827-2834
following Wilms' tumor, 1546-1556
of paclitaxel and doxorubicin regimen, in breast cancer, 2692-2694, 2696-2697
subclinical, 2830-2831
of vincristine, epirubicin, etoposide, prednisolone regimen, 387-395
Carmustine
radiotherapy plus, dosing of, 599
resistance to, 2301-2308
Carmustine, cyclophosphamide, etoposide, bone marrow transplantation regimen, for lymphoid malignancies, 596-602
Carmustine, cyclophosphamide, etoposide, hydroxyurea regimen, in malignant lymphoma, 1089-1095
Carmustine, etoposide, cytarabine, melphalan regimen
in Hodgkin's disease, 396-402
protocol for, 397-398
results of, 400
Carmustine, etoposide, cytarabine, melphalan, bone marrow transplantation regimen, in non-Hodgkin's lymphoma, 588-595
Catheter(s)
comparative cost of, by catheterization duration, 1518
complications of, 1516-1517
cost of, 1517
double- *v* triple-lumen, complications of, 233-238
Hickman, complications of, 2320
Peripheral Access System Port and, 1514
placement of
complications in, 234
physician assistant, 1513-1519
tracking system for, 1514
CD30 antigen
expression of, in cutaneous large-cell lymphoma, 1343-1354
in high-grade non-Hodgkin's lymphoma, 373-380
CD30 molecule, soluble, in anaplastic large-cell lymphoma, 1355-1360
CD34 antigen, immunophenotyping for, 1923-1924
CD34+ cell
bone marrow, 706-707
cell content of, peripheral-blood stem-cell therapy and, 2552-2554
harvest of, in non-Hodgkin's lymphoma, 939
infused, 938
as prognostic factor, in hematopoietic recovery, 1922-1932
CD44 transcripts, 1916
CD44 variant isoforms
clinical features of, 1919
immunohistochemistry of, 1914
in ovarian cancer, 1912-1921
CD44-9v, in ovarian cancer, 1912-1921
CD44S, in ovarian cancer, 1912-1921
Ceftazidime
imipenem *v*, for febrile neutropenia, 165-176
toxicity of, 172-173
Cell kinetics
in head and neck cancer, 1843-1850
predictive value of, in radiotherapy, 1833-1836
Cervical cancer
diagnosis of, clinical stage at, 724
epirubicin, cisplatin, radiotherapy regimen in, 444-451
incidence of, 715
invasive, improved control of, 715-725
Chemoendocrine therapy
in breast cancer, 547-552
toxicity of, 551
Chemoprotectant
diethyldithiocarbamate as, 490-496
for in vitro purging, 543
Chemoradiotherapy
in breast cancer, 2906-2915, 435-443
for CNS, in childhood leukemia, 2480-2481
concurrent
phase II trial of, 869-875
response to, 872
toxicity of, 872-873
treatment schedule for, 871
failure patterns in, 674
fluorouracil dose reduction during, 881
granulocyte-macrophage colony-stimulating factor plus, in small-cell lung cancer, 1632-1641
in head and neck cancer, 876-883
interferon alfa-2a following, in breast cancer, 2924-2930
in oropharyngeal cancer, 671-680
phase III trial of, in non–small-cell lung cancer, 1425-1429
for pineoblastoma, 1380
prior to surgery, in non–small-cell lung cancer, 1880-1892
in supratentorial primitive neuroectodermal tumors, 1687-1696
toxicity of, 676, 879
Chemotherapy
adjuvant, *see* Adjuvant chemotherapy
antiemetic clinical trials based on, 1038-1041
Berlin-Frankfurt-Munster–based, for childhood acute lymphoblastic leukemia, 2497-2502
classification of, by emetogenic potential, 2119
for colorectal cancer, overview of, 1287-1290
combination, *see* Combination chemotherapy
concomitant chemoradiotherapy plus, in head and neck cancer, 876-883
cost-effectiveness of, in non–small-cell lung cancer, 2166-2173
eight-in-one
for primitive neuroectodermal tumors, 1687-1696

for pineoblastoma, 1377-1383
erythropoietin during, in small-cell lung cancer, 1623-1631
high-dose, *see* High-dose chemotherapy
induction, toxicities of, 879
intensive, diploid hematopoiesis with, 553-559
interleukin-6 following
for breast cancer, 2585-2593
for non–small-cell lung cancer, 2585-2593
intracavitary, in childhood cancer, 631-636
long-term complications of, 1534-1536
in malignant germ cell tumor, 1391-1397
neoadjuvant, *see* Neoadjuvant chemotherapy
ondansetron dose adjustment by, 2117-2122
in ovarian cancer, overview of, 726-732
perioperative
in breast cancer, 2712-2721
plus intraoperative radiation, in pancreatic cancer, 2764-2768
preirradiation, with carboplatin, etoposide regimen, 2247-2254
preoperative, *see* Neoadjuvant chemotherapy
primary neoadjuvant, in breast cancer, 424-429
radiotherapy plus, *see* Chemoradiotherapy
regimens of, in non-Hodgkin's lymphoma, 585
response to
angiogenesis prediction of, 772-773
prognostic factors for, 70-78
schemes for, in acute myelogneous leukemia, 560
in second cancer development, 284-285
secondary leukemia following, 287
sequential, prior to radiotherapy, in breast cancer, 2906-2915
single-agent, in lymphoma, 2524-2529
standard *v* experimental, patient preference for, 860-861, 866
standard *v* high-dose experimental, patient preference for, 860-861, 867-868
timed sequential, in acute myeloid leukemia, 11-18
toxicity of, 129-130
in Wilms' tumor, 126
Chest radiotherapy, preoperative chemotherapy plus, in non–small-cell lung cancer, 1880-1892
Chiasmatic-hypothalamic glioma, etoposide in, 2072-2076
Child(ren)
anaphylactoid reactions in, high-dose cyclosporine and, 2508-2516
astrocytoma in, vincristine, lomustine, prednisone *v* eight-drugs-in-one-day regimen for, 112-123
chemotherapy-associated relapse in, with acute lymphoblastic leukemia, 345-351
CNS relapse in, with acute lymphoblastic leukemia, 333-338
curing cancer in, 1837-1839
desmoid tumor in, recurrence of, 2813-2818
etoposide in, age-dependent dose calculation of, 2954-2960
Hodgkin's disease in, malignancies following, 603-609
high-grade astrocytoma in, 112-123
with leukemia, pulmonary thromboembolism in, 2805-2812
localized resectable neuroblastoma in, 884-893
lymphomas in, treatment for, 2666
neuroblastoma in
age-specific incidence of, 2033-2038
relapsed, high-dose melphalan for, 1786-1799
13-*cis*-retinoic acid for, 894-901
non-Hodgkin's lymphoma in, treatment stratified by histology for, 359-372
Chlorambucil, cladribine plus, 2439-2440
Chlorambucil, vinblastine, prednisolone, procarbazine, doxorubicin, vincristine, etoposide regimen, gonadal function following, 134-139
Chlorambucil, vinblastine, procarbazine, prednisone, etoposide, vincristine, doxorubicin regimen
dosing of, 2380
in Hodgkin's disease, 2379-2385
response to, 2381
survival following, 2382
2-Chlorodeoxyadenosine, 2433, 2439
chlorambucil plus, 2439-2440
clinical studies of, 2433, 2439
in chronic lymphocytic leukemia, 570-574, 983-988
immunosuppression with, 2440
infectious complications of, 992, 2431-2448
mechanism of action of, 2433
myelotoxicity of, 2436-2437
plasma levels of, 992
side effects of, 992
subcutaneous injections of, in hairy cell leukemia, 989-995
therapeutic effects of, 991
toxicity of, 986, 572
treatment with, 990
Cholesterol levels
interleukin-6 and, in non–small-cell lung cancer therapy, 2590
reduction of, by tamoxifen plus toremifene, 2900-2905
Cholinergic syndrome, acute, irinotecan-associated, 213
CHOP regimen, *see* Cyclophosphamide, doxorubicin, vincristine, prednisone regimen
Chromogranin A, as emesis marker, 681-687
Chromosomal translocation t[14:18], marker-positive, 1052-1054
Ciprofloxacin
adverse effects of, 244
bioavailability of, 246
organisms resistant to, 245
trimethoprim-sulfamethoxazole *v*, in bone marrow transplantation recipients, 239-250
Cisplatin
antiemetic clinical trials based on, 1040-1041
bleomycin plus, for carcinoma of unknown primary, 1720-1725
in chemoradiotherapy
plus granulocyte-macrophage colony-stimulating factor, 1632-1641
for non–small-cell lung cancer, 1425-1429
in combination chemotherapy
oral mucositis following, 2620-2628
for testicular cancer, 2681-2683
for small-cell lung cancer, 2594-2599
delayed emesis due to, ondansetron for, 2408-2416
emesis due to, granisetron *v* ondansetron for, 1242-1248
etoposide and, in stage II germ cell tumors, 2700-2704
etoposide plus, in small-cell lung cancer, 1871-1879
fluorouracil plus, in head and neck cancer, 1493-1500
intracavitary
in childhood cancer, 631-636
pharmacokinetics of, 632
response to, 633-634
toxicity of, 632-633
neurotoxicity associated with, glutathione prevention of, 26-32
in stage II germ cell tumors, 2700
thoracic irradiation plus, in non–small-cell lung cancer, 1425-1429
toxicity due to, diethyldithiocarbamate for, 490-496

vindesine plus
cost-effectiveness of, 2166-2173
incremental efficacy of, 2168
incremental survival benefit of, 2169
vinorelbine plus
cost-effectiveness of, 2166-2173
incremental efficacy of, 2168
incremental survival benefit of, 2169
Cisplatin, epirubicin, radiotherapy regimen, in cervical cancer, 444-451
Cisplatin, etoposide regimen
clinical results of, in small-cell lung cancer, 1639
in germ cell tumors, 470-476
response to, 472-473
survival following, 474
Cisplatin, etoposide, bleomycin regimen
fertility following, 2278-2280
for carcinoma of unknown primary, 1720-1725
in germ cell tumors, 470-476
response to, 472-473
survival following, 474
Cisplatin, etoposide, ifosfamide regimen
in small-cell lung cancer, 1209-1214
toxicity of, 1211
Cisplatin, etoposide, methylprednisone, cytarabine regimen, in non-Hodgkin's lymphoma, 1734-1741
Cisplatin, etoposide, radiotherapy regimen, in non–small-cell lung cancer, 1880-1892
Cisplatin, leucovorin, fluorouracil regimen
in head and neck cancer, 1656-1662
pharmacokinetics of, 1658-1659
response to, 1658
toxicity of, 1658
Cisplatin, fluorouracil, epirubicin regimen
in breast cancer, 424-429
toxicity of, 427
Cisplatin, fluorouracil, leucovorin, interferon alfa-2b induction regimen, in head and neck cancer, 876-883
Cisplatin, ifosfamide, etoposide regimen
granulocyte-macrophage colony-stimulating factor plus, for germ cell tumor, 79-86
hematologic efficacy of, 82
infection analysis following, 81-82
recycling intervals following, 82-83
toxicity of, 83, 84
Cisplatin, ifosfamide, vinblastine regimen
granulocyte-macrophage colony-stimulating factor plus, for germ cell tumor, 79-86
hematologic efficacy of, 82
infection analysis following, 81-82
recycling intervals following, 82-83
toxicity of, 83, 84
Cisplatin, methotrexate, vinblastine, doxorubicin regimen, neoadjuvant, in bladder cancer, 1384-1390
Cisplatin, methotrexate, vinblastine, doxorubicin, granulocyte-macrophage colony-stimulating factor regimen
in bladder cancer, 2272-2277
hematologic toxicity of, 2275
infection following, 2274
Cisplatin, mitomycin, vindesine regimen, concurrent radiotherapy plus, 869-875
Cisplatin, paclitaxel, etoposide regimen
response to, 1433
in small-cell lung cancer, 1430-1435
survival following, 1433-1434
toxicity of, 1432-1433
treatment schema for, 1431
Cisplatin, teniposide, doxorubicin, melphalan, total-body irradiation regimen, for bone marrow transplantation, 2789-2795
Citrovorum factor, 361
Cladribine, *see* 2-chlorodeoxyadenosine
Clinical research
federal funding of, 2984-2985
misconceptions about, 2983-2985
support for, 2982
Clinical trial(s)
cisplatin-based, for emesis, 1040-1041
design of, for antiemetics, 1037-1038
non–cisplatin-based, for emesis, 1038-1040
patient perception in, 1062-1072
phase I, ethics of, 1049-1051
physician perceptions in, 1062-1072
women participants in, 293-299
Clodronate
adverse events with, 932-933
calcium excretion following, 931-932
compliance with, 930, 932-933
hydroxyproline excretion following, 931-932
in metastatic bone disease, 929-934
oral, for bone pain, 2427-2430
response to, 930
treatment regimen for, 930
CNOP regimen, *v* CHOP regimen, in elderly, 2533
CNS
acute lymphoblastic leukemia relapse in, 333-338, 2497-2502
embryonal tumors of, carboplatin, etoposide regimen in, 2247-2254
leukemia of, overview of, 310-313
Cognitive tests, following cranial radiation, for acute lymphoblastic leukemia, 2492
Colon cancer
postoperative interferon gamma in, 2324-2329
stage II
adjuvant fluorouracil plus levamisole in, 2936-2943
prognostic factors in, 2938, 2941-2942
Colony assay, circulating hematopoietic progenitor evaluation by, 936-937
Colony-stimulating factor
granulocyte, *see* Granulocyte colony-stimulating factor
granulocyte-macrophage, *see* Granulocyte-macrophage colony-stimulating factor
M-, 1025
peripheral-blood stem-cell collection following, 2547-2555
Colorectal cancer
advanced
combination chemotherapy for, 2613-2619
fluorouracil modulation in, 1303-1311
fluorouracil plus interferon alfa-2b in, 1297-1302
brain tumor associated with, 2931-2935
chemotherapy for, overview of, 1287-1290
fluorouracil, folinic acid, dipyridamole regimen in, 1201-1208
high-dose melphalan in, 1795
interferon alfa-2a plus fluorouracil in, 921-928
interferon alfa-2b plus fluorouracil in, 2317-2323

leucovorin acid plus fluorouracil in, 921-928
metastatic
carmustine resistance in, 2301-2308
in O6-alkylguanine alkyltransferase modulation, 2301-2308
prognosis in, transfusions and, 1671-1678
Combination chemotherapy
early evaluation of, with PET studies, 1470-1477
for non-Hodgkin's lymphoma, 2666-2668
see also specific regimens
Combined modality therapy
for lung cancer, radiation pneumonitis following, 2606-2612
in non–small-cell lung cancer, 1880-1892
in pancreatic cancer, 2764-2768
peripheral-blood stem-cell collection and, 2548
in rectal cancer, 1409-1416
second cancer following, in Hodgkin's disease, 2016-2022
treatment schema for, 2765
Compliance, in tumor-node-metastasis staging, of gastric cancer, 22-24
Computed tomography
in melanoma staging, 2104-2108
in primary tumor diagnosis, 2101
Computer tomography, of extraocular retinoblastoma, 904
Connective tissue disease, patient characteristics in, 2404
Cordotomy
bilateral percutaneous cervical, 1509-1512
complications following, 1511
percutaneous cervical, 1509-1512
Corticosteroids
for brain metastases, 662
in paraneoplastic Cushing's syndrome, 157-164
Cost(s)
of antiemetics, 1042
comparative catheter, by catheterization duration, 1518
of high-dose therapy plus autologous transplantation, 969-973
of hospitalization, for high-dose therapy plus autologous transplantation, 971
of paclitaxel plus carboplatin, in non–small-cell lung cancer, 1841
of prophylactic warfarin, 44-45
of unknow primary tumor evaluation, 2101
of vascular-access device, 1517
Cost analysis
of ciprofloxacin, in non–small-cell lung cancer, 2458
of granulocyte colony-stimulating factor, in non–small-cell lung cancer, 2458
funding of, 2152-2154, 2457-2463
of lung cancer chemotherapy, 2166-2173
overview of, 2152-2154
types of, 2458-2459
Cost-accounting, 2459
Cost-benefit, 2459
Cost-effectiveness, 2459
incremental, of medical interventions, 2170
of vindesine, cisplatin regimen, 2166-2173
of vinorelbine, cisplatin regimen, 2166-2173
of vinorelbine, in non–small-cell lung cancer, 2166-2173
Cost-minimization, 2459
Cost-utility, 2459
Cox proportional hazard model, 1352
p53 mutations and, 2748
of survival, 1309
CPT-11, *see* Irinotecan
Cranial irradiation
for acute lymphoblastic leukemia, 2490-2495
combination chemotherapy plus, residual lymphoma following, 594
effect of, on childhood leukemia survivors, 2503-2507
for childhood acute lymphoblastic leukemia, 2497-2502
in R-11 protocol, for acute lymphoblastic leukemia CNS relapse, 335
Craniospinal irradiation
lomustine plus, pulmonary function following, 1481-1482
lung disease following, 1478-1485
Cremophor EL
concentrations of, in drugs associated with anaphylactoid reactions, 2513
role of, in childhood anaphylactoid reactions, 2508-2516
CSF
AS101 effect on, 2350
ventricular, methotrexate concentration in, position for, 177-179
Cure, possibility of, in breast cancer, 62-69
Cushing's syndrome, paraneoplastic, ketoconazole for, 157-164
Cyclophosphamide
acute myeloid leukemia following, 1557-1563
in chemoradiotherapy, plus granulocyte-macrophage colony-stimulating factor, 1632-1641
in CHOP regimen, for non-Hodgkin's lymphoma, 2666-2667
in combination chemotherapy
following etoposide, carboplatin regimen, 906
for desmoid tumor, 2815
for mantle-cell lymphoma, 2819-2826
for non-Hodgkin's lymphoma, 585, 2530-2539
residual lymphoma following, 594
for rhabdomyosarcoma, 610-623
high-dose, plus escalating-dose paclitaxel, 1160-1166
ifosfamide *v*, overview of, 307-309
in high-dose chemotherapy regimen
for breast cancer, 840-846
for metastatic breast cancer, 2484
in non-Hodgkin's lymphoma therapy, stratified by histology, 359-372
N,N-diethy-2-[4-(phenylmethyl)phenoxy]ethanamine plus, in prostate cancer, 1398-1403
paclitaxel plus
stem-cell mobilization with, 1714-1719
toxicity of, 1715-1716
in peripheral-blood progenitor-cell recruitment, 840-846
in preparative bone marrow transplantation regimen, 1704-1713
for stage II germ cell tumors, 2700
toxicity of, for stem-cell mobilization, 1715-1716
Cyclophosphamide, busulfan regimen, as allogeneic bone marrow transplantation conditioning regimen, 2973-2979
Cyclophosphamide, carmustine, etoposide, bone marrow transplantation regimen, for lymphoid malignancies, 596-602
Cyclophosphamide, carmustine, etoposide, hydroxyurea regimen, in malignant lymphoma, 1089-1095
Cyclophosphamide, daunorubicin, asparaginase, methotrexate, vincristine, prednisone regimen, 1368-1376
Cyclophosphamide, doxorubicin, etoposide regimen, in small-cell lung cancer, 1639
Cyclophosphamide, doxorubicin, fluorouracil regimen
in breast cancer, 1443-1452
oophorectomy plus, in breast cancer, 1453-1458
response to, 1447

time to treatment failure following, 1447
toxicity of, 1448-1449
treatment schema for, 1445
Cyclophosphamide, doxorubicin, methotrexate, fluorouracil regimen
in breast cancer, 831-839
disease-free survival following, 833-834
second malignancy following, 836
survival following, 834-835
toxicity of, 835-836
Cyclophosphamide, doxorubicin, vincristine regimen
clinical results of, in small-cell lung cancer, 1639
high-dose, for neuroectodermal tumor, 2796-2804
Cyclophosphamide, doxorubicin, vincristine, prednisone regimen
dose intensity of, 2390
dosing of, 2387
in elderly, with non-Hodgkin's lymphoma, 2386-2393
for non-Hodgkin's lymphoma, 2666-2667
outcome following, 2389-2390
survival following, 2391
toxicity following, 2392
weekly, 2386-2393
Cyclophosphamide, doxorubicin, vincristine, prednisone, granulocyte colony-stimulating factor regimen
high-dose, in non-Hodgkin's lymphoma, 2916-2923
response to, 2920-2921
toxicity of, 2918-2920
Cyclophosphamide, epirubicin, fluorouracil regimen, granulocyte colony-stimulating factor plus, in breast cancer, 1564-1571
Cyclophosphamide, epirubicin, fluorouracil regimen, lenogastrim plus, 1564-1571
Cyclophosphamide, epirubicin, vincristine, prednisone, bleomycin regimen
dosing of, 954
in non-Hodgkin's lymphoma, 953-960
toxicity of, 957
Cyclophosphamide, etoposide, prednisone, vincristine, doxorubicin, dexverapamil regimen, 1995-2004
phase I trial of, 1985-1994
response to, 1999-2000
toxicity of, 2000
Cyclophosphamide, interleukin-3, carboplatin regimen
in ovarian cancer, 733-740
side effects of, 737-738
Cyclophosphamide, methotrexate, fluorouracil, vincristine, prednisone regimen
in breast cancer, 831-839, 1443-1452
disease-free survival following, 833-834
response to, 1447
second malignancy following, 836
survival following, 834-835
time to treatment failure following, 1447
toxicity of, 835-836, 1448-1449
treatment schema for, 1445
Cyclophosphamide, methotrexate, fluorouracil regimen
disease-free survival following, 37
low-dose adjuvant, in breast cancer, 33-41
overall survival following, 37-38
time to distant metastases following, 36
time to local relapse following, 36
toxicity of, 35
Cyclophosphamide, thiotepa, granulocyte-macrophage colony-stimulating factor regimen, for mobilization, 705-714
Cyclophosphamide, vincristine, doxorubicin, dacarbazine regimen
dose-intensity analysis of, 1542, 1545
doxorubicin *v*, for soft tissue sarcoma, 1537-1545
nonhematologic toxicity of, 1544
survival following, 1540
toxicity of, 1540-1542
Cyclophosphamide, thiotepa, novobiocin regimen, with autologous bone marrow transplantation, in breast cancer, 1136-1143
Cyclosporine
carboplatin plus
discontinuation of, 2243
dose-limiting toxicities of, 2241-2242
nonhematologic toxicities of, 2242-2243
phase I trial of, 2238-2246
high-dose, anaphylactoid reactions in children following, 2508-2516
in preparative bone marrow transplantation regimen, 1704-1713
infusion of, maximal-tolerated dose of, 2238-2246
platelet toxicity associated with, 2241, 2242
Cystitis, hemorrhagic, following bone marrow transplantation, BK virus and, 1103-1109
Cytarabine
in combination regimen
for non-Hodgkin's lymphoma, 585
residual lymphoma following, 594
in consolidation, 3
in non-Hodgkin's lymphoma therapy, stratified by histology, 359-372
in peripheral-blood diploid cell collection, 553-559
in R-11 protocol, for acute lymphoblastic leukemia CNS relapse, 335
response rates following, 2
as single agent, in non-Hodgkin's lymphoma, 586
Cytarabine, carmustine, etoposide, melphalan regimen
in Hodgkin's disease, 396-402
protocol for, 397-398
results of, 400
Cytarabine, carmustine, etoposide, melphalan, bone marrow transplantation regimen, in non-Hodgkin's lymphoma, 588-595
Cytarabine, etoposide, methylprednisone, cisplatin regimen, in non-Hodgkin's lymphoma, 1734-1741
Cytarabine, etoposide, mitoxantrone regimen
in acute myeloid leukemia, 11-18
disease-free survival following, 15
efficacy of, 14-15
induction of, 13
postinduction reception of, 13-14
survival following, 14
Cytokeratin 19, expression of, in lung cancer, 2769-2775
Cytokine(s)
concentrations of
following MDX-210, 2287
in isolated limb perfusion, 266-268
currently approved, 1023-1025
induction of, 485-486
in leukemia, 1031
levels of, following isolated limb perfusion, 264-273
not yet released, 1025-1028
production of, 1946-1947
Cytokine receptor, differences in, 543
Cytopenia
bone marrow failure due to, 1029-1030

chemotherapy-associated, growth factors for, 1028-1029
following bone marrow transplantation, 1030
following high-dose chemotherapy, 1030
CYVADIC regimen, *see* Cyclophosphamide, vincristine, doxorubicin, dacarbazine regimen

Dacarbazine, in CYVADIC regimen
dose-intensity analysis of, 1542, 1545
for soft tissue sarcoma, 1537-1545
nonhematologic toxicity of, 1544
survival following, 1540
toxicity of, 1540-1542
Dactinomycin
in combination chemotherapy
for desmoid tumor, 2815
for rhabdomyosarcoma, 610-623
for stage II germ cell tumors, 2700
Dactinomycin, vincristine regimen
outcome following, 130
in Wilms' tumor, 124-133
Dana-Farber Cancer Institute, clinical trials in, women participation in, 293-299
Daunorubicin
for induction, 2
in non-Hodgkin's lymphoma therapy, stratified by histology, 359-372
liposomal, *see* Liposomal duanorubicin
in peripheral-blood diploid cell collection, 553-559
response rates following, 2
Daunorubicin, asparaginase, methotrexate, cyclophosphamide, vincristine, prednisone regimen, 1368-1376
DaunoXome, 996-1003
Death, physician-assisted, definition of, 1061
Decision Board
for breast irradiation, following lumpectomy, 847-853
patient acceptance of, 850
patient comprehension of, 850
pretesting of, 848
schematic of, 848
true or false statements of, 849
Decision instrument
clinic post-, 849
clinic pre-, 849
development of, 847-848
for radiotherapy, in node-negative lumpectomy, 847-853
patient comprehension of, evaluation of, 849
statistical analysis of, 849
testing results of, 849-850
Decision making, patient
in laryngeal cancer, 2369-2378
social well being and, 1255-1264
Decision tree, radiation *v* surgery for, in laryngeal cancer, 2371
Depression
following pancreas cancer diagnosis, 748-755
in pancreas cancer, 751-752
postmenopausal estrogen replacement therapy and, in breast cancer, 2740
symptoms of, 751-752
Desmoid tumor, pediatric, recurrence of, 2813-2818
Dexamethasone
adverse events following, 2424
in combination regimen
for non-Hodgkin's lymphoma, 585
residual lymphoma following, 594
dose adjustment of, by chemotherapy, 2117-2122
efficacy of, 2120, 2417-2426
granisetron plus, efficacy of, 2417-2426
in M-BACOD regimen, for non-Hodgkin's lymphoma, 2666-2667
in non-Hodgkin's lymphoma therapy, stratified by histology, 359-372
ondansetron plus, efficacy of, 2120
premedication with, toxicity and, 2898
safety of, 2121
Dexverapamil
cardiovascular toxicity of, 1961
dose escalation of, 1987-1988
pharmacokinetics of, 1988-1990
phase I trial of, 1985-1994
in refractory lymphomas, 1995-2004
toxicity of, 1988
vinblastine plus
hematologic toxicity of, 1960
in renal cell cancer, 1958-1965
treatment schema for, 1959
Dexverapamil, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin regimen, 1995-2004
phase I trial of, 1985-1994
response to, 1999-2000
toxicity of, 2000
Diarrhea
fluoropyrimidine-induced, octreotide acetate for, 222-226
irinotecan-associated, 213
loperamide treatment of, 211-212
Diethyldithiocarbamate
for cisplatin-induced toxicity, 490-496
response to, 494
Differential stromal adherence, for in vitro purging, 543
Differentiation marker, in stage I non–small-cell lung cancer, 1271-1272
Dihydropyrimidine dehydrogenase, inhibition of, in fluorouracil therapy, 1663-1670
Dihydropyrimidine reductase, fluorouracil responsiveness and, 1663-1670
Dimethylsulfoxide
topical, 2851-2855
in ulceration prevention, 2852-2853
Diphtheria toxin fusion protein, in combination regimen, for non-Hodgkin's lymphoma, 585
Dipyridamole, leucovorin, fluorouracil regimen
in colorectal cancer, 1201-1208
dose-intensity of, 1204
oral, toxicity of, 1203-1204
Disclosure
of bad news, 2451
full, 2451
individualized, 2451
model for, 2450
principles for, 2453
procedure for, 2452-2453
publications on, 2452
recommendations for, 2452
steps for, 2453-2454
DNA, sequence alterations of, in benign breast tissue, 2297
DNA content, in stage I non–small-cell lung cancer, 1272-1273

Docetaxel
in advanced breast cancer, 314-322
in breast cancer, phase II trial of, 2879-2885
carboplatin following, in ovarian cancer, 1584-1588
clinical trials of, 2643-2652
current status of, 2865-2868
efficacy of, 318-319
fluid retention with, 318
hematologic toxicities of, 317, 648
in melanoma, phase II trial of, 2895-2899
nonhematologic toxicities of, 317, 648
pharmacokinetics of, 2645-2646
phase II trial of, 314-322, 645-651
for platinum-refractory non–small-cell lung cancer, 645-651
preclinical evaluation of, 2643-2645
response to, 647-648, 2888-2889
safety profile of, 2889-2891
survival following, 319
tolerance to, 317-318
in phase II trials, 2650-2652
toxicity of, 648-649, 2881-2883, 2897
in vitro activity of, 2644
in vivo activity of, 2645
Dopamine, prophylaxis with, for cisplatin-induced side effects, 1231-1237
Dose administration, of paclitaxel and doxorubicin, in breast cancer, 2689
Dose intensity
in anthracycline-refractory advanced breast cancer, 2569-2570
of gemcitabine, for advanced breast cancer, 2731-2732
in combined modality therapy, for advanced soft tissue sarcoma, 2629-2636
in elderly patients with non-Hodgkin's lymphoma, 2533
of intravenous vinorelbine, for advanced breast cancer, 2724-2725
radiation pneumotitis and, 2608-2609
Dose-intensity analysis
of CYVADIC regimen, for soft tissue sarcoma, 1542, 1545
of doxorubicin, for soft tissue sarcoma, 1542, 1545
of ifosfamide, doxorubicin regimen, for soft tissue sarcoma, 1542, 1545
ovarian cancer outcome and, 1589-1599
Dosing, in clinical trials, patient perceptions of, 1062-1072
Doxifluridine
in combination chemotherapy, for advanced colorectal cancer, 2613-2619
pharmacokinetics of, 2614-2618
Doxorubicin
breast cancer resistant to, docetaxel in, 2879-2885, 2886-2894
cardiac mechanics following, 1552
in chemoradiotherapy, plus granulocyte-macrophage colony-stimulating factor, 1632-1641
in CHOP regimen, for non-Hodgkin's lymphoma, 2666-2667
in combination chemotherapy
for breast cancer, 1443-1452
following etoposide, carboplatin regimen, 906
plus granulocyte colony-stimulating factor, for advanced soft tissue sarcoma, 2629-2636
for mantle-cell lymphoma, 2819-2826
for non-Hodgkin's lymphoma, 585, 2530-2539
residual lymphoma following, 594
for rhabdomyosarcoma, 610-623
cyclophosphamide, vincristine, doxorubicin, dacarbazine regimen *v*, 1537-1545
in CYVADIC regimen, 1537-1545
dose-intensity analysis of, 1542, 1545
ifosfamide, doxorubicin regimen *v*, for soft tissue sarcoma, 1537-1545
late cardiotoxicity following, 1546-1556
left ventricular performance following, 1551
liposomal, *see* Liposomal doxorubicin
in nasal lymphoma, 666-670
in non-Hodgkin's lymphoma therapy, stratified by histology, 359-372
nonhematologic toxicity of, 1544
in ovarian cancer, 726-732
pharmacokinetics of, 1990-1991
plus paclitaxel, for metastatic breast cancer, 2688-2699
for sarcoma, overview of, 1531-1533
as second cancer risk factor, 1856
in Stanford V regimen
dosing of, 1086
for Hodgkin's disease, 1081
survival following, 1540
in testicular lymphoma, 1361-1367
toxicity of, 1540-1542
Doxorubicin, chlorambucil, vinblastine, procarbazine, prednisolone, etoposide, vincristine regimen, gonadal function following, 134-139
Doxorubicin, chlorambucil, vinblastine, procarbazine, prednisone, etoposide, vincristine regimen
dosing of, 2380
in Hodgkin's disease, 2379-2385
response to, 2381
survival following, 2382
Doxorubicin, cyclophosphamide, etoposide regimen, clinical results of, in small-cell lung cancer, 1639
Doxorubicin, cyclophosphamide, fluorouracil regimen
in breast cancer, 1443-1452
oophorectomy plus, in breast cancer, 1453-1458
response to, 1447
time to treatment failure following, 1447
toxicity of, 1448-1449
treatment schema for, 1445
Doxorubicin, cyclophosphamide, methotrexate, fluorouracil regimen
disease-free survival following, 833-834
in breast cancer, 831-839
second malignancy following, 836
survival following, 834-835
toxicity of, 835-836
Doxorubicin, cyclophosphamide, vincristine regimen
clinical results of, in small-cell lung cancer, 1639
high-dose, for neuroectodermal tumor, 2796-2804
Doxorubicin, cyclophosphamide, vincristine, prednisone regimen
dose-intensity of, 2390
dosing of, 2387
in elderly, with non-Hodgkin's lymphoma, 2386-2393
outcome following, 2389-2390
survival following, 2391
toxicity following, 2392
weekly, 2386-2393
Doxorubicin, cyclophosphamide, vincristine, prednisone, granulocyte colony-stimulating factor regimen
high-dose, in non-Hodgkin's lymphoma, 2916-2923
response to, 2920-2921
toxicity of, 2918-2920

Doxorubicin, etoposide, prednisone, vincristine, cyclophosphamide, dexverapamil regimen, 1995-2004
phase I trial of, 1985-1994
response to, 1999-2000
toxicity of, 2000
Doxorubicin, etoposide, vinblastine regimen
in relapsed Hodgkin's disease, 2005-2011
toxicity of, 2009
Doxorubicin, fluorouracil, mitomycin regimen, adjuvant, in gastric cancer, 2757-2763
Doxorubicin, ifosfamide regimen
dose-intensity analysis of, 1542, 1545
doxorubicin *v*, for soft tissue sarcoma, 1537-1545
nonhematologic toxicity of, 1544
survival following, 1540
toxicity of, 1540-1542
Doxorubicin, methotrexate, vinblastine, cisplatin regimen, neoadjuvant, in bladder cancer, 1384-1390
Doxorubicin, methotrexate, vinblastine, cisplatin, granulocyte-macrophage colony-stimulating factor regimen
in bladder cancer, 2272-2277
hematologic toxicity of, 2275
infection following, 2274
Doxorubicin, teniposide, melphalan, cisplatin, total-body irradiation regimen, for bone marrow transplantation, 2789-2795
Doxorubicin, vinblastine, thiotepa, halotestin regimen
in breast cancer, 1443-1452
response to, 1447
time to treatement failure following, 1447
toxicity of, 1448-1449
treatment schema for, 1445
Drugs, new
funding of, 2459-2460
funding strategies for, 2460-2462
societal strategies for, 2461

Echocardiography, following doxorubicin, 1549
Economic analysis, *see* Cost analysis
Ectopic adrenocorticotropin production, Cushing's syndrome secondary to, ketoconazole for, 157-164
Edatrexate
hematologic toxicity of, 1652
methotrexate *v*, in head and neck cancer, 1649-1655
nonhematologic toxicity of, 1653
survival duration following, in head and neck cancer, 1654
survival following, in head and neck cancer, 1652
Eight-drugs-in-one-day regimen
for pineoblastoma, 1377-1383
survival following, 116
toxicity of, 118
v vincristine, lomustine, prednisone regimen, phase III trial of, 112-123
Elderly, cyclophosphamide, doxorubicin, vincristine, prednisone regimen in, 2386-2393
EMA-86 regimen, 12
disease free survival following, 15
efficacy of, 14-15
induction of, 13
survival following , 14
toxicity of, 15-16
Embryonal tumor, of CNS, carboplatin, etoposide regimen for, 2247-2254
Emesis
chemotherapy-induced, 5-hydroxytryptamine-3 receptor antagonist for, 1036-1043
cisplatin-based clinical trials for, 1040-1041
cisplatin-induced, granisetron *v* ondansetron for, 1242-1248
delayed, oral ondansetron for, 2408-2416
dexamethasone plus granisetron for, 2417-2426
marker in, chromogranin A as, 681-687
non–cisplatin based clinical trials for, 1038-1040
pathophysiology of, 1036-1037
End-systolic wall stress, following doxorubicin, 1548, 1551
Endocrine therapy, response to, angiogenesis prediction of, 772-773
Endometrial cancer, brain tumor associated with, 2931-2935
Endoscopy, basal, in nonsteroidal antiinflammatory drug cancer pain management, 2638
Enterochromaffin cell, 1037
gastrointestinal, 681-687
Epidural metastasis, spinal cord compression due to, 2330-2335
Epirubicin, dose intensity of
by age, 958
by complete remission, 958
Epirubicin, cisplatin, radiotherapy regimen, in cervical cancer, 444-451
Epirubicin, cyclophosphamide, fluorouracil regimen
granulocyte colony-stimulating factor plus, in breast cancer, 1564-1571
lenogastrim plus, 1564-1571
Epirubicin, cyclophosphamide, vincristine, prednisone, bleomycin regimen
dosing of, 954
in non-Hodgkin's lymphoma, 953-960
Epirubicin, fluorouracil, cisplatin regimen
in breast cancer, 424-429
toxicity of, 427
Epirubicin, vincristine, etoposide, prednisolone regimen
acute toxicity of, 390
in Hodgkin's disease, 387-395
mortality associated with, 390-391
Epstein-Barr virus, in human immunodeficiency virus-associated Hodgkin's disease, 1762
Erwinia, in asparaginase development, 339
Escherichia coli, 244
in asparaginase development, 339
Estrogen receptor, in node-negative breast cancer, 697-704
Estrogen replacement therapy
breast cancer and, 2737-2744
patient willingness and, 2740-2741
Ethics
of conflict of interest, 2465-2466
of conflict resolution, 2468-2469
general principles of, 2464-2465
of phase I trials, 1049-1051
in oncology, 2464-2470
of patient bedside decision-making, 2465
primer in, 2464-2467
principles of, practical application of, 2466-2467
of risk management, 2466
Etoposide
age-dependent dose calculation of, 2954-2960
carboplatin plus
in embryonal CNS tumors, 2247-2254
in extraocular retinoblastoma, 902-909

phase II trial of, 902-909
response to, 2249, 2252
survival following, 2249-2250
toxicity of, 2250-2251
tumor response to, 903
chemical structure of, 2836
in chemoradiotherapy, plus granulocyte-macrophage colony-stimulating factor, 1632-1641
in chiasmatic-hypothalamic glioma, 2072-2076
cisplatin and, in stage II germ cell tumors, 2700-2704
cisplatin plus
efficacy of, 1438-1439
myelotoxicity of, 1441
in small-cell lung cancer, 1436-1442, 1871-1879
toxicity of, 1439-1440
treatment regimen for, 1437
clearance of, by age, 2957
in combination chemotherapy
for desmoid tumor, 2815
following etoposide, carboplatin regimen, 906
for neuroectodermal tumor, 2797, 2802
for non-Hodgkin's lymphoma, 585, 2530
residual lymphoma following, 594
for small-cell lung cancer, 2594-2599
for testicular cancer, 2681-2683
complications of, AS101 prevention of, 2342-2353
daily oral
in germ cell tumors, 1167-1169
response to, 196
dosing of
in Stanford V regimen, 1086
secondary leukemias and, 288-289
hyperfractionated oral, 191-199
in high-dose chemotherapy regimen, for breast cancer, 840-846
in Stanford V regimen, for Hodgkin's disease, 1081
levels of, by age, 2957
limited-sampling model for, 193-194
for maintenance, in germ cell tumors, 1167-1169
pharmacokinetics of, 193, 1990-1991, 2835-2841
pharmcodynamics of, 194-195
in R-11 protocol, for acute lymphoblastic leukemia CNS relapse, 335
scheduling of, phase III trial of, 1871-1879
as single agent, in non-Hodgkin's lymphoma, 586
3-day intravenous, with intravenous cisplatin, 1871-1879
toxicity of, 194-195
21-day oral, with intravenous cisplatin, 1871-1879
Etoposide phosphate
chemical structure of, 2836
cisplatin plus
efficacy of, 1438-1439
myelotoxicity of, 1441
in small-cell lung cancer, 1436-1442
toxicity of, 1439-1440
treatment regimen for, 1437
formulation of, 202
intravenous, etoposide bioequivalence of, 2835-2841
limited-sampling modeling of, 202, 204-206
neutropenia following, 203
nonhematologic toxicity of, 204
pharmacokinetics of, 204-206, 2838
phase I trial of, 200-209
plasma levels of, 205
Etoposide, carboplatin, radiation regimen
metastasis-free survival following, 455
in non–small-cell lung cancer, 452-458
response to, 456
survival following, 454
Etoposide, carmustine, cyclophosphamide, hydroxyurea regimen, in malignant lymphoma, 1089-1095
Etoposide, carmustine, cytarabine, melphalan regimen
in Hodgkin's disease, 396-402
protocol for, 397-398
results of, 400
Etoposide, carmustine, cytarabine, melphalan, bone marrow transplantation regimen, in non-Hodgkin's lymphoma, 588-595
Etoposide, chlorambucil, vinblastine, prednisolone, procarbazine, doxorubicin, vincristine regimen, gonadal function following, 134-139
Etoposide, chlorambucil, vinblastine, prednisone, procarbazine, doxorubicin, vincristine regimen
dosing of, 2380
in Hodgkin's disease, 2379-2385
response to, 2381
survival following, 2382
Etoposide, cisplatin regimen
clinical results of, in small-cell lung cancer, 1639
in germ cell tumors, 470-476
response to, 472-473
survival following, 474
Etoposide, cisplatin, bleomycin regimen
fertility following, 2278-2280
for carcinoma of unknown primary, 1720-1725
in germ cell tumors, 470-476
response to, 472-473
survival following, 474
Etoposide, cisplatin, radiotherapy regimen, in non–small-cell lung cancer, 1880-1892
Etoposide, cyclophosphamide, carmustine, bone marrow transplantation regimen, for lymphoid malignancies, 596-602
Etoposide, cyclophosphamide, doxorubicin regimen, clinical results of, in small-cell lung cancer, 1639
Etoposide, ifosfamide, carboplatin regimen
dosing escalation of, 325-326
hematologic toxicity of, 326
hematopoietic recovery following, 327
in small-cell lung cancer, 1615-1622
maximum-tolerated doses of, 323-332
nonhematologic toxicity of, 326-329
outcomes of, 329
phase I dosing trial of, 323-332
published maximum-tolerated doses of, 331
toxic deaths of, 329
toxicity of, 1618-1619
Etoposide, ifosfamide, carboplatin, granulocyte colony-stimulating factor regimen
doubling dose-intensity of, with blood reinfusion, 148-156
hematologic toxicity of, 154
toxicity of, 152-154
Etoposide, ifosfamide, cisplatin regimen
granulocyte-macrophage colony-stimulating factor plus, for germ cell tumor, 79-86
hematologic efficacy of, 82
infection analysis following, 81-82

recycling intervals following, 82-83
in small-cell lung cancer, 1209-1214
toxicity of, 83, 84, 1211
Etoposide, ifosfamide, mitoxantrone, bleomycin regimen
dosing of, 954
in non-Hodgkin's lymphoma, 953-960
toxicity of, 957
Etoposide, mesna, ifosfamide, mitoxantrone regimen, in non-Hodgkin's lymphoma, 1734-1741
Etoposide, methylprednisone, cytarabine, cisplatin regimen
in non-Hodgkin's lymphoma, 1734-1741
Etoposide, mitoxantrone, cytarabine regimen
in acute myeloid leukemia, 11-18
disease-free survival following, 15
efficacy of, 14-15
induction of, 13
postinduction reception of, 13-14
survival following, 14
Etoposide, paclitaxel, cisplatin regimen
response to, 1433
in small-cell lung cancer, 1430-1435
survival following, 1433-1434
toxicity of, 1432-1433
treatment schema for, 1431
Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, dexverapamil regimen
phase I trial of, 1985-1994
response to, 1999-2000
toxicity of, 2000
Etoposide, vinblastine, doxorubicin regimen
in relapsed Hodgkin's disease, 2005-2011
toxicity of, 2009
Etoposide, vincristine, epirubicin, prednisolone regimen
acute toxicity of, 390
in Hodgkin's disease, 387-395
mortality associated with, 390-391
Etoposide, vincristine, ifosfamide, carboplatin regimen
response to, 656-657
in small-cell lung cancer, 652-659
toxicity of, 656
Etoposide, vincristine, ifosfamide, carboplatin, granulocyte colony-stimulating factor regimen
response to, 656-657
in small-cell lung cancer, 652-659
toxicity of, 656
European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire, test and retest study of, 1249-1254
Euthanasia
active, oncologist attitude toward, 1055-1061
definition of, 1061
passive, attitude toward, 1059
Ewing's sarcoma
high-dose melphalan in, 1794-1795
pelvic, surgery in, 2336-2341
Extended lymph node dissection, in gastric cancer, 5-7
Extramedullary leukemia
acute myelogenous leukemia induction chemotherapy in, 1806
as acute myelogenous leukemia recurrence, 1808-1809
in acute nonlymphocytic leukemia, 1800-1816
at acute nonlymphocytic leukemia presentation, 1806-1807
adult, 1808
blast differentiation in, 1803
blast functional capacity in, 1803
cell-surface markers in, 1802-1803
chromosome abnormalities in, 1802
cytogenetics in, 1801-1802
follow-up of, 1809-1810
incidence of, 1800-1801
infantile, 1807
lymphoma chemotherapy regimens in, 1807
manifestations of, 1801
pathologic features of, 1804
pediatric, 1807-1808
predisposing risk factors for, 1801-1804
primary, features of, 1804-1805
radiographic features of, 1804
risk factors for, 1803-1804
temporal definitions of, 1801
treatment of, 1809-1810
Extranodal lymphoma, frequency of, 2665-2666
Extraocular retinoblastoma
computed tomography of, 904
etoposide plus carboplatin in, phase II trial of, 902-909

18-F-2-fluoro-2-deoxy-D-glucose, PET studies with, in therapy evaluation, 1470-1477
FACT-B scale
in breast cancer, 860
scores on, 862
Factor VIII-related antigen, in gastric cancer, 477-481
Febrile episode, following peripheral-blood progenitor-cell transplant, 939
Fertility, following cisplatin, etoposide, bleomycin regimen, 2278-2280
Fever
ceftazidime *v* imipenem for, 165-176
unexplained, clinical outcome in, 169-170
FISH, *see* Fluorescent in situ hybridization
Flow cytometry
circulating hematopoietic progenitor evaluation by, 936-937
in stage I non–small-cell lung cancer, 1272-1273
Fludarabine
2-chlorodeoxyadenosine and, 983-988
in combination chemotharpy, for non-Hodgkin's lymphoma, 585
infectious complications of, 2431-2448
myelotoxicity of, 2434-2436
in peripheral-blood diploid cell collection, 553-559
as single agent, in non-Hodgkin's lymphoma, 586
Fluid retention, following docetaxel, 645-651
Fluorescent in situ hybridization
analysis of, in peripheral-blood mononuclear cells, 558
in cytogenetics, 554, 556
in p53 analysis, 813
of poorly differentiated cancer of unknown primary site, 277-279
Fluoropyrimidine, diarrhea associated with, octreotide acetate for, 222-226
Fluorouracil
adjuvant levamisole plus, in colon cancer, 2936-2943
bolus of, plus interferon alfa-2b, 1297-1302
bolus *v* infusional, 1303-1311
carboplatin plus, in head and neck cancer, 1493-1500
cisplatin plus, in head and neck cancer, 1493-1500
in combination chemotherapy

for desmoid tumor, 2815
oral mucositis following, 2620-2628
continuous infusion, interferon alfa-2b plus, 1486-1492
hepatic arterial, plus leucovorin, 2968-2972
interferon alfa-2b plus
in colorectal cancer, 2317-2323
complications following, 1489
for neuroendocrine tumors, 1486-1492
outcome following, 1489-1490
survival following, 1299, 1301, 2320-2321
toxicity of, 1300, 2320
leucovorin plus
dose escalation of, 2969
response to, 2970-2971
schedule of, 2969
toxicity of, 2969-2970
modulation of, in colorectal cancer, 1303-1311
predicting response to, in breast cancer, 419-423
predictive assay for, 419-423
protracted infusion of, plus radiotherapy
compliance with, 228-229
for pancreaticobiliary tumors, 227-232
survival following, 230
toxicity of, 229
protracted venous infusion of, 2317-2323
received *v* expected dose of, 924
response to, 1307
dihydropyrimidine dehydrogenase and, 1663-1670
survival following, 1307-1309
toxicity of, 1305-1307
Fluorouracil, cisplatin, leucovorin, interferon alfa-2b induction regimen, in head and neck cancer, 876-883
Fluorouracil, cyclophosphamide, doxorubicin regimen
in breast cancer, 1443-1452
oophorectomy plus, in breast cancer, 1453-1458
response to, 1447
time to treatment failure following, 1447
toxicity of, 1448-1449
treatment schema for, 1445
Fluorouracil, cyclophosphamide, methotrexate regimen
disease-free survival following, 37
low-dose adjuvant, in breast cancer, 33-41
overall survival following, 37-38
time to distant metastases following, 36
time to local relapse following, 36
toxicity of, 35
Fluorouracil, cyclophosphamide, methotrexate, vincristine, prednisone regimen
in breast cancer, 831-839, 1443-1452
disease-free survival following, 833-834
response to, 1447
second malignancy following, 836
survival following, 834-835
time to treatment failure following, 1447
toxicity of, 1448-1449, 835-836
treatment schema for, 1445
Fluorouracil, doxorubicin, cyclophosphamide, methotrexate regimen
disease-free survival following, 833-834
in breast cancer, 831-839
second malignancy following, 836
survival following, 834-835
toxicity of, 835-836
Fluorouracil, doxorubicin, mitomycin regimen, adjuvant, in gastric cancer, 2757-2763
Fluorouracil, epirubicin, cisplatin regimen
in breast cancer, 424-429
toxicity of, 427
Fluorouracil, epirubicin, cyclophosphamide regimen
granulocyte colony-stimulating factor plus, in breast cancer, 1564-1571
lenogastrim plus, 1564-1571
Fluorouracil, leucovorin regimen
in colorectal cancer, 921-928
phase III trial of, 921-928
response to, 923
survival following, 924-925
toxicity of, 924-925
treatment start until death with, 925
Fluorouracil, leucovorin, cisplatin regimen
in head and neck cancer, 1656-1662
pharmacokinetics of, 1658-1659
response to, 1658
toxicity of, 1658
Fluorouracil, leucovorin, dipyridamole regimen
dose intensity of, 1204
in colorectal cancer, 1201-1208
toxicity of, 1203-1204
Fluorouracil, hydroxyurea, radiotherapy regimen
dose intensity of, 879
in head and neck cancer, 876-883
Fluorouracil, interferon alfa-2a regimen
in colorectal cancer, 921-928
phase III trial of, 921-928
response to, 923
survival following, 924-925
toxicity of, 924-925
treatment start until death with, 925
Flutamide
prior to suramin, 2183
withdrawal of, suramin response and, 2219
hepatic arterial fluorouracil plus, 2968-2972
Forkhead gene, 2127
Fractional shortening
following doxorubicin, 1548, 1551
screening by, 1553
Functional Assessment of Cancer Therapy scale, for quality of life, 860
Functional Living Index Cancer, in pancreas cancer, 748-755

Gallium citrate scintigraphy
for benign hilar uptake *v* lymphoma, 942-946
for intermediate-grade non-Hodgkin's lymphoma, 945
for lymphoma, 942-946
in nonresponding high-grade non-Hodgkin's lymphoma, 944
quantitation technique in, 943
for seminoma residual masses, 2784-2788
Gastrectomy, in lymphoid tissue lymphoma, 2525
Gastric cancer
adjuvant fluorouracil, doxorubicin, mitomycin regimen in, 2757-2763
lymph node staging standards in, 2309-2316
recurrence in
anti-factor VIII-related antigen antibody for, 477-481
microvessel count for, 477-481

survival in, 5-7
urokinase-type plasminogen activator system in, 2084-2093
Western *v* Japanese survival rates of, 19-25
Gastric lymphoma, primary, single-agent chemotherapy for, 2524-2529
Gastrointestinal toxicity
due to small-bowel irradiation, 1409-1416
in nonsteroidal antiinflammatory drug cancer pain mangement, 2637-2642
Gemcitabine, phase II trial of, for advanced breast cancer, 2731-2736
Gene(s), rearrangement of, in cutaneous T-cell lymphoma, 1752
Gene-transduced cell, 410-418
Genetic analysis, of poorly differentiated cancer of unknown primary site, 276-278
Germ cell tumor
alpha-fetoprotein half-life in, 87-92
beta-human chorionic gonadotropin half-life in, 87-92
bleomycin in, 470-476
chemotherapy for
fertility following, 2278-2280
second leukemia following, 287
cisplatin, etoposide regimen in, 470-476
cisplatin, etoposide, bleomycin regimen in, 470-476
in human immunodeficiency virus-infected men, 1391-1397
ifosfamide-based chemotherapy for, with granulocyte-macrophage colony-stimulating factor, 79-86
Indiana staging system for, 471
maintenance etoposide in, 1167-1169
metastatic, marker half-life in, 87-92
residual mass histology of, 1177-1187
stage I nonseminomatous testicular
recurrence detection in, 1188-1194
watchful waiting follow-up in, 1188-1194
stage II, combination chemotherapy for, 2700-2704
stage of, at presentation, 1392
teratoma *v*, model prediction of, 1183
testicular, human immunodeficiency virus and, 2705-2711
Glioma
chiasmatic-hypothalamic, etoposide in, 2072-2076
malignant, radiosurgery for, 1642-1648
Glutathione, 1787
hemotransfusion requirements following, 30
neuroprotective effect of, following cisplatin, 26-32
toxicities associated with, 30
Glutathione S-transferase pi
for chemotherapy response, 70-78
distribution of, in ovarian cancer, 73
as ovarian cancer prognostic factor, 70-78
Gonadal function, following chemotherapy, in Hodgkin's disease, 134-139
Gonadal toxicity, of vincristine, epirubicin, etoposide, prednisolone regimen, 387-395
Graft-versus-host disease
minimal residual disease patterns associated with, 1704-1713
prevention of, in allogeneic bone marrow transplantation, 1313-1314
Granisetron
adverse events following, 2424
dexamethasone plus, 2417-2426
efficacy of, 2417-2426
ondansetron *v*, for cisplatin-induced emesis, 1242-1248
Granulocyte colony-stimulating factor
combination chemotherapy and, for soft tissue sarcoma, 2629-2636
effect of, on outcome parameters, 1326
following peripheral-blood progenitor-cell transplant, in non-Hodgkin's lymphoma, 935-941
following stem-cell transplantation, 1323-1327
for induction chemotherapy, in breast cancer, 1564-1571
for neutrophil engraftment, 1323-1327
paclitaxel, cyclophosphamide regimen plus, for stem-cell mobilization, 1714-1719
plasma concentrations of, following MDX-210, 2288
in small-cell lung cancer, 652-659
Granulocyte colony-stimulating factor, cyclophosphamide, doxorubicin, vincristine, prednisone regimen
high-dose, in non-Hodgkin's lymphoma, 2916-2923
response to, 2920-2921
toxicity of, 2918-2920
Granulocyte colony-stimulating factor, ifosfamide, carboplatin, etoposide regimen
doubling dose-intensity of, with blood reinfusion, 148-156
hematologic toxicity of, 154
toxicity of, 152-154
Granulocyte colony-stimulating factor, vincristine, ifosfamide, carboplatin, etoposide regimen, 652-659
response to, 656-657
toxicity of, 656
Granulocyte-macrophage colony-stimulating factor
chemoradiotherapy plus, in small-cell lung cancer, 1632-1641
in head and neck cancer, 2620-2628
with ifosfamide-based chemotherapy, 79-86
in peripheral-blood progenitor cell recruitment, 840-846
interleukin-3 fusion protein, 1026-1027
Granulocyte-macrophage colony-stimulating factor, cyclophosphamide, thiotepa regimen, for mobilization, 705-714
Granulocyte-macrophage colony-stimulating factor, methotrexate, vinblastine, doxorubicin, cisplatin regimen
in bladder cancer, 2272-2277
hematologic toxicity of, 2275
infection following, 2274
Growth, pubertal, following cranial irradiation, 2503-2507
Growth factor, hematopoietic, *see* Hematopoietic growth factor

H-Ley-Leb antigens, in stage I non–small-cell lung cancer, 1272
Hair, AS101 sparing of, 2342-2353
Halotestin, vinblastine, doxorubicin, thiotepa regimen
in breast cancer, 1443-1452
response to, 1447
time to treatment failure following, 1447
toxicity of, 1448-1449
treatment schema for, 1445
Halsted theory, 8
Hand-foot syndrome, associated with liposomal doxorubicin, 1780
Head and neck cancer
carboplatin plus fluorouracil in, 1493-1500
cell kinetics in, 1843-1850
cisplatin, fluorouracil, leucovorin regimen in, 1656-1662
cisplatin plus fluorouracil in, 1493-1500
granulocyte-macrophage colony-stimulating factor efficacy and, in head and neck cancer, 2620-2628
induction chemotherapy plus concomitant chemoradiotherapy in, 876-883

prognostic factors in, 880-881
squamous cell, edatrexate *v* methotrexate in, 1649-1655
Head tumor, 620
see also Head and Neck cancer
Heart disease, estrogen replacement therapy and, 2742
Hematopoietic growth factor
clinical applications of, 1023-1035
future directions in, 1032
profile of, 1025
toxicities associated with, 1031-1032
Hematopoietic rescue
clinical outcome variables in, 1331
following peripheral-blood stem-cell transplantation, 939, 1922-1932
Hemoglobin
levels of, interleukin-6 and, in non–small-cell lung cancer therapy, 2589-2590
pretreatment levels of, laryngeal cancer survival and, 2077-2083
Hemolysis, immune-mediated, 2403
Hemorrhagic cystitis, BK virus and, 1103-1109
HER-2-*neu*
anti-, monoclonal antibody MDX-210 as, 2281-2292
low-level expression of, in benign breast tissue, 2293-2300
overexpression of, following hormonal therapy, 1129-1135
p53 interaction with, 823-825
in stage I non–small-cell lung cancer, 1270
Hickman catheter
complications of, 2320
placement of, 234
High-dose chemotherapy
in acute myelogneous leukemia, 1-4
autologous stem-cell support plus, in breast cancer, 2043-2049, 2050-2055
autologous transplantation plus, costs of, 969-973
in breast cancer, 2477-2479
four-step sequential, with double hematopoietic rescue, 840-846
hematopoietic rescue following, 1328-1335, 2483-2489
in malignant lymphoma, 1089-1095
for multiple myeloma, 1291-1296
High-performance liquid chromatography, 2955
Histologic grade, physician perception of, in node-negative breast cancer, 1459-1469
Histologic subtype
failure site by, 368
treatment by, 365
Hodgkin's disease
and human immunodeficiency virus infection, 1758-1767
bone marrow involvement in, 403-409
carmustine, etoposide, cytarabine, melphalan regimen in, 396-402
chlorambucil, vinblastine, prednisolone, procarbazine, doxorubicin, vincristine, etoposide regimen in, 134-139
combined modality therapy in, second cancer following, 2016-2022
etoposide, vinblastine, doxorubicin regimen in, 2005-2011
genotypic analysis of, 1759-1760
gonadal function in, following chemotherapy, 134-139
high-dose therapy plus autologous transplantation in, 970
Homosexuals, malignancies in, 2540-2546, 2684-2687
Hormonal therapy
decreased response to, elevated serum c-*erb*B-2 and, 1129-1135
HER-2-*neu* overexpression following, 1129-1135
response to, angiogenesis prediction of, 772-773
tumor flare following, for breast cancer, 1123-1128
Hormone receptor status, physician perception of, 1459-1469
Hospital ethics committee, for resolving conflicts, 2468-2469
Hospitalization
average costs of, for high-dose therapy plus autologous transplantation, 971
following peripheral-blood progenitor-cell transplant, 939
5-HT3 receptor antagonist, *see* 5-Hydroxytryptamine-3 receptor antagonist
Human immunodeficiency virus
human immunodeficiency virus-associated Epstein-Barr virus in, 1762
survival in, 1764
in homosexual men, 2540-2545
laparotomy-staged IA to IIA, mantle irradiation for, 947-952
mantle study in, 948
mechlorethamine, vinblastine, prednisolone, procarbazine regimen in, 134-139
presenting clinical characteristics in, 404-405
relapse rates in, by prognostic factor, 949
relapse site in, 949
Stanford regimen in, 1080-1088
therapy of, malignancies following, 603-609
vincristine, epirubicin, etoposide, prednisolone regimen in, 387-395
virologic analysis of, 1759-1760
yttrium 90-labeled antiferritin in, survival following, 2394-2400
-associated neoplasias, 2540-2546, 2684-2687
in CD30(Ki-1)+ anaplastic large-cell lymphoma, 373-380
infection due to, Hodgkin's disease and, 1758-1767
malignant germ cell tumors and, 1391-1397
testicular germ cell tumors and, 2705-2711
HYB-241 monoclonal antibody, 1962
Hydrocortisone
in R-11 protocol, for acute lymphoblastic leukemia CNS relapse, 335
suramin plus
in prostate cancer, 2208-2213
response to, 2218-2219
6-alpha-Hydroxylpaclitaxel
identification of, 183
pharmacokinetics of, 183-185
5-Hydroxytryptamine-3 receptor antagonist
for chemotherapy-induced emesis, 1036-1043
comparative trials of, 1039
pharmacology of, 1036-1037
Hydroxyurea
continuous-infusion, dosing of, 1094
oral *v* intravenous, toxicity of, 1089-1095
Hydroxyurea, fluorouracil, radiotherapy regimen
dose intensity of, 879
in head and neck cancer, 876-883
Hydroxyurea, carmustine, cyclophosphamide, etoposide regimen, in malignant lymphoma, 1089-1095
Hypermetabolism, inflammatory mediators and, in lung cancer therapy, 2602
Hypothyroidism, immune-mediated, 2403

I(12p), in germ cell tumors, 274
Idarubicin, cardiomyopathy following, 2827-2834
Idiopathic pneumonia syndrome, following cyclophosphamide, carmustine, etoposide, bone marrow transplantation regimen, 596-602

Ifosfamide
in combination chemotherapy
for desmoid tumor, 2815
with granulocyte-macrophage colony-stimulating factor, 79-86
for neuroectodermal tumor, 2797, 2802
for non-Hodgkin's lymphoma, 585
for small-cell lung cancer, 2594-2599
for soft tissue sarcoma, 2629-2636
cyclophosphamide *v*, overview of, 307-309
high-dose
in soft tissue sarcoma, 1600-1608
response to, 1604
mesna following, dosing of, 325
Ifosfamide, carboplatin, etoposide regimen
dosing escalation of, 325-326
hematologic toxicity of, 326
hematopoietic recovery following, 327
maximum-tolerated doses of, 323-332
nonhematologic toxicity of, 326-329
outcomes of, 329
phase I dosing trial of, 323-332
published maximum-tolerated doses of, 331
in small-cell lung cancer, 1615-1622
toxic deaths of, 329
toxicity of, 1618-1619
Ifosfamide, carboplatin, etoposide, granulocyte colony-stimulating factor regimen
doubling dose-intensity of, with blood reinfusion, 148-156
hematologic toxicity of, 154
toxicity of, 152-154
Ifosfamide, cisplatin, etoposide regimen
granulocyte-macrophage colony-stimulating factor plus, for germ cell tumor, 79-86
hematologic efficacy of, 82
infection analysis following, 81-82
recycling intervals following, 82-83
in small-cell lung cancer, 1209-1214
toxicity of, 83, 84, 1211
Ifosfamide, cisplatin, vinblastine regimen
granulocyte-macrophage colony-stimulating factor plus, for germ cell tumor, 79-86
hematologic efficacy of, 82
infection analysis following, 81-82
recycling intervals following, 82-83
toxicity of, 83, 84
Ifosfamide, doxorubicin regimen
dose-intensity analysis of, 1542, 1545
doxorubicin *v*, for soft tissue sarcoma, 1537-1545
nonhematologic toxicity of, 1544
survival following, 1540
toxicity of, 1540-1542
Ifosfamide, etoposide, mitoxantrone, bleomycin regimen
dosing of, 954
in non-Hodgkin's lymphoma, 953-960
toxicity of, 957
Ifosfamide, mesna, mitoxantrone, etoposide regimen, in non-Hodgkin's lymphoma, 1734-1741
Ifosfamide, vincristine, carboplatin, etoposide regimen
response to, 656-657
in small-cell lung cancer, 652-659
toxicity of, 656
Ifosfamide, vincristine, carboplatin, etoposide, granulocyte colony-stimulating factor regimen
response to, 656-657
in small-cell lung cancer, 652-659
toxicity of, 656
Imipenem
ceftazidime *v*, for febrile neutropenia, 165-176
toxicity of, 172-173
Immune-mediated complication, interferon alfa and, 2401-2407
Immunohistochemical study
with anti-latent membrane protein-1, 1759
antibodies and reagents for, of p53, 822
of p53, 821-830
of pepsinogen C, 55
Immunoperoxidase study, paraffin, in T-cell-rich B-cell lymphoma, 1743
Immunophenotyping
of cutaneous T-cell lymphoma, 1753
of pediatric large-cell non-Hodgkin's lymphoma, 2023-2032
Immunosuppressive therapy
lymphoproliferative disorders associated with, 961-968
protocols for, 962
Immunotherapy
adoptive, with tumor-infiltrating lymphocytes and interleukin-2, 1939-1949
home-therapy trial of, 497-501
with interferon alpha-2a plus interleukin-2, 1110-1122
in renal cell cancer, 1939-1949
In vitro cell line, establishment of, in stage I non–small-cell lung cancer, 1274
Indiana staging system
for germ cell tumor, 471
for testicular cancer, 1171
Infant, etoposide in, age-dependent dose calculation of, 2954-2960
Infection
ceftazidime *v* imipenem for, 170-172
following peripheral-blood progenitor-cell transplant, 939
Inflammatory mediators, measurement of, in lung cancer therapy, 2601
Insurance reform, 2981
Interferon(s), 774
for maintenance, in multiple myeloma, 2354-2360
survival following, 2356-2358
toxicity following, 2356
Interferon alfa
in chronic myelogenous leukemia, 2401-2407
complication incidence following, 2406
immune-mediated complications and, 2401-2407
for in vitro purging, 543
porphyria cutanea tarda following, 2405
Interferon alfa-2, interleukin-2 plus
hematologic effects of, 500
in renal cell cancer, 497-501
renal toxicity of, 500
response to, 498-499
toxicity of, 499-500
Interferon alfa-2a
all-*trans*-retinoic acid plus
in Kaposi's sarcoma, 1966-1974
response to, 1970-1971
toxicity of, 1970
as maintenance therapy, in small-cell lung cancer, 2924-2930
13-*cis*-retinoic acid plus, in renal cell cancer, 1950-1957
in combination chemotherapy, for mantle-cell lymphoma, 2819-2826

dosing of, 259, 2928
interleukin-2 plus
for metastatic cancer, 1110-1122
response duration following, 1117
response to, 1112-1113
toxicity of, 1113-1115, 1119
in malignant melanoma, 2776-2783
overall survival following, 978, 2781
pentostatin *v*, in hairy cell leukemia, 974-982
phototherapy plus
in mycosis fungoides, 257-263
response to, 259-260
in Sézary syndrome, 257-263
toxicity of, 260-261
relapse-free survival following, 978
response to, 977
soluble, in stage I non–small-cell lung cancer, 1274-1275
survival following, 2780
toxicity of, 978, 2780-2781, 2928
treatment with, 975
Interferon alfa-2a, fluorouracil regimen
in colorectal cancer, 921-928
phase III trial of, 921-928
response to, 923
survival following, 924-925
toxicity of, 924-925
treatment start until death with, 925
Interferon alfa-2b
fluorouracil plus
in colorectal cancer, 1297-1302, 2317-2323
complications following, 1489
for neuroendocrine tumors, 1486-1492
outcome following, 1489-1490
survival following, 1299, 1301, 2320-2321
toxicity of, 1300, 2320
toxicity of, 1489
Interferon alfa-2b, cisplatin, fluorouracil, leucovorin induction regimen, in head and neck cancer, 876-883
Interferon gamma
dosage administration schedule for, 2325
postoperative, in colon cancer, 2324-2329
survival following, 2327
time to relapse following, 2326-2327
toxicity of, 2327-2328
Interferon gamma, tumor necrosis factor, melphalan regimen
administration of, 265-266
in isolated limb perfusion, 264-273
response to, 268-270
toxicity of, 268-269
Interleukin-1, 1028
Interleukin-1 alpha, AS101 effect on, 2350
Interleukin-1 beta, interleukin-2 plus
hematologic effects of, 485
immunologic effects of, 484-485
phase I trial of, 482-489
toxicities of, 484
Interleukin-2
administration of, 1942
in combination chemotherapy, for non-Hodgkin's lymphoma, 585
high-dose
adverse effects of, 694
efficacy of, 690-692
in renal cell cancer, 688-696
response to, 693
toxicity of, 692-693
IL-1 beta plus
hematologic effects of, 485
immunologic effects of, 484-485
phase I trial of, 482-489
toxicities of, 484
interferon alfa-2 plus
hematologic effects of, 500
in renal cell cancer, 497-501
renal toxicity of, 500
response to, 498-499
toxicity of, 499-500
interferon alfa-2a plus
for metastatic cancer, 1110-1122
response duration following, 1117
response to, 1112-1113
toxicity of, 1113-1115, 1119
low-dose, clinical response to, 1942-1943
in melanoma, 1939-1949
in renal cancer, 1939-1949
response duration following, 1942-1944
toxicities of, 1943
Interleukin-3, 1025-1026
in ovarian cancer, 733-740
Interleukin-3, carboplatin, cyclophosphamide regimen
in ovarian cancer, 733-740
phase I trial of, 733-740
side effects of, 737-738
Interleukin-6, 1027-1028
AS101 effect on, 2350
assays for, 576
following chemotherapy
for breast cancer, 2585-2593
for non–small-cell lung cancer, 2585-2593
levels of, 266-268
disease characteristics and, 577-578
in non-Hodgkin's lymphoma, 575-582
plasma concentrations of, following MDX-210, 2288
Interleukin-8, levels of, 266-268
Interleukin-11, 1028
International Prognostic Index
in B-cell lymphoma, 1336-1342
in testicular lymphoma, 1361-1367
International Staging System, for lung cancer, 1265-1266
Intracellular adhesion molecule, levels of, 266-268
Intravenous access, for protracted fluorouracil venous infusion, 2317-2323
Ipsilateral breast tumor recurrences, 537
Irinotecan
antitumor response to, 214-215
chemical structure of, 211
dose-escalation scheme for, 213
hematologic toxicity of, 214-215
intestinal toxicity associated with, 213
nonhematologic toxicities of, 213-214
pharmacokinetics of, 212, 215
phase I trial of, 210-221
as single agent, in non-Hodgkin's lymphoma, 586
Iron, metabolism of, 1626-1627
Isolated limb perfusion

cytokine levels following, 264-273
postoperative care in, 266
procedure of, 265-266
Italian Cooperative Group for Neuroblastoma Staging Criteria, 885

Kaposi's sarcoma
as human immunodeficiency virus-associated neoplasia, 2684-2687
interferon alfa-2a plus all-*trans*-retinoic acid in, 1966-1974
intermittent tretinoin in, 1966-1974
liposomal doxorubicin in, phase II trial of, 914-920
prognostic criteria in, 915
Karyotyping, of poorly differentiated cancer of unknown primary site, 277, 279
Ketoconazole
all-*trans* retinoic acid plus, phase I trial of, 1501-1508
in paraneoplastic Cushing's syndrome, 157-164
KI-67 nuclear antigen, in stage I non–small-cell lung cancer, 1272-1273
Kiel classification, of nasal lymphoma, 668
Ki-ras mutation
detection of, 1680
in bile system cancer, 1679-1686

L-methyl-11C-methionine, PET studies with, in early therapy evaluation, 1470-1477
Lactate dehydrogenase level, elevated, in melanoma, 2106
Laryngeal cancer
patient-decision making in, 2369-2378
survival in, pretreatment hemoglobin levels and, 2077-2083
Latent membrane protein-1, anti-, immunohistochemistry with, 1759
Laurin's intesinal type cancer, 2086
Left ventricular afterload, following doxorubicin, 1550
Left ventricular performance, following doxorubicin, 1551
Lenograstim
in combination chemotherapy, for soft tissue sarcoma, 2629-2636
for induction chemotherapy, in breast cancer, 1564-1571
Leucovorin
in combination chemotherapy
for advanced colorectal cancer, 2613-2619
for non-Hodgkin's lymphoma, 2530
oral mucositis following, 2620-2628
in M-BACOD regimen, for non-Hodgkin's lymphoma, 2666-2667
pharmacokinetics of, in advanced colorectal cancer, 2614-2618
Leucovorin, fluorouracil regimen
in colorectal cancer, 921-928
dose escalation of, 2969
phase III trial of, 921-928
response to, 923, 2970-2971
schedule of, 2969
survival following, 924-925
toxicity of, 924-925, 2969-2970
treatment start until death with, 925
Leucovorin, cisplatin, fluorouracil, interferon alfa-2b induction regimen, in head and neck cancer, 876-883
Leucovorin, cisplatin, fluorouracil regimen
in head and neck cancer, 1656-1662
pharmacokinetics of, 1658-1659
response to, 1658
toxicity of, 1658
Leucovorin, dipyridamole, 5-fluorouracil regimen
in colorectal cancer, 1201-1208
dose intensity of, 1204
toxicity of, 1203-1204
Leukapheresis
for doubling chemotherapy dose-intensity, 148-156
large volume, 705-714
advantages of, 706
six-hour, 707-708
Leukemia
acute, high-dose melphalan in, 1795
acute lymphoblastic
CNS relapse of, 333-338
combined modality therapy for, 2497-2502
CSF L-asparagine levels in, 339-344
maintenance therapy in, 345-350
p53 mutations in, 812-820
therapy for, 1698
varicella immunoglobulin in, 1701-1702
varicella virus in, 1697-1703
acute myelogenous
high-dose chemotherapy in, 1-4
improved survival in, 560-569
acute myeloid
all-*trans* retinoic acid and, 2517-2523
etoposide, mitoxantrone, cytarabine regimen in, 11-18
following adjuvant chemotherapy, 1557-1563
idarubicin in, cardiomyopathy following, 2827-2834
timed sequential chemotherapy in, 11-18
acute nonlymphocytic, extramedullary myeloid cell tumors in, 1800-1816
acute promyelocytic, all-*trans* retinoic acid and, 2517-2523
childhood
CNS chemoradiotherapy for, 2480-2481
pubertal growth following, 2503-2507
pulmonary thromboembolism in, 2805-2812
childhood acute lymphoblastic
chemotherapy-associated relapse in, 345-351
cranial irradiation in, 2490-2495
late bone marrow relapse in, 352-358
in second remission, 352-358
chronic lymphocytic
2-chlorodeoxyadenosine in, 570-574
Rai stage of, 571
chronic myelogenous
interferon alfa in, 2401-2407
minimal residual disease patterns in, 1704-1713
peripheral-blood diploid cell collection in, 553-559
phases of, 554-555
chronic myeloid
hematopoietic stem-cell purging in, 541-546
Ph-negative cell in, 541-542
CNS, overview of, 310-313
cytokines in, 1031
etoposide-related, incidence of, 2703
extramedullary, *see* Extramedullary leukemia
hairy cell
pentostatin *v* interferon in, 974-982
2-subcutaneous chlorodeoxyadenosine injections in, 989-995
treatment schema for, 975
relapsed chronic lymphocytic, 2-chlorodeoxyadenosine in, 983-988
secondary
etoposide dosing and, 288-289

risk of, 286-288
Leukocyte counts, interleukin-6 and, in non–small-cell lung cancer therapy, 2588-2589
Levamisole, adjuvant fluorouracil plus, in colon cancer, 2936-2943
Li-Fraumeni syndrome, 1014
Life cycle analyses, p53 mutations and, 2748-2749
Likert scale, 762
Linomide, pharmacologic characteristics of, 776
Liposomal doxorubicin
administration of, 1779
antitumor activity of, 1781-1782
cardiac function following, 1782
description of, 1778-1779
hand-foot syndrome in, 1780
hematologic toxicity of, 917
intercurrent infections with, 917
for Kaposi's sarcoma, 914-920
liposome composition in, 915
myelosuppression of, 1780
neutropenia due to, 917
nonhematologic toxicity of, 917
in ovarian cancer, 1783
phase I trial of, 1777-1785
phase II trial of, for Kaposi's sarcoma, 914-920
in renal cell cancer, with lung metastases, 1783
response to, 915-916
toxicities of, 1779-1781
treatment regimen of, in Kaposi's sarcoma, 915
Liposomal daunorubicin
administration cycles of, 1001
clinical toxicity of, 998
hematologic adverse effects of, 1000
nonhematologic toxicities of, 1001
pharmacokinetic parameters of, 999
pharmacokinetics of, 998
phase I-II trial of, 996-1003
prognostic factors and, 1001
survival following, 999-1000
therapy with, clinical monitoring of, 997
tumor response to, 999
Liposome, polyethylene-glycol-coated, for doxorubicin, 1777-1785
Liquid chromatography analysis, high-performance, in leukemia, 2519
Lomustine, craniospinal irradiation plus
lung disease following, 1478-1485
pulmonary function following, 1481-1482
Lomustine, vincristine, prednisone regimen
survival following, 116
toxicity of, 118
Lomustine, vincristine, prednisone radiotherapy regimen, in primitive neuroectodermal tumors, 1687-1696
Loperamide, 211-212
Lumpectomy
breast irradiation selection post-, 851
node-negative
decision instrument following, 847-853
radiotherapy decision following, 847-853
radiotherapy selection in, reasons for, 851
radiotherapy following, decision instrument for, 847-853
Lung
adenocarcinoma of, 1895
squamous cell carcinoma of, 1895
Lung cancer
chemotherapy in, cost-effectiveness of, 2166-2173
combined modality therapy for, radiation pneumonitis following, 2606-2612
cytokeratin 19 expression in, 2769-2775
extensive-disease small-cell
etoposide plus cisplatin in, 1871-1879
ifosfamide, carboplatin, etoposide regimen in, 1615-1622
paclitaxel in, 1430-1435
increased resting energy and, 2600-2605
International Staging System of, 1265-1266
limited-stage small-cell, interferon alfa-2a maintenance in, 2924-2930
metastatic non–small-cell, 1-hour paclitaxel infusion in, 1609-1614
non–small-cell
cisplatin, etoposide, radiotherapy, surgery regimen in, 1880-1892
cisplatin plus vinorelbine in, 2166-2173
combined modality therapy in, 2585-2593
locally advanced, chemoradiotherapy regimen in, 1425-1429
management of, personal beliefs in, 1904-1911
p53 expression in, 1893-1903
paclitaxel plus carboplatin in, 1840-1842, 1860-1870
phase II trial of, docetaxel and, 2649
as second cancer, 104-105
survival in, prognostic factors for, 1221-1230
therapy costs in, 2168
treatment choices in, 1906
vindesine plus cisplatin in, 2166-2173
vinorelbine in, 2166-2173
platinum-refractory non–small-cell, docetaxel in, 645-651
recurrent small-cell, etoposide, ifosfamide, cisplatin regimen in, 1209-1214
as second cancer, 106-107
small-cell
brain metastases from, teniposide for, 660-665
chemoradiotherapy plus granulocyte-macrophage colony-stimulating factor in, 1632-1641
chemotherapy for, erythropoietin during, 1623-1631
cisplatin plus etoposide in, 1436-1442
cisplatin plus etoposide phosphate in, 1436-1442
combination chemotherapy for, 2594-2599
combined modality therapy for, 2606-2612
docetaxel in, 2649
granulocyte colony-stimulating factor in, 652-659
long-term survival in, 1215-1220
second cancers following, imaging of, 105, 108
survivors of, second cancers in, 101-111
stage I non–small-cell
anatomic markers in, 1268
differentiation markers in, 1271-1272
metastatic propensity markers in, 1274-1275
molecular genetic markers in, 1269-1271
molecular markers in, 1265-1279
pathologic markers in, 1268-1269
proliferation markers in, 1272-1274
stage II non–small-cell, physician perception of, 1905-1906
stage III non–small-cell, radiation, carboplatin, etoposide regimen in, 452-458
stage III non–small-cell, trimodality regimen in, 1880-1892
stage IIIb non–small-cell, physician perception of, 1906-1908

stage intravenous non–small-cell
physician perception of, 1908-1909
weekly oral vinorelbine in, 637-644
unresectable stage III non–small-cell
concurrent chemoradiotherapy in, 869-875
first recurrence in, 872
survival in, 872
Lung disease, following lomustine plus craniospinal irradiation, 1478-1485
Lung metastasis, of renal cell cancer, liposomal doxorubicin therapy in, 1783
LY231514
administration of, 2844
antitumor activity of, 2849
clearance of, 2848
dose escalation of, 2844-2845
mean plasma concentrations of, 2846
pharmacokinetic parameters of, 2847
pharmacokinetics of, 2846-2849
phase I trial of, 2842
structure of, 2843
toxicities of, 2845-2846
Lymph node(s)
cutaneous melanoma metastases to, size of, 2362-2368
staging standards of, in gastric cancer, 2309-2316
Lymph node dissection, extended, in gastric cancer, 5-7
Lymph node status
physician perception of, in breast cancer, 1459-1469
Western *v* Japanese, in gastric cancer, 20
Lymphadenectomy, limited *v* extended, in gastric cancer, 19-25
Lymphoid malignancy, high-dose therapy plus autologous transplantation for, costs of, 969-973
Lymphoid tissue, mucosa-associated, single-agent chemotherapy for, 2524-2529
Lymphoma
anaplastic large-cell, soluble CD30 in, 1355-1360
benign hilar uptake *v*, gallium citrate scintigraphy for, 942-946
CD30(Ki-1)+ anaplastic large-cell
clinical features of, 376
extranodal sites in, 376
human immunodeficiency virus infection in, 373-380
immunophenotypes in, 379
pathologic features of, 376-377
pharyngeal site of, 378
treatment toxicity in, 377
CNS, brain tumor associated with, 2931-2935
cutaneous T-cell
clonal evolution of, 1751-1757
gene rearrangement in, 1752
immunohistochemistry of, 1754, 1756
large-cell transformation of, 1751-1757
minimal residual disease in, 1751-1757
diffuse aggressive B-cell, bone marrow involvement in, 1336-1342
diffuse large-cell, prognosis in, interleukin-6 levels and, 575-582
extranodal, frequency of, 2665-2666
large-cell, histologic types of, 2025
localized lymphoblastic, definition of, 1369
lymphoid tissue, single-agent chemotherapy for, 2524-2529
malignant
carmustine, cyclophosphamide, etoposide, hydroxyurea regimen in, 1089-1095
high-dose melphalan in, 1793-1794
peripheral-blood-stem cell treatment for, 2547-2555
mantle cell, combination chemotherapy in, 2819-2826
non-Hodgkin's, *see* Non-Hodgkin's lymphoma
pediatric large-cell, B-cell lineage in, 2023-2032
pediatric lymphoblastic, 1368-1376
relapse site in, 1371-1372
pleomorphic T-cell, prognosis in, 359-372
primary gastric, single-agent chemotherapy for, 2524-2529
primary nasal, 666-670
recurrent follicular
management of, 141
patient characteristics in, 142
prognostic factors in, 143
response rates in, 145
successive remission durations following, 146
survival in, 140-147
survival patterns following, 142
therapy outcome following, 142
refractory low-grade, allogeneic bone marrow transplantation for, 1096-1102
T-cell-rich B-cell, 1742-1750
clinical features of, 1745-1746
clinicopathologic features in, 1744-1745, 1748
histologic features of, 1743
immunologic features of, 1743
marrow transplantation in, 1746
paraffin immunoperoxidase studies of, 1743
survival in, 1746
therapy in, 1745
testicular
clinical characteristics in, 1362
disease features in, 1363
failure patterns in, 1364
late relapses in, 1361-1367
poor outcome in, 1361-1367
salvage therapy in, 1364-1365
studies of, 1362
Lymphomatoid granulomatosis, 669
Lymphoproliferative disorder(s)
B-cell monomorphic, 964
B-cell polymorphic, 963
cutaneous
clinicopathologic subdivision of, 1348
histopathologic type of, 1346
survival in, 1350-1352
cutaneous CD30 positive, 1343-1354
posttransplant, *see* Posttransplant lymphoproliferative disorder(s)
somatostatin in, 2012-2015
T-cell polymorphic, clinical features of, 964

MACOP-B regimen, for non-Hodgkin's lymphoma, 2666-2667
Macrophage-stimulating factor, 1025
Mafosfamide, 543
Magnetic resonance imaging
in asymptomatic multiple myeloma, 251-256
gadolinium-enhanced brain, 904
gadolinium-enhanced spinal, 905
of pineoblastoma, 1378
MAID, *see* Mesna, doxorubicin, ifosfamide, doxorubicin regimen
Malignancy(ies)
human immunodeficiency virus-related, in homosexual men, 2540-2546

non–human immunodeficiency virus-related, in homosexual men, 2540-2546
primary, definition of, 2096
Managed care, oncology workforce in, 2985
Mantle irradiation, in Hodgkin's disease, 947-952
Marker, *see* Biomarker(s)
Marker half-life
calculation of, 88
in germ cell tumor, 87-92
prognostic significance of, 87-92
Mast cell growth factor, 1027
Mastectomy
chemoradiotherapy following, 435-443
radiotherapy following, 2861-2864, 2869-2878
Mdr-1, expression of, 2001
MDX-210
administration of, 2282
antibody development to, 2289-2290
biopsy following, 2289
cellular pharmacokinetics of, 2284
dose escalation of, 2282
HAMA response to, 2290
hematologic changes following, 2284
immunologic effects of, 2286-2287
localization of, 2287-2289
maximum-tolerated dose of, 2281-2292
nonhematologic toxicity of, 2284
pharmacokinetics of, 2287
plasma concentrations of, 2283
plasma pharmacokinetics of, 2284-2286
preparation of, 2282
response to, 2290
toxicity of, 2283-2284
Mechlorethamine
in combination chemotherapy
for mantle-cell lymphoma, 2819-2826
for non-Hodgkin's lymphoma, 2530
dosing of, in Stanford V regimen, 1086
in Stanford V regimen, for Hodgkin's disease, 1081
Mechlorethamine, vinblastine, prednisolone, procarbazine regimen, gonadal function following, 134-139
Mechlorethamine, vinblastine, prednisone, procarbazine regimen
dosing of, 2380
in Hodgkin's disease, 2379-2385
response to, 2381
survival following, 2382
Medroxyprogesterone acetate, in breast cancer, 1572-1577
Melanoma
advanced cutaneous malignant, docetaxel in, 2895-2899
cutaneous, lymph node metastasis size in, 2362-2368
metastatic, temozolomide phase II trial in, 910-913
metastatic malignant, immunotherapy in, 1939-1949
occult, detection of, 2109-2116
staging of, computed tomography in, 2104-2108
surgical adjuvant therapy of, 2776-2783
Melphalan
in acute leukemia, 1795
in anthracycline-refractory breast cancer, 2567-2574
in breast cancer, 1794
clinical pharmacology of, 1787-1789
clinical studies with, 1789-1795
in colorectal cancer, 1795
development of, 1786-1787
in Ewing's sarcoma, 1794-1795
high-dose
future directions in, 1795-1796
toxicities of, 1795
in high-dose chemotherapy regimen, for breast cancer, 840-846
high-dose intravenous, in neuroblastoma, 1786-1799
in malignant lymphoma, 1793-1794
mechanism of action of, 1786-1787
in myeloma, 1789-1792
in neuroblastoma, 1794-1795
in ovarian cancer, 1792-1793
for stage I ovarian tumor, 2752-2756
Melphalan, carmustine, etoposide, cytarabine regimen
in Hodgkin's disease, 396-402
protocol for, 397-398
results of, 400
Melphalan, carmustine, etoposide, cytarabine, bone marrow transplantation regimen, in non-Hodgkin's lymphoma, 588-595
Melphalan, prednisone regimen, interferon following, 2354-2360
Melphalan, teniposide, doxorubicin, cisplatin, total-body irradiation regimen, for bone marrow transplantation, 2789-2795
Melphalan, tumor necrosis factor, interferon gamma regimen
administration of, 265-266
in isolated limb perfusion, 264-273
response to, 268-270
toxicity of, 268-269
Memorial Pain Assessment Card, in pancreatic cancer, 750-751
Memory, following brain irradiation, 2263-2271
Meningeal nodule
gadolinium-enhanced brain magnetic resonance imaging for, 904
gadolinium-enhanced spinal magnetic resonance imaging for, 905
Menopausal status, physician perception of, in node-negative breast cancer, 1459-1469
Menopausal symptoms, among breast cancer patients, 2737-2744
Mercaptopurine
metabolites of, acute lymphoblastic leukemia relapse associated with, 345-351
in non-Hodgkin's lymphoma therapy, stratified by histology, 359-372
Mesna
in combination chemotherapy
for neuroectodermal tumor, 2797, 2802
for non-Hodgkin's lymphoma, 585
for soft tissue sarcoma, 2629-2636
following ifosfamide, dosing of, 325
high-dose ifosfamide plus, in soft tissue sarcoma, 1600-1608
Mesna, ifosfamide, mitoxantrone, etoposide regimen, in non-Hodgkin's lymphoma, 1734-1741
Mesna, doxorubicin, ifosfamide, doxorubicin regimen, 2629-2636
Metastasis
to bone, clodronate for, 929-934
detecting, for lymph node staging, 2311
epidural, spinal cord compression due to, 2330-2335
lymph node, size of, 2362-2368
Methotrexate
in combination chemotherapy
for desmoid tumor, 2815
for non-Hodgkin's lymphoma, 585, 2530
residual lymphoma following, 594
in combined modality therapy, for acute lymphoblastic leukemia, 2490-2495

concentration of, following intralumbar administration, 177-179
edatrexate *v*, 1649-1655
in head and neck cancer, 1649-1655
hematologic toxicity of, 1652
in high-dose chemotherapy regimen, for breast cancer, 840-846
intralumbar, body position and, for ventricular CSF concentrations, 177-179
intrathecal, for childhood acute lymphoblastic leukemia, 2497-2502
in M-BACOD regimen, for non-Hodgkin's lymphoma, 2666-2667
metabolites of, acute lymphoblastic leukemia relapse associated with, 345-351
nonhematologic toxicity of, 1653
in preparative bone marrow transplantation regimen, 1704-1713
in R-11 protocol, for acute lymphoblastic leukemia CNS relapse, 335
structure of, 2843
survival duration following, 1654
survival following, 1652
Methotrexate, cyclophosphamide, fluorouracil, vincristine, prednisone regimen
in breast cancer, 831-839
disease-free survival following, 833-834
second malignancy following, 836
survival following, 834-835
toxicity of, 835-836
Methotrexate, cyclophosphamide, fluorouracil regimen
disease-free survival following, 37
low-dose adjuvant, in breast cancer, 33-41
overall survival following, 37-38
time to distant metastases following, 36
time to local relapse following, 36
toxicity of, 35
Methotrexate, daunorubicin, asparaginase, cyclophosphamide, vincristine, prednisone regimen, 1368-1376
Methotrexate, doxorubicin, cyclophosphamide, fluorouracil regimen
in breast cancer, 831-839
disease-free survival folowing, 833-834
second malignancy following, 836
survival folowing, 834-835
toxicity of, 835-836
Methotrexate, vinblastine, doxorubicin, cisplatin regimen, neoadjuvant, in bladder cancer, 1384-1390
Methotrexate, vinblastine, doxorubicin, cisplatin, granulocyte-macrophage colony-stimulating factor regimen
in bladder cancer, 2272-2277
hematologic toxicity of, 2275
infection following, 2274
Methylglyoxal bis guanylhydrazone, as single agent, in non-Hodgkin's lymphoma, 586
Methylhydrazine, in combination chemotherapy, for desmoid tumor, 2815
Methylprednisolone, in combination regimen, for non-Hodgkin's lymphoma, 585
Methylprednisone, etoposide, cytarabine, cisplatin regimen, in non-Hodgkin's lymphoma, 1734-1741
Microvessels, counting of, in gastric cancer recurrence, 477-481
Minimal residual disease
in cutaneous T-cell lymphoma, 1751-1757
patterns of, in chronic myelogenous leukemia, 1704-1713
Misoprostol, 2637-2642
Mitomycin, fluorouracil, doxorubicin regimen, adjuvant, in gastric cancer, 2757-2763
Mitomycin, vindesine, cisplatin regimen, concurrent radiotherapy plus, 869-875
Mitotic index, in stage I non–small-cell lung cancer, 1272-1273
Mitoxantrone
breast cancer resistant to, docetaxel in, 2879-2885
in combination chemotherapy, for non-Hodgkin's lymphoma, 585, 2530-2539
dose intensity of
by age, 958
by complete remission, 958
in high-dose chemotherapy regimen
for breast cancer, 840-846
for metastatic breast cancer, 2484
in peripheral-blood diploid cell collection, 553-559
as single agent, in non-Hodgkin's lymphoma, 586
Mitoxantrone, etoposide, cytarabine regimen
in acute myeloid leukemia, 11-18
disease-free survival following, 15
efficacy of, 14-15
induction of, 13
postinduction reception of, 13-14
survival following, 14
Mitoxantrone, etoposide, ifosfamide, bleomycin regimen
dosing of, 954
in non-Hodgkin's lymphoma, 953-960
toxicity of, 957
Mitoxantrone, mesna, ifosfamide, etoposide regimen, in non-Hodgkin's lymphoma, 1734-1741
Model, for breaking bad news, 2449-2456
Molecular marker, *see* Biomarker(s)
Monoclonal antibody
anti-B-cell, for posttransplant lymphoproliferative disorders, 961-968
HYB-241, 1962
MDX-210, 2281-2292
Monocyte counts, interleukin-6 and, in non–small-cell lung cancer therapy, 2589
Mood visual analog scale, 860
MOPP regimen, in adult Hodgkin's disease, 393
MOPP-ABVD regimen
in adult Hodgkin's disease, 393
Stanford V regimen *v*, in Hodgkin's disease, 1085-1087
Morphine
controlled-release suppository of, 1520-1527
oral *v* rectal, 1004-1008
subcutaneous, 1520-1527
Mortality rate
of cancer patients, 2983
of United State citizens, 2984
Mucositis
due to intravenous hydroxyurea, 1091
oral, granulocyte-macrophage colony-stimulating factor and, 2620-2628
Multidrug-resistance gene, 1017
Multiple myeloma
asymptomatic
diffuse pattern of, 252
focal pattern of, 253
magnetic resonance imaging in, 251-256
variegated pattern of, 252
bone marrow transplantation for, prognostic factors in, 1312-1322
high-dose melphalan in, 1789-1792

high-dose therapy for, 1291-1296
interferon maintenance in, 2354-2360
peripheral-blood stem-cell treatment for, 2547-2555
Mycosis fungoides, interferon alfa-2a plus phototherapy in, 257-263
Myelodysplasia
allogeneic bone marrow transplantation conditioning regimen for, 2973-2979
idarubicin in, cardiomyopathy following, 2827-2834
Myelodysplastic syndrome
age-dependent incidence of, following cyclophosphamide, 1561
following adjuvant chemotherapy, 1557-1563
Myeloma, multiple, *see* Multiple myeloma
Myelosuppression
factors predisposing to, 2442
following pyrazoloacridine, 1978-1980
with gemcitabine therapy, for advanced breast cancer, 2735
Myocardial contractility, following doxorubicin, 1550-1551

N,N-diethy-2-[4-(phenylmethyl)phenoxy]ethanamine, cyclophosphamide plus, in prostate cancer, 1398-1403
Nasal lymphoma, primary, 666-670
Nausea
delayed, oral ondansetron for, 2408-2416
due to gencitabine therapy, 2735
ondansetron treatment of, 212
probability of, prognostic factors for, 2422-2423
Neck cancer, *see* Head and neck cancer
Necrosis, germ cell tumor *v*, model prediction of, 1183
Neoadjuvant chemotherapy
carboplatin plus fluorouracil as, in head and neck cancer, 1493-1500
chemoendocrine therapy as, in breast cancer, 547-552
cisplatin plus fluorouracil as, in head and neck cancer, 1493-1500
primary, 424-429
in primary breast cancer, 537-540
tamoxifen plus, objective response following, 549
Neomycin, resistance to, 410-418
Neovascularization, 766
Neural-cell adhesion molecule, in extramedullary leukemia, 1802-1803
Neuroblastoma
age-specific incidence of, 2033-2038
autologous bone marrow transplantation for, 2789-2795
high-dose intravenous melphalan for, 1786-1799
high-dose melphalan for, 1794-1795
Italian Cooperative Group staging criteria for, 885
localized resectable, 884-893
pediatric
13-*cis*-retinoic acid in, 894-901
relapsed, 1786-1799
survival in, 889-890
Neuroectodermal tumor, poor-risk peripheral primitive, cyclophosphamide, doxorubicin, vincristine regimen for, 2796-2804
Neuroendocrine tumor, interferon alfa-2b plus fluorouracil for, 1486-1492
Neurologic function, classification of, 661
Neurotoxicity
associated with suramin, 2182-2183, 2201, 2223-2229
cisplatin-induced, glutathione prevention of, 26-32
following pyrazoloacridine, 1977-1978
Neutropenia
duration of, following bone marrow transplantation, 245
febrile
ceftazidime *v* imipenem for, 165-176
microbial isolates in, 169
following docetaxel, 645-651
lenograstim for, 1564-1571
paclitaxel-associated, by dose, 186
Neutrophil count
following peripheral-blood progenitor-cell transplant, 939, 2251
granulocyte colony-stimulating factor and, in soft tissue sarcoma, 2631-2633
interleukin-6 and, in non–small-cell lung cancer therapy, 2589
in non–small-cell lung cancer, 1221-1230
Neutrophil engraftment, 938
granulocyte colony-stimulating factor acceleration of, 1323-1327
time to, 1325
Non-Hodgkin's lymphoma
advanced diffuse, combination chemotherapy for, 2530-2539
associated with AIDS, 2669
carmustine, cyclophosphamide, etoposide, hydroxyurea regimen in, 1089-1095
carmustine, etoposide, cytarabine, melphalan, bone marrow transplantation regimen in, 588-595
childhood, histology-stratified treatment in, 359-372
classification of, 2660-2665
cyclophosphamide, epirubicin, vincristine, prednisone, bleomycin regimen in, 953-960
elderly with, cyclophosphamide, doxorubicin, vincristine, prednisone regimen in, 2386-2393
etoposide, ifosfamide, mitoxantrone, bleomycin regimen in, 953-960
extranodal lymphoma and, 2665-2666
high- *v* intermediate-grade, disease-free survival in, 955
high-dose therapy plus autologous transplantation in, 970-971
as human immunodeficiency virus-associated neoplasm, 2684-2687
interleukin-6 in, 575-582
low-grade, transformation from, 1726-1733
molecular marker-positive cells in, 1073-1079
overview of, 2656-2675
pathogenesis of, 2656-2660
pediatric lymphoblastic, 1368-1376
relapse site in, 1371-1372
peripheral-blood progenitor-cell transplant in, granulocyte colony-stimulating factor following, 935-941
poor-prognosis aggressive, cyclophosphamide, doxorubicin, vincristine, prednisone, granulocyte colony-stimulating factor regimen in, 2916-2923
refractory, three-hour paclitaxel infusion in, 583-587
relapsed
etoposide, methylprednisone, cytarabine, cisplatin regimen in, 1734-1741
mesna, ifosfamide, mitoxantrone, etoposide regimen in, 1734-1741
paclitaxel in, 381-386
single-agent therapy in, 586
salvage therapy for, 2669
time to treatment failure in, by risk group, 957
treatment of, 2666-2668
Nondisclosure, of bad new, model for, 2449-2451
Nonseminoma, in human immunodeficiency virus patients, 2707
Nonsteroidal antiinflammatory drug, for cancer pain, 2637-2642
NORs, in stage I non–small-cell lung cancer, 1272, 1274

Norverapamil, plasma levels of, 1961-1962
Novobiocin, bone marrow transplantation plus, in breast cancer, 1136-1143
Novobiocin, cyclophosphamide, thiotepa regimen, with autologous bone marrow transplantation, in breast cancer, 1136-1143
Nuclear grade, physician perception of, in node-negative breast cancer, 1459-1469
Nurse, attitude of, toward pain, 2160

O6-alkylguanine alkyltransferase, modulation of, 2301-2308
Octreotide acetate
  for fluoropyrimidine-induced diarrhea, 222-226
  phase I trial of, 222-226
  response to, 224
  toxicity of, 224
Oligometastasis, 8-10
Oliguria, following interferon-alfa 2a plus interleukin-2, 1119
Oncogene, repression of, by DNA-binding protein, 543
Oncologist
  attitude of
    in phase I trials, 1062-1072
    to physician-associated death, 1055-1061
    toward disclosure, 2451-2452
    toward pain, 2160
  perception of, *see* Physician, perception of
Oncologist-patient dialogue
  at cancer diagnosis, 1820
  honest disclosure in, 1820-1822
  providing hope in, 1818-1820
  at relapse, 1821
  at remission, 1821
  at therapy initiation, 1820-1821
Oncology
  ethical considerations in, 2464-2470
  globalization of, 2987
  workforce of, in managed care environment, 2985
Ondansetron, 212
  dexamethasone plus, 2120-2121
  dose adjustment of, by chemotherapy, 2117-2122
  efficacy of, 2120
  granisetron *v*, for cisplatin-induced emesis, 1242-1248
  oral
    adverse events following, 2414
    for delayed emesis, 2408-2416
    safety of, 2413
  safety of, 2121
Oophorectomy, in breast cancer
  cyclophosphamide, doxorubicin, fluorouracil regimen plus, 1453-1458
  tamoxifen *v*, 521
Opioids, addiction to, 2158-2165
Oral mucositis, granulocyte-macrophage colony-stimulating factor efficacy and, 2620-2628
Orbit tumor, 620
Orbito-ocular granulocytic sarcoma, in acute myelomonocytic leukemia, 1803-1804
Orchiectomy, in malignant germ cell tumor, 1391-1397
Organ transplantation, lymphoproliferative disorders following, 961-968
Oropharyngeal cancer, organ preservation in, 671-680
Osteoporosis, estrogen replacement therapy and, 2742
Ototoxicity, cisplatin-induced, dopamine prophylaxis of, 1231-1237

Ovarian cancer
  advanced, doxorubicin in, 726-732
  c-*erb*B-2 in, as prognostic factor, 70-78
  chemotherapy in, overview of, 726-732
  cyclophosphamide, interleukin-3, carboplatin regimen in, 733-740
  docetaxel in, 2649
  dose-intensive therapy in, 1589-1599
  epithelial, CD44 variant expression in, 1912-1921
  glutathione S-transferase pi in, as prognostic factor, 70-78
  high-dose cyclophosphamide plus paclitaxel in, 1160-1166
  high-dose melphalan in, 1792-1793
  interleukin-3 in, 733-740
  liposomal doxorubicin therapy in, 1783
  natural history of, 783
  p-53 in, as prognostic factor, 70-78
  p-glycoprotein in, as prognostic factor, 70-78
  paclitaxel in, carboplatin following, 1584-1588
  prognostic factors in, 70-78
  risk factor for, 783-784
  screening for, 783-793
  screening principles in, 784-785
  serum tumor markers in, 785-787
  sonographic morphology index in, 790
  transabdominal ultrasonography in, 788-789
  transvaginal color Doppler imaging in, 790-791
  transvaginal ultrasonography in, 789-790
  ultrasound screening in, 787-788
Ovarian cystectomy, in low malignant potential ovarian tumor, 2755
Ovarian tumor, low malignant potential of, 2752-2756
Ovary, normal surface epithelial cells of
  immunoreactivity of, 1918
  isolation of, 1913

P-glycoprotein
  for chemotherapy response, 70-78
  distribution of, in ovarian cancer, 73
  as ovarian cancer prognostic factor, 70-78
P210 tyrosine kinase, tyrphostin inhibition of, 543
p53 gene
  alterations of
    in cancer, 1010-1012
    detection of, 1016
  assay for, in cancer detection, 1014-1015
  cancer etiology and, 1012-1013
  as cancer therapy target, 1016-1017
  carcinogen exposure and, 1013
  clinical implications of, 1012-1017
  in clinical oncology, 1009-1022
  consistent features of, 1013
  disease progression by, 1898
  distribution of, in ovarian cancer, 73
  evidence for, 1011
  expression of
    by histologic type, 1895
    in non–small-cell lung cancer, 1893-1903
  fluorescence-in-situ hybridization analysis of, 813
  function of, 1009-1010
  genetic alterations of, 1011
  as genetic risk marker, 1013-1014
  HER2-*neu* interaction with, 823-825
  immunohistochemical study of, 821-830
  as independent marker, 1015-1016

mechanism of action of, 1010
mutations of
in benign breast tissue, 2293-2300
in Burkitt's lymphoma, 812-820
frequency of, 1012
in invasive bladder cancer, 1384-1390
as ovarian cancer prognostic factor, 70-78
in papillary adenocarcinoma, 73
prognostic value of
in bladder cancer, 1384-1390
for chemotherapy response, 70-78
in non–small-cell lung cancer, 1900
and radiotherapy, in breast cancer, 2745-2751
role of, in cancer, 808-811
sequence-based analysis of, 2746
single-strand conformation polymorphism analysis of, 813
in stage I non–small-cell lung cancer, 1270-1271
structure of, 1009-1010
in tumor progression, 1015-1016
wild-type, biochemical functions of, 1010
Paclitaxel
carboplatin plus
cost of, 1841
dose-adjustment schema for, 1862
dose intensity of, 1865
granulocytopenia following, 1864
in non–small-cell lung cancer, 1840-1842, 1860-1870
in ovarian cancer, 1584-1588
protocol schema for, 1862
response to, 1865-1867
thrombocytopenia following, 1865
toxicity of, 1863-1864
in chemotherapy-refractory breast cancer, 2056-2065
cyclophosphamide plus
stem-cell mobilization with, 1714-1719
toxicity of, 1715-1716
dose escalation of, with high-dose cyclophosphamide, 1160-1166
dosing modifications for, 2067
dosing of, 187, 585, 2063
efficacy of, 2965
hematologic toxicity of, 1153
in metastatic breast cancer, 1152-1159
infusion schedule of, 187
96-hour infusion of, in relapsed non-Hodgkin's lymphoma, 381-386
nonhematologic toxicity of, 586
nonlinear pharmacokinetics of, 180-190
one hour infusion of
in non–small-cell lung cancer, 1609-1614
toxicity of, 1611-1613
peak plasma concentrations of, 2966
pharmacokinetic-pharmacodynamic relationships of, 185-186
pharmacokinetics of, R-verapamil and, 2039-2042
pharmacologic studies of, 2965-2966
phase II trial of, for breast cancer, 2575-2581
plus doxorubicin, for breast cancer, 2688-2699
for recurrent brain tumor, 2066-2071
in relapsed non-Hodgkin's lymphoma, 381-386
response to, 383, 2069
in small-cell lung cancer, 1430-1435
as single agent, in non-Hodgkin's lymphoma, 586
three-hour infusion of, in non-Hodgkin's lymphoma, 583-587
topotecan plus
hematologic toxicity of, 2232-2233
nonhematologic toxicity of, 2233-2234
phase I trial of, 2230-2237
toxicity of, 383-384, 585, 1157, 2059-2062, 2068-2069, 2963-2965
weekly intraperitoneal, phase I trial of, 2961-2967
Paclitaxel, etoposide, cisplatin regimen
response to, 1433
in small-cell lung cancer, 1430-1435
survival following, 1433-1434
toxicity of, 1432-1433
treatment schema for, 1431
Pain
audit tools for, 2161
bilateral percutaneous cervical cordotomy for, 1509-1512
cancer, mechanisms of, 1005
controlled-release morphine suppository for, 1520-1527
intensity of, in pancreatic cancer, 750-751
location of, in pancreatic cancer, 750
management of
barriers to, 2163
currriculum for, 2162
effectiveness of, 762
institutional commitment to, 2158-2165
overview of, 2149-2151
supportive care services for, 757-759
team members for, 760
oral *v* rectal morphine in, 1004-1008
in pancreas cancer, 748-755
percutaneous cervical cordotomy for, 1509-1512
physician attitude toward, 2160
prevalence of, at pancreatic cancer diagnosis, 750
subcutaneous morphine for, 1520-1527
Pancreatic cancer, newly diagnosed
combined intraoperative radiation plus perioperative chemotherapy in, 2764-2768
depression in, 748-755
pain in, 748-755
radiotherapy plus protracted fluorouracil infusion in, 227-232
Parameningeal tumor, 621
Paratesticular tumor, 620
Patient(s)
breaking bad news to, 2449-2456
decision-making, in laryngeal cancer, 2369-2378
elderly, with non-Hodgkin's lymphoma, 2530-2539
providing hope for, 1818-1822
Patient monitoring, of paclitaxel and doxorubicin regimen, in breast cancer, 2689
Patient preference
for metastatic breast cancer therapy, 858-868
for participation, 863
for randomized trial treatment, 861
for standard chemotherapy, 865
for standard chemotherapy *v* hormonal therapy, 866-867
for standard *v* experimental chemotherapy, 860-861, 866
for standard *v* high-dose experimental chemotherapy, 861-862, 867-868
for treatment by incremental survival time, 862-863
for treatment by symptom status, 863
Patient-oncologist dialogue
at cancer diagnosis, 1820

honest disclosure in, 1820-1822
providing hope in, 1818-1820
at relapse, 1821
at remission, 1821
at therapy initiation, 1820-1821
PAX3 gene, 2127
PCNA, in stage I non–small-cell lung cancer, 1272, 1274
Pelvis, Ewing's sarcoma of, surgery in, 2336-2341
Pentosan polysulfate, pharmacologic characteristics of, 776
Pentostatin
clinical trials of, 2440-2441
immunosuppression with, 2441
infectious complications of, 2431-2448
interferon alfa-2a *v*, in hairy cell leukemia, 974-982
myelotoxicity of, 2438
overall survival following, 978
relapse-free survival following, 978
response to, 977
toxicity of, 978
treatment with, 975
Pentoxifylline
in anorexia, 2856-2859
in cachexia, 2856-2859
Pepsinogen C
in breast cancer, 54-61
purification of, 55
survival associated with, 58-60
Performance status, in stage I non–small-cell lung cancer, 1267
Peripheral Access System Port catheter system, physician assistant insertion of, 1513-1519
Peripheral-blood progenitor cell
autologous
collection of, 2547-2555
engraftment of, 2548
following high-dose chemotherapy, 1328-1335
survival following, 1332
collection of, 554, 1329
cyclophosphamide recruitment of, 840-846
Peripheral-blood progenitor-cell mobilization, 1030-1031
following single leukapheresis, 705-714
high *v* low collections following, 709
high-dose cyclophosphamide plus paclitaxel for, 1160-1166
with paclitaxel, cyclophosphamide, granulocyte colony-stimulating factor regimen, 1714-1719
predictive factors for, 705-714
Peripheral-blood progenitor-cell transplantion
autologous, granulocyte colony-stimulating factor following, 1323-1327
CD34+ cell subsets following, 1922-1932
granulocyte colony-stimulating factor following, in non-Hodgkin's lymphoma, 935-941
hematopoietic recovery following, 1922-1932
infused, quality of, 937
molecular marker-positive cells following, 1073-1079
molecular markers and, 1052-1054
protocol for, 936
Peripheral stem-cell therapy, bone marrow transplantation and, for non-Hodgkin's lymphoma, 2669
Ph-negative cell, *see* Philadelphia-negative cell
Pharmacodynamics
of amonafide, 741-747
of daily oral etoposide, 194-195
of paclitaxel, 185-187
Pharmacokinetics
of all-*trans*-retinoic acid, 1969
in acute promyelocytic leukemia, 2517-2523
on intermittent schedule, 1238-1241
cellular, of MDX-210, 2284
of dexverapamil, 1988-1990
of doxorubicin, 1990-1991
of etoposide phosphate, 204-206, 2838
of etoposide, 193, 1990-1991, 2835-2841
of hepatic arterial fluorouracil plus leucovorin, 2968-2972
of 6 alpha-hydroxylpaclitaxel, 183-185
of irinotecan, 212, 215
of liposomal daunorubicin, 996-1003
of MDX-210, 2287
of paclitaxel, 180-190, 2039-2042
for metastatic breast cancer, 2579
plasma, of MDX-210, 2284-2286
of 13-*cis*-retinoic acid, 895
of SN-38, 217-218
of suramin, 2198-2199
of weekly oral vinorelbine, 641
of yttrium 90-labeled antiferritin, 2396
Phase I trial
of all-*trans* retinoic acid plus ketoconazole, 1501-1508
of carboplatin plus cyclosporine infusion, 2238-2246
of dexverapamil, 1985-1994
of docetaxel, for breast cancer, 2646-2647
ethics of, 1049-1051
of etoposide phosphate, 200-209
of hepatic arterial fluorouracil plus leucovorin, 2968-2972
of ifosfamide, carboplatin, etoposide regimen dosing, 323-332
of interleukin-3, carboplatin, cyclophosphamide regimen, in ovarian cancer, 733-740
of interleukin-1 beta plus interleukin-2, 482-489
of irinotecan, 210-221
of liposomal doxorubicin, 1777-1785
of LY231514, 2842
of octreotide acetate, 222-226
of paclitaxel plus topotecan, 2230-2237
patient perception in, 1062-1072
physician perception in, 1062-1072
of pyrazoloacridine, 1975-1984
of 13-*cis*-retinoic acid, in neuroblastoma, 894-901
of suramin, 2196-2207
in prostate cancer, 2174-2186
of 24-hour topotecan infusion, 1768-1776
of weekly intraperitoneal paclitaxel, 2961-2967
Phase I-II trial
of carmustine, cyclophosphamide, etoposide, hydroxyurea regimen, 1089-1095
of dexverapamil plus vinblastine, in renal cell cancer, 1958-1965
of interferon alfa-2a plus all-*trans*-retinoic acid, 1966-1974
of liposomal daunorubicin, 996-1003
Phase Ia-Ib trial, of MDX-210, 2281-2292
Phase II trial
of carboplatin plus etoposide, in extraocular retinoblastoma, 902-909
of cisplatin plus etoposide, in small-cell lung cancer, 1436-1442
of cisplatin plus etoposide phosphate, in small-cell lung cancer, 1436-1442
of cisplatin, leucovorin, fluorouracil regimen, in head and neck cancer, 1656-1662

of concurrent chemoradiotherapy, in non–small-cell lung cancer, 869-875
of cyclophosphamide, doxorubicin, vincristine, prednisone regimen, 2386-2393
of docetaxel, 645-651
in breast cancer, 2879-2885, 2886-2894
in cutaneous malignant melanoma, 2895-2899
of doxetaxel, 314-322, 2647-2652
of etoposide, ifosfamide, cisplatin regimen, for small-cell lung cancer, 1209-1214
of fluorouracil modulation, 1303-1311
of gemcitabine, for advanced breast cancer, 2731-2736
of ifosfamide, carboplatin, etoposide regimen, in small-cell lung cancer, 1615-1622
of interferon alfa-2a plus 13-*cis*-retinoic acid, in renal cell cancer, 1950-1957
of interferon alfa-2b plus fluorouracil, for neuroendocrine tumors, 1486-1492
of liposomal doxorubicin, for Kaposi's sarcoma, 914-920
of paclitaxel
in relapsed non-Hodgkin's lymphoma, 381-386
in small-cell lung cancer, 1430-1435
of somatostatin, 2012-2015
of temozolomide, for melanoma, 910-913
of teniposide, for small-cell lung cancer, 660-665
of vinorelbine, for advanced breast cancer, 2728-2729
of weekly oral vinorelbine, 637-644
Phase III, of adjuvant fluorouracil, doxorubicin, mitomycin regimen, in gastric cancer, 2757-2763
Phase III trial
of chemoradiotherapy, in non–small-cell lung cancer, 1425-1429
of edatrexate *v* methotrexate, in head and neck cancer, 1649-1655
of etoposide scheduling, 1871-1879
of leucovorin, fluorouracil regimen, in colorectal cancer, 921-928
of fluorouracil plus interferon alfa-2b, 1297-1302
funding of, 2457-2463
of interferon alfa-2a, fluorouracil regimen, in colorectal cancer, 921-928
of thoracic irradiation plus cisplatin, in non–small-cell lung cancer, 1425-1429
of vincristine, lomustine, prednisone *v* eight-drugs-in-one-day regimen, 112-123
Philadelphia-negative cell, in chronic myeloid leukemia, 541-542
Philadelphia-positive cell, following chemotherapy, 557
Phototherapy, interferon alfa-2a plus
in mycosis fungoides, 257-263
response to, 259-260
in Sézary syndrome, 257-263
toxicity of, 260-261
Physician(s)
attitude of
in phase I trials, 1062-1072
to physician-associated death, 1055-1061
toward disclosure, 2451-2452
toward pain, 2160
consensus guidelines for, in breaking bad news, 2449-2456
perception of
of adjuvant therapy, in node-negative breast cancer, 1459-1469
in non–small-cell lung cancer management, 1904-1911
of stage II non–small-cell lung cancer, 1905-1906
of stage IIIb non–small-cell lung cancer, 1906-1908
of stage intravenous non–small-cell lung cancer, 1908-1909
Physician assistant, implantable catheter insertion by, 1513-1519
Physician-assisted death, oncologist attitude toward, 1055-1061
Pineoblastoma
magnetic resonance imaging of, 1378
pediatric, 1377-1383
PIXY321, 1026-1027
Plasminogen activator inhibitor-1, in gastric cancer, 2084-2093
Platelet(s)
engraftment of, 938
following peripheral-blood progenitor-cell transplant, 939
Platelet transfusion, peripheral-blood stem-cell therapy and, 2552
Platinum, in combination regimen, for non-Hodgkin's lymphoma, 585
Pneumonitis, radiation, 2610-2611
Polymerase chain reaction assay
multiple-marker, in occult melanoma detection, 2109-2116
reverse-transcriptase, *see* Reverse-transcriptase polymerase chain reaction
Porphyria cutanea tarda, following interferon alfa, 2405
Position, intralumbar methotrexate and, for ventricular CSF concentrations, 177-179
Positron emission tomography, in breast cancer, for early therapy evaluation, 1470-1477
Posttransplant lymphoproliferative disorder(s)
clinical outcome in, 964-965
clinical presentation in, 962
clonality in, 964
immunosuppressive protocols in, 962
pathologic findings in, 962-964
survival rate in, 965
Potential doubling time, in head and neck cancer, 1843-1850
Practice guideline(s)
adoption of, 508
clinical modulating factors for, 506-507
decision-making question in, 505
development cycle for, 504
development of, 502-512
independent review of, 507
provincial model for, 508-509
scientific evidence levels for, 505
topic selection for, 504
Prednisolone, in non-Hodgkin's lymphoma therapy, 359-372
Prednisolone, chlorambucil, vinblastine, procarbazine, doxorubicin, vincristine, etoposide regimen, gonadal function following, 134-139
Prednisolone, mechlorethamine, vinblastine, procarbazine regimen, gonadal function following, 134-139
Prednisolone, vincristine, epirubicin, etoposide regimen
acute toxicity of, 390
in Hodgkin's disease, 387-395
mortality associated with, 390-391
Prednisone
in combination chemotherapy
for mantle-cell lymphoma, 2819-2826
for non-Hodgkin's lymphoma, 585
residual lymphoma following, 594
in CHOP regimen, for non-Hodgkin's lymphoma, 2666-2667
in combination chemotherapy, for non-Hodgkin's lymphoma, 2530-2539
in non-Hodgkin's lymphoma therapy, 359-372
in R-11 protocol, for acute lymphoblastic leukemia CNS relapse, 335

in Stanford V regimen, for Hodgkin's disease, 1081
Prednisone, lomustine, vincristine, radiotherapy regimen, in primitive neuroectodermal tumors, 1687-1696
Prednisone, chlorambucil, vinblastine, procarbazine, etoposide, vincristine, doxorubicin regimen
dosing of, 2380
in Hodgkin's disease, 2379-2385
response to, 2381
survival following, 2382
Prednisone, cyclophosphamide, doxorubicin, vincristine regimen
dose-intensity of, 2390
dosing of, 2387
in elderly, with non-Hodgkin's lymphoma, 2386-2393
outcome following, 2389-2390
survival following, 2391
toxicity following, 2392
weekly, 2386-2393
Prednisone, cyclophosphamide, doxorubicin, vincristine, granulocyte colony-stimulating factor regimen
high-dose, in non-Hodgkin's lymphoma, 2916-2923
response to, 2920-2921
toxicity of, 2918-2920
Prednisone, cyclophosphamide, epirubicin, vincristine, bleomycin regimen
dosing of, 954
in non-Hodgkin's lymphoma, 953-960
toxicity of, 957
Prednisone, cyclophosphamide, methotrexate, fluorouracil, vincristine regimen
in breast cancer, 831-839
disease-free survival following, 833-834
second malignancy following, 836
survival following, 834-835
toxicity of, 835-836
Prednisone, cyclophosphamide, methotrexate, fluorouracil, vincristine regimen
in breast cancer, 1443-1452
response to, 1447
time to treatment failure following, 1447
toxicity of, 1448-1449
treatment schema for, 1445
Prednisone, daunorubicin, asparaginase, methotrexate, cyclophosphamide, vincristine regimen, 1368-1376
Prednisone, etoposide, vincristine, cyclophosphamide, doxorubicin, dexverapamil regimen, 1995-2004
phase I trial of, 1985-1994
response to, 1999-2000
toxicity of, 2000
Prednisone, mechlorethamine, vinblastine, procarbazine regimen
dosing of, 2380
in Hodgkin's disease, 2379-2385
response to, 2381
survival following, 2382
Prednisone, melphalan regimen, interferon following, 2354-2360
Prednisone, vincristine, lomustine regimen
survival following, 116
toxicity of, 118
Pregnancy, prognostic influence of, on breast cancer, 430-434
Primitive neuroectodermal tumor
chemoradiotherapy in, 1687-1696
eight-in-one chemotherapy for, 1687-1696
lomustine, vincristine, prednisone, radiotherapy regimen in, 1687-1696
supratentorial, in children, 1687-1696
therapy of, prognostic factors following, 1377-1383
Procarbazine, in combination chemotherapy
for mantle-cell lymphoma, 2819-2826
for non-Hodgkin's lymphoma, 585, 2530
Procarbazine, chlorambucil, vinblastine, prednisolone, doxorubicin, vincristine, etoposide regimen, gonadal function following, 134-139
Procarbazine, chlorambucil, vinblastine, prednisone, etoposide, vincristine, doxorubicin regimen
dosing of, 2380
in Hodgkin's disease, 2379-2385
response to, 2381
survival following, 2382
Procarbazine, mechlorethamine, vinblastine, prednisolone regimen, gonadal function following, 134-139
Procarbazine, mechlorethamine, vinblastine, prednisone regimen
dosing of, 2380
in Hodgkin's disease, 2379-2385
response to, 2381
survival following, 2382
Prodrug, etoposide phosphate as, phase I trial of, 200-209
Progenitor cell, ex vivo expansion of, 543
Progesterone receptor, in node-negative breast cancer, 697-704
Prognostic factor(s)
in allogeneic bone marrow transplantation, for multiple myeloma, 1312-1322
bone marrow involvement as
in B-cell lymphoma, 1336-1342
in Hodgkin's disease, 403-409
in carcinoma of unknown primary, 1720-1725
in combined modality therapy, small-cell lung cancer, 2606-2612
in head and neck cancer, 880-881
lymph node metastasis size as, in cutaneous melanoma, 2362-2368
microvessel count as, in gastric cancer, 477-481
for nausea probability, 2422-2423
in node-negative breast cancer, 697-704
in ovarian cancer, 70-78
p53 overexpression as, in non–small-cell lung cancer, 1893-1903
pepsinogen C as, 54-61
in pineoblastoma, 1377-1383
for relapse, in testicular seminoma, 2258
in stage I non–small-cell lung cancer, 1267-1276
in stage II colon cancer, 2938
for survival, in bladder cancer, 1388
for vomiting probability, 2421-2422
Proliferation marker, in stage I non–small-cell lung cancer, 1272-1274
ProMACE-CytaBOM regimen, for non-Hodgkin's lymphoma, 2666-2667
Prostatic cancer
advanced, hydrocortisone plus suramin in, 2208-2213
androgen-independent, hydrocortisone plus suramin in, 2208-2213, 2214-2222
circulating tumor cells in, 1195-1200
distribution of
by race, 95-97
by stage, 95
external-beam radiotherapy in, 464-469
hormonally unresponsive, *N,N*-diethy-2-[4-(phenylmethyl)phenoxy]ethanamine, cyclophosphamide regimen in, 1398-1403

hormone-refractory
prostate-specific antigen monitoring of, 2944-2953
suramin in, 2174-2186
incidence of, 93
prostatectomy in
by age, 95-98
by geographic area, 94-95
by race, 93-100
radical prostatectomy in, 93-100
radiotherapy in, normal prostate-specific antigen levels following, 459-463
suramin and, 2155-2157
Prostate-specific antigen
as biomarker, 2944-2953
following external-beam radiotherapy, 464-469
following radiotherapy, 459-463
in suramin therapy monitoring, 2944-2953
Prostatectomy
radical, in prostatic cancer, 93-100
rate of, by race, 93-100
Provider, attitude of, toward disclosure, 2451-2452
Pseudoallescheria boydii, 244
Psychosocial distress, in pancreas cancer, 751-752
Pulmonary thromboembolism
in childhood leukemia, 2805-2812
diagnosis of, 2808
outcome following, 2808-2809
Pulsatility index, 790
Purine analog therapy
immunologic consequences of, 2442
infectious complications of, 2431-2448
Pyrazoloacridine
clinical structure of, 1976
dose escalation of, 1977
multiple dosing of, 1979-1981
myelosuppression following, 1978-1980
neurotoxicity following, 1977-1978
pharmacologic study of, 1975-1984

Quality of life
following interferon alfa-2b plus fluorouracil, 2317-2323
in metastatic breast cancer, 2561-2562
Quality-of-life, European Organization for Research and Treatment of Cancer Core Questionnaire for, 1249-1254

R-11 protocol
for CNS relapse, in acute lymphoblastic leukemia, 335
late effects of, 336
responses to, 335-336
toxicity of, 336
R-verapamil, paclitaxel pharmacokinetics and, 2039-2042
Race, prostatectomy rate by, 93-100
Radiation
adjuvant, with surveillance, in testicular seminoma, 2255-2262
cranial, for acute lymphoblastic leukemia, 2490-2495
craniospinal, lung disease following, 1478-1485
external-beam, 2395
hyperfractionated, carboplatin, etoposide regimen plus, 452-458
intraoperative, plus perioperative chemotherapy
complications of, 2766
morbidity of, 2765-2766
in pancreatic cancer, 2764-2768
preoperative, tumor proliferation following, 1417-1424
small-bowel exposure to, gastrointestinal toxicity following, 1409-1416
surgery *v*, patient selection of, 2369-2378
Radiation dosimetry, in malignant glioma, 1644
Radiation pneumonitis, following combined modality therapy, 2606-2612
Radiation therapy
for breast cancer, troponin T levels during, 2582-2584
localized, for non-Hodgkin's lymphoma, 2666-2667
Radiosurgery
complications of, 1645-1646
stereotactic, for malignant glioma, 1642-1648
Radiotherapy
abdominal, as second cancer risk factor, 1856
adjuvant, in metastasis prevention, 2869-2878
in axillary extranodal tumor extension, 47-53
of brain
biphasic memeory deficits following, 2263-2271
early-delayed effects of, 2267
late-delayed effects of, 2267-2268
of breast, selection of, reasons for, 851
carmustine plus, dosing of, 599
concurrent mitomycin, vindesine, cisplatin regimen plus, 869-875
decision instrument for, in node-negative lumpectomy, 847-853
dosing of, in Stanford V regimen, 1082-1083
external-beam, in prostatic cancer, 464-469
following lumpectomy, decision instrument for, 847-853
in malignant germ cell tumor, 1391-1397
p53 and, in breast cancer, 2745-2751
pelvic, following epirubicin plus cisplatin, 444-451
for pineoblastoma, 1377-1383
plus protracted fluorouracil infusion
compliance with, 228-229
for pancreaticobiliary tumors, 227-232
survival following, 230
postmastectomy, 2861-2864, 2869-2878
prostate-specific antigen following, 459-463
in R-11 protocol, for acute lymphoblastic leukemia CNS relapse, 335
in second cancer development, 284-285
secondary leukemia following, 285
sequential chemotherapy before, in breast cancer, 2906-2915
Stanford V regimen plus, in Hodgkin's disease, 1080-1088
thoracic, cisplatin plus, 1425-1429
toxicity of, 129
tumor-cell kinetics in, predictive value of, 1833-1836
in Wilms' tumor, 126
Radiotherapy, fluorouracil, hydroxyurea regimen
dose intensity of, 879
in head and neck cancer, 876-883
Radiotherapy, carboplatin, etoposide regimen
metastasis-free survival following, 455
in non–small-cell lung cancer, 452-458
response to, 456
survival following, 454
Radiotherapy, cisplatin, etoposide regimen, surgery following, 1880-1892
Radiotherapy, epirubicin, cisplatin regimen, in cervical cancer, 444-451
Radiotherapy, lomustine, vincristine, prednisone regimen, in primitive neuroectodermal tumors, 1687-1696

Rai staging, of chronic lymphocytic leukemia, 570-574
Ranitidine, 2637-2642
Razoxane, pharmacologic characteristics of , 776
Rb protein, in stage I non–small-cell lung cancer, 1271
Rectal administration, of morphine, in cancer pain, 1004-1008
Rectal cancer
  combined modality therapy in, 1409-1416
  tumor proliferation in, following preoperative irradiation, 1417-1424
Reed-Sternberg cell, 1761
Renal cell cancer
  dexverapamil plus vinblastine in, 1958-1965
  immunotherapy in, 1939-1949
  interferon alfa-2a, plus 13-*cis*-retinoic acid in, 1950-1957
  metastatic
    high-dose interleukin-2 in, 688-696
    interleukin-2 plus interferon alfa-2 in, 497-501
  with lung metastases, liposomal doxorubicin therapy in, 1783
Renal toxicity, cisplatin-induced, dopamine prophylaxis of, 1231-1237
Residual disease, volume of, and ovarian cancer outcome, 1589-1599
Resistance index, 790
Retinoblastoma, extraocular, etoposide plus carboplatin in, 902-909
Retinoic acid
  all-*trans*-
    in acute promyelocytic leukemia, 2517-2523
    interferon alfa-2a plus, in Kaposi's sarcoma, 1966-1974
    intermittent schedule of, 1238-1241
    ketoconazole plus, phase I trial of, 1501-1508
    pharmacokinetics of, 1969
    toxicity of, 1970
    uptake of, in leukemia, 2517-2523
  13-*cis*-
    in children, following bone marrow transplantation, 894-901
    clinical response to, 897-898
    clinical trials with, women participation in, 293-299
    interferon alfa-2a plus, in renal cell cancer, 1950-1957
    peak serum cencentrations of, at different doses, 898
    pharmacokinetics of, 895, 898
    phase I trial of, 894-901
    in second cancer reduction, 293-299
    toxicity of, 896-897
Retinoids, 774
Retroperitoneal lymph node dissection, in malignant germ cell tumor, 1391-1397
Retroviral gene transduction, in tumor-infiltrating lymphocyte, 410-418
Reverse transcriptase-polymerase chain reaction
  for circulating tumor cell detection, 1195-1200
  for cytokeratin 19, 2769-2775
Rhabdomyosarcoma
  patient age in, anaphylactoid reactions and, 2511
  pediatric, 2123-2139
    clinical grouping system for, 2128
    clinical outcome in, by group, 2143
    clinical staging of, 2126-2128
    clinical trials of, by group, 2135
    future directions in, 2135-2136
    genetic features of, 2126
    histologic classification schemes for, 2125
    local therapy in, 2128-2130
    modified tumor-node-metastasis staging in, 2129
    molecular pathogenesis of, 2126
    primary sites of, 2131
    prognostic considerations in, 2126-2128
    risk-based treatment in, 2130-2134
    therapy effects in, 2135
    therapy intensification in, 610-630
    treatment history in, 2128
  treatment plans for, 613

S-phase fraction, in stage I non–small-cell lung cancer, 1272-1273
Salmonella litchfield, 244
Salpingo-oophorectomy, unilateral, in low malignant potential ovarian tumor, 2754
Sarcoma
  orbito-ocular granulocytic, in acute myelomonocytic leukemia, 1803-1804
  soft tissue
    first-line treatment of, 1537-1545
    granulocyte colony-stimulating factor and combination chemotherapy for, 2629-2636
    high-dose ifosfamide in, 1600-1608
  therapy for, improvement in, 1531-1533
Scintigraphic flare, following hormonal therapy, of breast cancer, 1123-1128
Screening, for neuroblastoma, 2033-2038
Second cancer
  brain tumors as, 2931-2935
  chemotherapy role in, 284-285
  following combined modality therapy, in Hodgkin's disease, 2016-2022
  following cyclophosphamide, methotrexate, fluorouracil, vincristine, prednisone regimen, 836
  following doxorubicin, fluorouracil, cyclophosphamide, methotrexate regimen, 836
  following Hodgkin's disease therapy, 603-609
  following radiotherapy, in testicular seminoma, 2258
  following small-cell lung cancer, 1217
  following testicular cancer, 283-292
  following Wilms' tumor therapy, 1851-1859
  leukemia as, 286-288
  radiotherapy role in, 284-285
  in small-cell lung cancer survivors, 101-111
Second infection, following bone marrow transplantation, 244
Seminoma
  in human immunodeficiency virus patients, 2707
  residual masses of, gallium scans for, 2784-2788
  stage I testicular
    adjuvant irradiation with surveillance in, 2255-2262
    irradiation in, second cancers following, 2258
    relapse in, prognostic factors for, 2258, 2259
    relapse sites in, 2257
Serotonin release, marker of, chromogranin A as, 681-687
Sex effects
  following acute lymphoblastic leukemia therapy, 2492-2493
  following cranial irradiation, 2505
Sézary syndrome, interferon alfa-2a plus phototherapy in, 257-263
Single-photon emission computed tomography
  for benign gallium uptake *v* lymphoma, 942-946
  for intermediate-grade non-Hodgkin's lymphoma, 945
  in nonresponding high-grade non-Hodgkin's lymphoma, 944
Single-strand conformation polymorphism, in p53 analysis, 813

Skin, CD30 positive lymphoproliferative disorders of, 1343-1354
Skin cancer, acitretin in, 1933-1938
Skin toxicity, associated with liposomal doxorubicin, 1781
Sleep disturbance, estrogen replacement therapy and, 2740
Small bowel, irradiation of, gastrointestinal toxicity due to, 1409-1416
Smoking, long-term small-cell lung cancer survival and, 1215-1220
SN-38, pharmacokinetics of, 217-218
Social well being, of cancer patients, decision making and, 1255-1264
Somatostatin
  in lymphoproliferative disorders, 2012-2015
  responses to, 2013
  toxicity of, 2014
Southern blot analysis, of poorly differentiated cancer of unknown primary site, 277-279
Southern blot autoradiogram, in human immunodeficiency virus-associated Hodgkin's disease, 1762
SPECT, *see* Single-photon emission computed tomography
Sperm count, following cisplatin, etoposide, bleomycin regimen, 2279
Spinal cord compression, surgical therapy of, 2330-2335
Spine
  bone marrow of
    diffuse myeloma pattern in, 252
    focal myeloma pattern in, 253
    variegated myeloma pattern in, 252
  cervical column of, lateral view of, 1510
  magnetic resonance imaging of, in asymptomatic multiple myeloma, 251-256
  radiation to, lung disease following, 1478-1485
Squalene, coversion of, to cholesterol, 2903
Squamous cell cancer, of head and neck, edatrexate *v* methotrexate in, 1649-1655
Stage, treatment by, in non-Hodgkin's lymphoma, 365
Staging
  International System for, of lung cancer, 1265-1266
  lymph node metastasis size in, 2362-2368
  of lymph nodes, in gastric cancer, 2309-2316
  of lung cancer, 1265-1266
  migration of, in gastric cancer survival rates, 19-25
  Western *v* Japanese, in gastric cancer, 19-25
Standard reference gamble, 2370
  in laryngeal cancer, 2372-2373
Stanford V regimen
  components of, 1081
  radiotherapy plus, in Hodgkin's disease, 1080-1088
  survival following, 1083
  toxicity of, 1084-1085
Stem-cell factor, 1027
Stem-cell support, high-dose therapy plus, costs of, 969-973
Stem-cell transplantation, *see* Peripheral-blood progenitor-cell transplantation
Stem-cell purging, in chronic myeloid leukemia, 541-546
Streptococcus viridans, 244
Streptozotocin, in O6-alkylguanine alkyltransferase modulation, 2301-2308
Stress velocity index
  definition of, 1548
  following doxorubicin, 1551
Subcutaneous port, placement of, 234
Suicide, assisted
  definition of, 1061
  oncologist attitude toward, 1055-1061
Supportive care services
  at National Cancer Institute centers, 756-764
  pain management team members in, 760
Suramin, 775
  antitumor activity of, 2179-2181
  assay methodology for, 2198
  baseline parameters for, 2210
  chronic toxicities of, 2179
  discontinuation of, reasons for, 2177
  dose escalalation of, 2199
  dose-limiting malaise associated with, 2178
  dosing regimen for, 2197
  fixed dosing scheme for, 2187-2195
  flutamide prior to, 2183
  hormonal therapy prior to, 2210
  in hormone-refractory prostate cancer, prostate-specific antigen monitoring of, 2944-2953
  hydrocortisone plus
    in prostatic cancer, 2208-2213
    response to, 2218-2219
  intermittent bolus injection of, 2187-2195
  intermittent infusion of, without adaptive control, 2196-2207
  intravenous infusion of, schematic for, 2224
  measurable response to, 2180
  monitoring of, 2188
  neurotoxicity associated with, 220, 2223-2229
  peak and trough plasma concentrations of, 2204
  pharmacokinetics of, 2198-2199
  pharmacologic characteristics of, 776
  plasma concentrations of, 2203-2204
  in prostatic cancer, 2155-2157, 2174-2186
  renal dysfunction following, 2178-2179
  response to, 2191, 2198, 2203, 2211
  scheduling of, 2188
  survival following, 2182, 2184, 2193
  toxicity of, 2177-2178, 2191, 2199-2203, 2211-2212, 2219-2220
  treatment plan with, 2175-2176
Surgery
  following cisplatin, etoposide, radiotherapy regimen, 1880-1892
  for node-negative patients, with p53 mutations, 2747
  for pediatric desmoid tumor, 2813-2818
  in pelvic Ewing's sarcoma, 2336-2341
  radiation *v*, patient selection of, 2369-2378
  second look, in rhabdomyosarcoma, 621
  for spinal cord compression, 2330-2335
  in Wilms' tumor, 126, 128-129
Surveillance, with adjuvant radiation, in testicular seminoma, 2255-2262
Surveillance, Epidemiology, and End-Results Program, in prostate cancer, 93-100
Survival rate(s)
  all-*trans* retinoic acid and, in leukemia, 2520-2521
  in anthracycline-refractory breast cancer, 2570-2572
  in breast cancer, 2714-2717
    with p53 mutations, 2747-2750
  of cancer patients, 2983
  Cox modeling of, 1309
  in cutaneous lymphoproliferative disorders, 1350-1352
  in elderly patients with non-Hodgkin's lymphoma, 2531-2536
  following autologous *v* allogeneic bone marrow transplantation, 564-566

following combination chemotherapy, in childhood acute lymphoblastic leukemia, 2499-2500
following cranial irradiation, 2503-2507
following doxifluridine and leucovorin therapy, for colorectal cancer, 2616
following fluorouracil, 1302-1309
following high-dose chemotherapy, for metastatic breast cancer, 2487-2488
following intravenous vinorelbine, for advanced breast cancer, 2725-2728
following 3-hour paclitaxel infusion, for metastatic breast cancer, 2577-2578
following yttrium 90-labeled antiferritin, 2394-2400
of human immunodeficiency virus patients with, testicular germ cell tumors and, 2708
improved, in acute myelogneous leukemia, 560-569
in laryngeal cancer, and pretreatment hemoglobin levels, 2077-2083
long-term
in breast cancer, 65
in small-cell lung cancer, 1215-1220
in lymphoid tissue lymphoma, 2525-2528
in metastatic breast cancer, 2558-2562
in non–small-cell lung cancer
by physician perception, 1907-1910
prognostic factors for, 1221-1230
p53 overexpression and, 1387-1388
pepsinogen C and, 58-60
prognostic factor for, lymph node metastasis size as, 2362-2368
in recurrent follicular lymphoma, 140-147
in small-cell lung cancer, 2596-2597
Western *v* Japanese rates of, in gastric cancer, 19-25
Sweden, improved cervical cancer control in, 715-725
Symptom management, supportive care services for, 761
Systemic inflammatory response, weight loss and, in lung cancer, 2600-2605

T-cell antigen, in extramedullary leukemia, 1802-1803
T-cell marker, of extramedullary leukemia, 1803
T-cell receptor-beta, gene rearrangements of, cloning of, 1752
Tamoxifen
adjuvant
medroxyprogesterone acetate following, 1572-1577
thyroid function test changes with, 854-857
trials of, 516
antitumor activity mechanisms of, 513-514
in breast cancer, 513-529
clinical pharmacology of, 514-515
endocrine effects of, 515
endometrial cancers following, 523
increased thyroxine following, 854-857
in metastatic breast cancer, 517-521, 2556-2566
toremifene plus, in breast cancer, 2900-2905
toxic effects of, 521-524
Taxol, *see* Paclitaxel
Taxotere, *see* Docetaxel
Temozolomide
phase II trial of, in melanoma, 910-913
toxicities of, 911
Teniposide
for brain metastases, of small-cell lung cancer, 660-665
in combination chemotherapy, for mantle-cell lymphoma, 2819-2826
hematologic toxicity following, 663
in non-Hodgkin's lymphoma therapy, 359-372
in R-11 protocol, for acute lymphoblastic leukemia CNS relapse, 335
response to, 663
survival following, 662-663
Teniposide, doxorubicin, melphalan, cisplatin, total-body irradiation regimen, for bone marrow transplantation, 2789-2795
Teratoma, germ cell tumor *v*, model prediction of, 1183
Terminal illness management, supportive care services for, 759-760
Testicular cancer
adjuvant therapy for, 2681-2683
biologic risk in, for second cancers, 290
chemotherapy risk in, for second cancers, 290-291
current treatment strategies in, 289-291
human immunodeficiency virus and, 2705-2711
Indiana classification of, 1171
late relapse of, 1170-1176
prognostic survival factors in, 1173
radiotherapy risk in, for second cancers, 290
second neoplasia following, 283-292
therapy of, second cancer following, 285-286
Testicular lymphoma
clinical characteristics in, 1362
disease features in, 1363
failure patterns in, 1364
International Prognostic Index in, 1361-1367
salvage therapy in, 1364-1365
studies of, 1362
Testicular seminoma
adjuvant irradiation with surveillance in, 2255-2262
irradiation in, second cancers following, 2258
relapse in, prognostic factors for, 2258, 2259
relapse sites in, 2257
Thioguanine
in non-Hodgkin's lymphoma therapy, 359-372
response rates following, 2
Thioguanine nucleotides, acute lymphoblastic leukemia relapse associated with, 345-351
Thiotepa, in combination chemotherapy, following etoposide, carboplatin regimen, 906
Thiotepa, cyclophosphamide, granulocyte-macrophage colony-stimulating factor regimen, for mobilization, 705-714
Thiotepa, cyclophosphamide, novobiocin regimen, with autologous bone marrow transplantation, in breast cancer, 1136-1143
Thiotepa, vinblastine, doxorubicin, halotestin regimen
in breast cancer, 1443-1452
response to, 1447
time to treatment failure following, 1447
toxicity of, 1448-1449
treatment schema for, 1445
Third cancer, following Hodgkin's disease therapy, 606
Third Intergroup Rhabdomyosarcoma Study, 610-630
Thoracic irradiation, cisplatin plus, in non–small-cell lung cancer, 1425-1429
Thrombocytopenia
following interferon alfa-2a plus interleukin-2, 1119
following 2-chlorodeoxyadenosine, 572
Thromboembolism
pulmonary
in childhood leukemia, 2805-2812
diagnosis of, 2808

outcome following, 2808-2809
warfarin prevention of, costs of, 42-46
Thrombosis, indwelling venous access device and, 233-238
Thymidine labeling index, in stage I non–small-cell lung cancer, 1272-1273
3H-Thymidine labeling index, in node-negative breast cancer, 697-704
Thymidylate synthase, fluorouracil responsiveness and, 1663-1670
Thyroid, carcinoma of, in homosexual men, 2543
Thyroid function test, changes in, with adjuvant tamoxifen, 854-857
Thyroid-binding globulin, increased, with adjuvant tamoxifen, 854-857
Thyroxine, increased, with adjuvant tamoxifen, 854-857
Time trade-off, 2370
in laryngeal cancer, 2372-2373
TNP-470, pharmacologic characteristics of, 776
Tongue cancer, 677
Topotecan
chemical structure of, 1769
hematologic toxicity of, 1771
mean area under the curve of, 1773-1775
modeling pharmacokinetic-pharmacodynamic relationships with, 1772-1773
nonhematologic toxicity of, 1771
paclitaxel plus
hematologic toxicity of, 2232-2233
nonhematologic toxicity of, 2233-2234
phase I trial of, 2230-2237
pharmacokinetics of, 1771-1772
plasma concentration-time plot of, 1772
24-hour infusion of, phase I trial of, 1768-1776
Toremifene
for metastatic breast cancer, 2556-2566
tamoxifen plus, in breast cancer, 2900-2905
Total-body irradiation, in preparative bone marrow transplantation regimen, 1704-1713
Total-body irradiation, teniposide, doxorubicin, melphalan, cisplatin regimen, for bone marrow transplantation, 2789-2795
Toxicity
of anthracycline-refractory breast cancer, 2571-2572
of cisplatin and etoposide therapy, for stage II germ cell tumors, 2702-2703
cisplatin-induced, dopamine prophylaxis of, 1231-1237
of CNOP and CHOP regimens, 2537
of docetaxel, in preclinical trials, 2645
dose-limiting, definition of, 2198
of doxifluridine plus leucovorin therapy, 2616
of granulocyte colony-stimulating factor, 2631-2633
grading of, 2432
of ifosfamide, cisplatin, etoposide regimen, 2596-2597
of interleukin-6, in non–small-cell lung cancer therapy, 2587
of intravenous vinorelbine, 2723, 2725-2728
of paclitaxel, 2578-2579
of paclitaxel plus doxorubicin regimen, 2691-2694
of perioperative chemotherapy, 2716
pulmonary, radiation pneumonitis and, 2607
Transforming growth factor beta 1, 769
Transfusion, *see* Blood transfusion
Transplantation, organ, lymphoproliferative disorders following, 961-968
Transurethral endoscopic resection, in bladder cancer, 1404-1408
Trimethoprim-sulfamethoxazole
adverse effects of, 244
ciprofloxacin *v*, in bone marrow transplantation recipients, 239-250
Trimodality regimen, in non–small-cell lung cancer, 1880-1892
Troponin T, levels of, during breast-conserving radiation therapy, 2582-2584
Tumor flare, following hormonal therapy, of breast cancer, 1123-1128
Tumor marker
half-life of, in germ cell tumor, 87-92
soluble CD30 as, 1355-1360
Tumor necrosis factor, levels of, 266-268
Tumor necrosis factor, interferon gamma, melphalan regimen
administration of, 265-266
in isolated limb perfusion, 264-273
response to, 268-270
toxicity of, 268-269
Tumor size
in stage I non–small-cell lung cancer, 1267-1268
physician perception of, in node-negative breast cancer, 1459-1469
Tumor-cell kinetics, predictive value of, in radiotherapy, 1833-1836
Tumor-infiltrating lymphocyte(s)
cultures of, 1941-1942
cytokine production by, 1946-1947
cytolytic activity of, 1944-1946
immunologic parameters of, 1944
in melanoma, 1939-1949
in renal cancer, 1939-1949
retroviral gene transduction in, 410-418
Tumor-node-metastasis staging
modified, in rhabdomyosarcoma, 2129
standardizing lymph node staging in, 2309-2316
Western *v* Japanese, in gastric cancer, 21-24
Tursky scale, 750-751
Tyrphostin, for p210 tyrosine kinase inhibition, 543

United Kingdom Children's Cancer Study Group Trial, of Wilms' tumor, 124-133
Unknown primary tumor
disgnostic strategy for, 2094-2103
evaluation of, costs of, 2101
natural history of, 2094-2103
3H-Uridine uptake assay, for fluorouracil response, 419-423
Urokinase-type plasminogen activator, in gastric cancer, 2084-2093
Urokinase-type plasminogen activator-receptor, in gastric cancer, 2084-2093

Varicella zoster immunoglobulin, in leukemia, 1701-1702
Varicella zoster virus
clinical course of, in leukemia, 1698-1701
in acute lymphoblastic leukemia, 1697-1703
Vascular permeability factor, 773
Vascular status, physician perception of, in node-negative breast cancer, 1459-1469
Vascularization, intratumoral, prognosis and, 770
Venous access device
comparative cost of, by catheterization duration, 1518
complications of, 1516-1517
cost of, 1517
fate of, 234
indwelling

complications of, 233-238
placement complications of, 234
physician assistant insertion of, 1513-1519
removal of, 234-235
saphenous, 236
sepsis associated with, 235-236
thrombosis associated with, 235
Vinblastine
in combination chemotherapy, for desmoid tumor, 2815
in cisplatin, vinblastine, and bleomycin regimen, for stage II germ cell tumors, 2700
dexverapamil plus
hematologic toxicity of, 1960
in renal cell cancer, 1958-1965
treatment schema for, 1959
dosing of, in Stanford V regimen, 1086
hematologic toxicity of, 1960
in renal cell cancer, 1958-1965
in Stanford V regimen, for Hodgkin's disease, 1081
treatment schema for, 1959
in VAB-6 regimen, for stage II germ cell tumors, 2700
Vinblastine, chlorambucil, prednisolone, procarbazine, doxorubicin, vincristine, etoposide regimen, gonadal function following, 134-139
Vinblastine, chlorambucil, procarbazine, prednisone, etoposide, vincristine, doxorubicin regimen
dosing of, 2380
in Hodgkin's disease, 2379-2385
response to, 2381
survival following, 2382
Vinblastine, doxorubicin, thiotepa, halotestin regimen
in breast cancer, 1443-1452
response to, 1447
time to treatment failure following, 1447
toxicity of, 1448-1449
treatment schema for, 1445
Vinblastine, etoposide, doxorubicin regimen
in relapsed Hodgkin's disease, 2005-2011
toxicity of, 2009
Vinblastine, ifosfamide, cisplatin regimen
granulocyte-macrophage colony-stimulating factor plus, for germ cell tumor, 79-86
hematologic efficacy of, 82
infection analysis following, 81-82
recycling intervals following, 82-83
toxicity of, 83, 84
Vinblastine, mechlorethamine, prednisolone, procarbazine regimen, gonadal function following, 134-139
Vinblastine, mechlorethamine, procarbazine, prednisone regimen
dosing of, 2380
in Hodgkin's disease, 2379-2385
response to, 2381
survival following, 2382
Vinblastine, methotrexate, doxorubicin, cisplatin regimen, neoadjuvant, in bladder cancer, 1384-1390
Vinblastine, methotrexate, doxorubicin, cisplatin, granulocyte-macrophage colony-stimulating factor regimen
in bladder cancer, 2272-2277
hematologic toxicity of, 2275
infection following, 2274
Vincristine
in chemoradiotherapy, plus granulocyte-macrophage colony-stimulating factor, 1632-1641
in CHOP regimen, for non-Hodgkin's lymphoma, 2666-2667
in combination chemotherapy
for desmoid tumor, 2815
following etoposide, carboplatin regimen, 906
for mantle-cell lymphoma, 2819-2826
for non-Hodgkin's lymphoma, 585, 2530-2539
residual lymphoma following, 594
for rhabdomyosarcoma, 610-623
in CYVADIC regimen
dose-intensity analysis of, 1542, 1545
for soft tissue sarcoma, 1537-1545
nonhematologic toxicity of, 1544
survival following, 1540
toxicity of, 1540-1542
dosing of, in Stanford V regimen, 1086
in high-dose chemotherapy regimen
for breast cancer, 840-846
for metastatic breast cancer, 2484
in non-Hodgkin's lymphoma therapy, 359-372
outcome following, 130
in R-11 protocol, for acute lymphoblastic leukemia CNS relapse, 335
in Stanford V regimen, for Hodgkin's disease, 1081
in Wilms' tumor, 124-133
Vincristine, chlorambucil, vinblastine, prednisolone, procarbazine, doxorubicin, etoposide regimen, gonadal function following, 134-139
Vincristine, chlorambucil, vinblastine, procarbazine, prednisone, etoposide, doxorubicin regimen
dosing of, 2380
in Hodgkin's disease, 2379-2385
response to, 2381
survival following, 2382
Vincristine, cyclophosphamide, doxorubicin regimen
clinical results of, in small-cell lung cancer, 1639
high-dose, for neuroectodermal tumor, 2796-2804
Vincristine, cyclophosphamide, doxorubicin, prednisone regimen
dose intensity of, 2390
dosing of, 2387
in elderly, with non-Hodgkin's lymphoma, 2386-2393
outcome following, 2389-2390
survival following, 2391
toxicity following, 2392
weekly, 2386-2393
Vincristine, cyclophosphamide, doxorubicin, prednisone, granulocyte colony-stimulating factor regimen
high-dose, in non-Hodgkin's lymphoma, 2916-2923
response to, 2920-2921
toxicity of, 2918-2920
Vincristine, cyclophosphamide, epirubicin, prednisone, bleomycin regimen
dosing of, 954
in non-Hodgkin's lymphoma, 953-960
toxicity of, 957
Vincristine, cyclophosphamide, methotrexate, fluorouracil, prednisone regimen
disease-free survival following, 833-834
in breast cancer, 831-839
second malignancy following, 836
survival following, 834-835
toxicity of, 835-836
Vincristine, cyclophosphamide, methotrexate, fluorouracil, prednisone regimen

in breast cancer, 1443-1452
response to, 1447
time to treatment failure following, 1447
toxicity of, 1448-1449
treatment schema for, 1445
Vincristine, dactinomycin regimen
outcome following, 130
in Wilms' tumor, 124-133
Vincristine, daunorubicin, asparaginase, methotrexate, cyclophosphamide, prednisone regimen, 1368-1376
Vincristine, epirubicin, etoposide, prednisolone regimen
acute toxicity of, 390
in Hodgkin's disease, 387-395
mortality associated with, 390-391
Vincristine, etoposide, prednisone, cyclophosphamide, doxorubicin, dexverapamil regimen, 1995-2004
phase I trial of, 1985-1994
response to, 1999-2000
toxicity of, 2000
Vincristine, ifosfamide, carboplatin, etoposide regimen
response to, 656-657
in small-cell lung cancer, 652-659
toxicity of, 656
Vincristine, ifosfamide, carboplatin, etoposide, granulocyte colony-stimulating factor regimen
response to, 656-657
in small-cell lung cancer, 652-659
toxicity of, 656
Vincristine, lomustine, prednisone, radiotherapy regimen, in primitive neuroectodermal tumors, 1687-1696
Vincristine, lomustine, prednisone regimen
survival following, 116
toxicity of, 118
Vindesine, cisplatin plus
cost-effectiveness of, 2166-2173
incremental efficacy of, 2168
incremental survival benefit of, 2169
Vindesine, mitomycin, cisplatin regimen, concurrent radiotherapy plus, 869-875
Vinorelbine
in anthracycline-refractory breast cancer, 2567-2574
cisplatin plus
cost-effectiveness of, 2166-2173
incremental efficacy of, 2168
incremental survival benefit of, 2169
cost-effectiveness of, 2152-2153
in non–small-cell lung cancer, 2166-2173
incremental efficacy of
in non–small-cell lung cancer, 2168
incremental survival benefit of, in non–small-cell lung cancer, 2169
intravenous, for breast cancer, 2722-2730
for stage intravenous non–small-cell lung cancer, 637-644
weekly oral
dosing of, 639
pharmacokinetics of, 641
phase II trial of, 637-644
survival following, 640-641
toxicities of, 640-641
Visual analog linear scale, 750-751
Vomiting, probability of, prognostic factors for, 2421-2422

Warfarin
prophylactic, costs of, 44-45
for thromboembolism prophylaxis, in breast cancer, 42-46
very low-dose, economic impact of, 43
Weight gain, following interferon-alfa 2a plus interleukin-2, 1119
Weight loss
in stage I non–small-cell lung cancer, 1267
systemic inflammatory response and, in lung cancer, 2600-2605
Whole-brain radiotherapy, for small-cell lung cancer brain metastases, 660-665
Wilms' tumor
cardiac function following, 1546-1556
chemotherapy in, 126
chemotherapy toxicity in, 129-130
radiotherapy in, 126
radiotherapy toxicity in, 129
surgery in, 126
surgery toxicity in, 128-129
therapy of, second cancers following, 1851-1859
United Kingdom Children's Cancer Study Group Trial of, 124-133
Women, participation of, in clinical trials, 293-299
Working Formulation, in nasal lymphoma, 668
World Health Organization performance status rating, 860

Yttrium 90-labeled antiferritin
in Hodgkin's disease, survival following, 2394-2400
pharmacokinetics of, 2396
toxicity of, 2397